[go: up one dir, main page]

WO2024249812A2 - Variants d'egf et leurs méthodes d'utilisation - Google Patents

Variants d'egf et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2024249812A2
WO2024249812A2 PCT/US2024/031938 US2024031938W WO2024249812A2 WO 2024249812 A2 WO2024249812 A2 WO 2024249812A2 US 2024031938 W US2024031938 W US 2024031938W WO 2024249812 A2 WO2024249812 A2 WO 2024249812A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
egfr
peptide
acid residue
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/031938
Other languages
English (en)
Other versions
WO2024249812A3 (fr
Inventor
Zachary CROOK
Natalie Winblade Nairn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blaze Bioscience Inc
Original Assignee
Blaze Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blaze Bioscience Inc filed Critical Blaze Bioscience Inc
Publication of WO2024249812A2 publication Critical patent/WO2024249812A2/fr
Publication of WO2024249812A3 publication Critical patent/WO2024249812A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • soluble and cell surface proteins Accumulation or over-expression of soluble and cell surface proteins is indicated in a variety of human diseases, ranging from neurodegenerative diseases to cancer. Furthermore, numerous diseases are associated with mutations in soluble or cell surface proteins resulting in constitutive activity, resistance to treatment, or dominant negative activity. However, many of these proteins have been deemed “undruggable,” “difficult to drug,” or “yet to be drugged” targets due to challenges in targeting them with small molecule therapeutics. For example, the oncoprotein EGFR drives cell growth through both scaffolding and kinase functions, and current therapeutic modalities typically address one but not the other, leaving cancer cells prone to continued signaling through mutation or other adaptations.
  • compositions and methods to target and selectively deplete soluble and cell surface proteins associated with disease There is a need for compositions and methods to target and selectively deplete soluble and cell surface proteins associated with disease.
  • the oncoprotein EGFR drives cell growth through both scaffolding and kinase functions, and current therapeutic modalities typically address one but not the other, leaving cancer cells prone to continued signaling through mutation or other adaptations.
  • the present disclosure provides an EGFR-binding peptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and there are eight amino acid residues between the fifth cysteine amino acid residue and the sixth cysteine amino acid residue; and at least six mutations
  • the EGFR-binding peptide comprises a sequence having at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 494 or a fragment thereof.
  • the sequence further comprises one or more mutations relative to SEQ ID NO: 317 comprising DI 1R, I23S, V35E, E51P, L52E, R53E, or a combination thereof.
  • the sequence further comprises one or more mutations relative to SEQ ID NO: 317 comprising E51H, L52H, R53H, or a combination thereof.
  • the EGFR-binding peptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 458 - SEQ ID NO: 493 or a fragment thereof.
  • the sequence comprises SEQ ID NO: 494.
  • the sequence comprises any one of SEQ ID NO: 458 - SEQ ID NO: 493.
  • the fragment comprises at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, or at least 50 amino acid residues.
  • the EGFR-binding peptide is capable of binding to EGFR without activating the EGFR. In some aspects, the EGFR-binding peptide blocks binding of EGF to EGFR when the EGFR-binding peptide is bound to the EGFR. In some aspects, the EGFR- binding peptide inhibits EGFR when the EGFR-binding peptide is bound to the EGFR. In some aspects, the EGFR-binding peptide prevents dimerization of EGFR when the EGFR-binding peptide is bound to the EGFR.
  • the present disclosure provides a peptide complex comprising: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and
  • the EGFR-binding peptide is the EGFR-binding peptide as described herein.
  • the affinity of the EGFR-binding peptide for the target molecule, the affinity of the cellular receptor binding peptide for the cellular receptor, or both is pH- independent.
  • the affinity of the EGFR-binding peptide for the target molecule, the affinity of the cellular receptor binding peptide for the cellular receptor, or both is pH dependent.
  • the affinity of the EGFR-binding peptide for the target molecule, the affinity of the cellular receptor-binding peptide for the cellular receptor, or both is ionic strength dependent.
  • the cellular receptor-binding peptide is a transferrin receptor-binding peptide or a PD-L1 -binding peptide.
  • the cellular receptor is a transferrin receptor or PD-L1.
  • the cellular receptor is a cation-independent mannose 6 phosphate receptor (CI-M6PR), an asialoglycoprotein receptor (ASGPR), CXCR7, folate receptor, or Fc receptor (including but not limited to neonatal Fc receptor (FcRn) or FcyRIIb).
  • the cellular receptor-binding peptide binds to the cellular receptor at a pH of from pH 4.5 to pH 7.4, from pH 5.5 to pH 7.4, from pH 5.8 to pH 7.4, or from pH 6.5 to pH 7.4.
  • the cellular receptor-binding peptide is capable of binding the cellular receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • the cellular receptor-binding peptide is capable of binding the cellular receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • the cellular receptor-binding peptide is capable of binding the cellular receptor with a dissociation rate constant (k o ff or kd) of no more than 1 s' 1 , no more than 5x10' 1 s' 1 , no more than 2x10' 1 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 5x1 O' 2 s' 1 , no more than 2x1 O' 2 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 5x1 O' 3 s' 1 , no more than 2x1 O' 3 s' 1 , no more than 1x1 O' 3 s' 1 , no more than 5x1 O' 4 s' 1 , or no more than 2x1 O' 4 s' 1 at pH 5.5.
  • k o ff or kd dissociation rate constant
  • the affinity of the cellular receptor-binding peptide for the cellular receptor is pH-independent. In some aspects, the affinity of the EGFR-binding peptide for the target molecule is pH-dependent. In some aspects, the affinity of the EGFR-binding peptide for the target molecule is pH-independent. In some aspects, the affinity of the cellular receptorbinding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5 -fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of the cellular receptor-binding peptide for the cellular receptor is pH dependent. In some aspects, the affinity of the cellular receptor-binding peptide for the cellular receptor decreases as pH decreases. In some aspects, the affinity of the cellular receptor-binding peptide for the cellular receptor is higher at pH 7.4 than at pH 5.5. In some aspects, the affinity of the cellular receptor-binding peptide for the cellular receptor is higher at pH 7.4 than at pH 5.8.
  • the affinity of the EGFR-binding peptide for the target molecule is pH dependent. In some aspects, the affinity of the EGFR-binding peptide for the target molecule decreases as pH decreases. In some aspects, the affinity of the EGFR-binding peptide for the target molecule is higher at a higher pH than at a lower pH. In some aspects, the higher pH is pH 7.4, pH 7.2, pH 7.0, or pH 6.8. In some aspects, the lower pH is pH 6.5, pH 6.0, pH 5.8, pH 5.5, pH 5.0, or pH 4.5. In some aspects, the affinity of the EGFR-binding peptide for the target molecule is higher at pH 7.4 than at pH 6.0.
  • the affinity of the EGFR-binding peptide for the target molecule is higher at pH 7.4 than at pH 5.5. In some aspects, the affinity of the EGFR-binding peptide for the target molecule is higher at pH 7.4 than at pH 5.8.
  • the EGFR-binding peptide is capable of binding the target molecule with an equilibrium dissociation constant (KD) of no more than 500 nM, no more than 200 nM, 100 nM, no more than 50 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, no more than 1 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • the EGFR-binding peptide is capable of binding the target molecule with a dissociation rate constant (koff or kd) of no more than 1x10' 1 s’ 1 , 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , no more than 2x1 O’ 4 s’ 1 , no more than 1x1 O’ 4 s’ 1 , no more than 5xl0’ 5 s’ 1 , or no more than 2xl0’ 5 s’ 1 at pH 7.4.
  • koff or kd dissociation rate constant
  • the EGFR-binding peptide is capable of binding the target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 5.5.
  • a dissociation rate constant koff or kd
  • the EGFR-binding peptide is capable of binding the target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x10’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 5.8.
  • koff or kd dissociation rate constant
  • the dissociation rate constant (koff or kd) for EGFR-binding peptide binding the target molecule is at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.5 than at pH 7.4.
  • the dissociation rate constant (koff or kd) for EGFR-binding peptide binding the target molecule is at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.8 than at pH 7.4.
  • the EGFR-binding peptide is capable of binding the target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • the EGFR-binding peptide is capable of binding the target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 5.8.
  • KD equilibrium dissociation constant
  • the affinity of the EGFR-binding peptide for the target molecule at pH 7.4 is at least 1.5-fold, 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the EGFR-binding peptide for the target molecule at pH 5.5.
  • the affinity of the EGFR-binding peptide for the target molecule at pH 7.4 is at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7- fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the EGFR-binding peptide for the target molecule at pH 5.8.
  • the affinity of the EGFR-binding peptide for the target molecule at pH 7.4 is less than 0.5-fold, less than 1-fold, less than, 1.5-fold, less than 2-fold, less than 3-fold, or less than 10-fold, greater than the affinity of the EGFR-binding peptide for the target molecule at pH 5.8.
  • the EGFR-binding peptide comprises one or more histidine amino acid residues. In some aspects, the affinity of the EGFR-binding peptide for the target molecule decreases as ionic strength increases. In some aspects, the EGFR-binding peptide comprises one or more polar or charged amino acid residues capable of forming polar or charge-charge interactions with the target molecule. [0021] In some aspects, the cellular receptor-binding peptide is fused to, linked to, complexed with, or conjugated to the EGFR-binding peptide.
  • the cellular receptor-binding peptide is fused to, linked to, complexed with, or conjugated to the EGFR-binding peptide via a polymer linker.
  • the polymer linker is a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer comprising proline, alanine, serine, or a combination thereof, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, a palmitic acid, an albumin, or an albumin binding molecule.
  • PEG polyethylene glycol
  • a hydroxyethyl starch polyvinyl alcohol
  • a water soluble polymer a zwitterionic water soluble polymer
  • a water soluble poly(amino acid) a
  • the cellular receptor-binding peptide and the EGFR-binding peptide form a single polypeptide chain.
  • the peptide complex comprises a dimer dimerized via a dimerization domain.
  • a distance between the cellular receptorbinding peptide and the EGFR-binding peptide is at least 1 nm, at least 2 nm, at least 5 nm, at least 10 nm, at least 20 nm, at least 50 nm, or at least 100 nm.
  • the dimerization domain comprises an Fc domain.
  • the dimer is a homodimer dimerized via a homodimerization domain.
  • the homodimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 535, SEQ ID NO: 706, or SEQ ID NO: 246.
  • the dimer is a heterodimer dimerized via a first heterodimerization domain and a second heterodimerization domain.
  • the first heterodimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 536, SEQ ID NO: 707, or SEQ ID NO: 709.
  • the second hetero dimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 537, SEQ ID NO: 708, or SEQ ID NO: 710.
  • the EGFR-binding peptide is linked to the dimerization domain via a peptide linker. In some aspects, the cellular receptor-binding peptide is linked to the dimerization domain via a peptide linker. In some aspects, the cellular receptor-binding peptide is linked to the EGFR-binding peptide via a peptide linker. In some aspects, the peptide linker has a length of from 1 to 50 amino acid residues, from 2 to 40 amino acid residues, from 3 to 20 amino acid residues, or from 3 to 10 amino acid residues. In some aspects, the peptide linker comprises glycine and serine amino acids.
  • the peptide linker has a persistence length of no more than 6 A, no more than 8 A, no more than 10 A, no more than 12 A, no more than 15 A, no more than 20 A, no more than 25 A, no more than 30 A, no more than 40 A, no more than 50 A, no more than 75 A, no more than 100 A, no more than 150 A, no more than 200 A, no more than 250 A, or no more than 300 A.
  • the peptide linker is derived from an immunoglobulin peptide. In some aspects, the peptide linker is derived from a doubleknot toxin peptide.
  • the peptide linker comprises a sequence of any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 223 - SEQ ID NO: 223 - SEQ ID NO: 227, SEQ ID NO: 194, SEQ ID NO: 391, SEQ ID NO: 538, or SEQ ID NO: 540 - SEQ ID NO: 541.
  • the cellular receptor-binding peptide, the EGFR-binding peptide, peptide complex, or a combination thereof comprises a miniprotein, a nanobody, an antibody, an antibody fragment, an scFv, a DARPin, or an affibody.
  • the antibody comprises an IgG, or wherein the antibody fragment comprises a Fab, a F(ab)2, an scFv, or an (scFv)2.
  • the miniprotein comprises a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • the cellular receptor-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the EGFR-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the peptide complex comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the cellular receptorbinding peptide comprises at least six cysteine residues. In some aspects, the at least six cysteine residues are positioned at amino acid positions 4, 8, 18, 32, 42, and 46 of the cellular receptorbinding peptide. In some aspects, the at least six cysteine residues form at least three disulfide bonds.
  • the cellular receptor-binding peptide comprises a sequence of any one of SEQ ID NO: 148 - SEQ ID NO: 177. In some aspects, the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of
  • the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 96, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 96.
  • the cellular receptor-binding peptide comprises a sequence of SEQ ID NO: 96.
  • the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 66, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 66.
  • the cellular receptor-binding peptide comprises a sequence of SEQ ID NO: 66.
  • the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 65, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 65.
  • the cellular receptor-binding peptide comprises a sequence of SEQ ID NO: 65.
  • the cellular receptor-binding peptide comprises a sequence of any one of SEQ ID NO: 392 - SEQ ID NO: 399. In some aspects, the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241.
  • the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 187, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 400, or SEQ ID NO: 401 or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 187.
  • the cellular receptor-binding peptide comprises a sequence of SEQ ID NO: 187.
  • the fragment comprises at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, or at least 50 amino acid residues.
  • the cellular receptor-binding peptide comprises one or more histidine residues at a cellular receptor-binding interface.
  • the EGFR-binding peptide comprises one or more histidine residues at a EGFR-binding interface.
  • the target molecule comprises an EGFR.
  • the EGFR is wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, EGFR mutant T790M, a cetuximab-resistant EGFR, a panitumumab-resistant EGFR, or a combination thereof.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • an off rate of the cellular receptor-binding peptide from the cellular receptor is slower than a recycling rate of the cellular receptor.
  • a half-life of dissociation of the cellular receptor-binding peptide from the cellular receptor is no faster than 1 minute, no faster than 2 minutes, no faster than 3 minutes, no faster than 4 minutes, no faster than 5 minutes, no faster than 7 minutes, no faster than 10 minutes, no faster than 15 minutes, no faster than 20 minutes, no faster than 30 minutes, no faster than 45 minutes, no faster than 60 minutes, no faster than 90 minutes, or no faster than 120 minutes.
  • a rate of dissociation of the EGFR-binding peptide from the target molecule is faster than a recycling rate of the cellular receptor.
  • a half-life of dissociation of the target binding-binding peptide from the target molecule is less than 10 seconds, less than 20 seconds, less than 30 seconds, less than 1 minute, less than 2 minutes, less than 5 minutes, less than 10 minutes, less than 20 minutes, less than 30 minutes, less than 45 minutes, or less than 60 minutes in endosomal conditions.
  • the peptide complex is capable of being endocytosed via receptor- mediated endocytosis.
  • the receptor-mediated endocytosis is transferrin receptor-mediated endocytosis.
  • the receptor-mediated endocytosis is PD-L1- mediated endocytosis.
  • the cellular receptor-binding peptide remains bound to the cellular receptor inside an endocytic vesicle.
  • the peptide complex is recycled to the cell surface when the cellular receptor-binding peptide is bound to the cellular receptor and the cellular receptor is recycled.
  • the target molecule is released or dissociated from the EGFR-binding peptide after the peptide complex is endocytosed via receptor-mediated endocytosis.
  • the target molecule is an extracellular protein, a circulating protein, or a soluble protein. In some aspects, the target molecule is a cell surface protein. In some aspects, the target molecule is a transmembrane protein.
  • the peptide complex further comprises a half-life modifying agent coupled to the cellular receptor-binding peptide, the EGFR-binding peptide, or both.
  • the half-life modifying agent is a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, an albumin, or a molecule that binds to albumin.
  • PEG polyethylene glycol
  • a hydroxyethyl starch polyvinyl alcohol
  • a water soluble polymer a zwitterionic water soluble polymer
  • a water soluble poly(amino acid) a
  • the molecule that binds to albumin is a serum albumin-binding peptide.
  • the serum albumin-binding peptide comprises a sequence of any one of SEQ ID NO: 178, SEQ ID NO: 179, or SEQ ID NO: 193.
  • the cellular receptor-binding peptide, the EGFR-binding peptide, or both is recombinantly expressed.
  • the EGFR-binding peptide is configured to dissociate from the target molecule at pH 6.5, pH 6.0, pH 5.8, pH 5.5, pH 5.0, or pH 4.5.
  • the cellular receptor-binding peptide is configured to dissociate from the cellular receptor at pH 6.5, pH 6.0, pH 5.5, pH 5.0, or pH 4.5.
  • the peptide complex comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 499 - SEQ ID NO: 501, SEQ ID NO: 504, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 508, or SEQ ID NO: 511 - SEQ ID NO: 526.
  • the peptide complex comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 495 - SEQ ID NO: 497, SEQ ID NO: 503, or SEQ ID NO: 506.
  • the present disclosure provides a peptide-active agent complex comprising a peptide complexed to an active agent, wherein the peptide comprises the EGFR- binding peptide as described herein or the peptide complex as described herein.
  • the active agent comprises a peptide, a peptidomimetic, an oligonucleotide, a DNA, an RNA, an antibody, a single chain variable fragment (scFv), an antibody fragment, an aptamer, or a small molecule.
  • the DNA comprises cDNA, ssDNA, or dsDNA.
  • the RNA comprises RNAi, microRNA, snRNA, dsRNA, or an antisense oligonucleotide.
  • the active agent is a therapeutic agent or a detectable agent.
  • the detectable agent comprises a dye, a fluorophore, a fluorescent biotin compound, a luminescent compound, a chemiluminescent compound, a radioisotope, nanopartide, a paramagnetic metal ion, or a combination thereof.
  • the therapeutic agent comprises a chemical agent, a small molecule, a therapeutic, a drug, a peptide, an antibody protein, any fragment thereof, or any combination thereof.
  • the therapeutic agent comprises an oncology agent, an autoimmune disease agent, an acute and chronic neurodegeneration agent, a pain management agent, or an anti-cancer agent.
  • the anti-cancer agent comprises a radionuclide, radioisotope, a chemotherapeutic agent, a platinum therapeutic, a toxin, an enzyme, a sensitizing drug, an anti- angiogenic agent, cisplatin, an anti-metabolite, an anti-metabolic therapeutic, a mitotic inhibitor, a growth factor inhibitor, paclitaxel, temozolomide, topotecan, fluorouracil, vincristine, vinblastine, procarbazine, decarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide
  • the present disclosure provides a pharmaceutical composition
  • an EGFR-binding peptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and there are eight amino acid residues between the fifth cysteine amino acid residue and the sixth cysteine amino acid residue
  • the EGFR-binding peptide comprises a sequence having at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 494 or a fragment thereof.
  • the EGFR-binding peptide is the EGFR-binding peptide as described herein.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a peptide complex comprising: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth
  • the peptide complex is the peptide complex as described herein or the peptide-active agent complex as described herein.
  • the present disclosure provides a method of administering a pharmaceutical composition
  • a pharmaceutical composition comprising: an EGFR-binding peptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and there are eight amino acid residues between the fifth cysteine amino acid residue and the sixth
  • the EGFR-binding peptide comprises a sequence having at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 494 or a fragment thereof.
  • the EGFR-binding peptide is the EGFR-binding peptide as described herein.
  • the present disclosure provides a method of administering a pharmaceutical composition
  • a pharmaceutical composition comprising: a peptide complex comprising: (i) a cellular receptorbinding peptide; and (ii) an EGFR-binding peptide
  • the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino
  • the peptide complex is the peptide complex as described herein or the peptide-active agent complex as described herein.
  • the pharmaceutical composition is the pharmaceutical composition as described herein.
  • the present disclosure provides a method of inhibiting EGFR in a subject, the method comprising: administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition comprises: an EGFR-binding peptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid amino
  • the EGFR-binding peptide comprises a sequence having at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 494 or a fragment thereof.
  • the EGFR-binding peptide is the EGFR-binding peptide as described herein.
  • the present disclosure provides a method of inhibiting EGFR in a subject, the method comprising: administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition comprises: a peptide complex comprising: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residue
  • the peptide complex is the peptide complex as described herein or the peptide-active agent complex as described herein.
  • the pharmaceutical composition is the pharmaceutical composition as described herein.
  • the EGFR- binding peptide inhibits activation of the EGFR by disrupting multimerization, dimerization, or heterodimerization of the EGFR on the cell of the subject that expresses EGFR.
  • the present disclosure provides a method of selectively depleting a target molecule, the method comprising: (a) contacting a peptide complex to a cell expressing a cellular receptor, wherein the peptide complex comprises: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue,
  • the method further comprises (e) dissociating the EGFR-binding peptide from the target molecule, the cellular-receptor-binding peptide from the cellular receptor, or both, under endosomal or lysosomal conditions. In some aspects, the method further comprises (f) degrading the target molecule, thereby further depleting the target molecule. In some aspects, the method further comprises recycling the peptide complex and the cellular receptor to the cell surface.
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising: an EGFR-binding peptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and there is administering a pharmaceutical composition
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising: administering a pharmaceutical composition comprising: an EGFR-binding peptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, there is one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and
  • the EGFR-binding peptide comprises a sequence having at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 494 or a fragment thereof.
  • the EGFR-binding peptide is the EGFR-binding peptide as described herein.
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising: a peptide complex comprising: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third cyst
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising: administering a pharmaceutical composition comprising: a peptide complex comprising: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, there are ten amino acid residues between the third
  • the pharmaceutical composition is the pharmaceutical composition as described herein.
  • the EGFR comprises wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, EGFR mutant T790M, a cetuximab-resistant EGFR, or a panitumumab- resistant EGFR.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising: (a) administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a peptide complex comprising: (i) a cellular receptor-binding peptide; and (ii) an EGFR-binding peptide, wherein: the EGFR-binding peptide comprises a sequence having at least 80% sequence identity to SEQ ID NO: 494 or a fragment thereof, wherein the sequence comprises: a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue, wherein: there are seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, there are five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue,
  • the peptide complex is the peptide complex as described herein or the peptide-active agent complex as described herein.
  • the pharmaceutical composition is the pharmaceutical composition as described herein.
  • the method further comprises (e) dissociating the EGFR-binding peptide from the target molecule, the cellular-receptor-binding peptide from the cellular receptor, or both under endosomal conditions. In some aspects, the method further comprises (f) degrading the target molecule.
  • the target molecule comprises an EGFR.
  • the EGFR comprises wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, EGFR mutant T790M, a cetuximab-resistant EGFR, or a panitumumab-resistant EGFR.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • the disease or condition is a cancer.
  • the cancer expresses EGFR, overexpresses EGFR, or contains mutant EGFR.
  • the cancer is breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin lymphoma, myeloma, blood-cell-derived cancer, lung cancer, sarcoma, stomach cancer, a gastrointestinal cancer, glioblastoma, head and neck cancer, squamous head and neck cancer, non-small-cell lung cancer, squamous non-small cell lung cancer, pancreatic cancer, ovarian cancer, endometrial cancer, blood cancer, skin cancer, liver cancer, kidney cancer, or colorectal cancer.
  • the cancer is TKI-resistant, cetuximab-resistant, necitumumab-resistant, or panitumumab-resistant.
  • the cancer has one or more of the following: overexpresses EGFR, KRAS mutation, KRAS G12S mutation, KRAS G12C mutation, PTEN loss, EGFR exonl9 deletion, EGFR L858R mutation, EGFR T790M mutation, PIK3CA mutation, TP53 R273H mutation, PIK3CA amplification, PIK3CA G118D, TP53 R273H, EGFR C797X mutation, EGFR G724S mutation, EGFR L718Q mutation, EGFR S768I mutation, an EGFR mutation, a cetuximab-resistant EGFR, a panitumumab-resistant EGFR, or a combination thereof.
  • the cancer expresses or has upregulated c-MET, Her2, Her3 that heterodimerizes with EGFR.
  • the cancer is a primary cancer, an advanced cancer, a metastatic cancer, a metastatic cancer in the central nervous system, a primary cancer in the central nervous system, metastatic colorectal cancer, metastatic head and neck cancer, metastatic non-small-cell lung cancer, metastatic breast cancer, metastatic skin cancer, a refractory cancer, a KRAS wild type cancer, a KRAS mutant cancer, or an exon20 mutant non- small-cell lung cancer.
  • the method further comprises administering an additional therapy to the subject.
  • the additional therapy is adjuvant, first-line, or combination therapy.
  • the additional therapy targets other oncogenic signaling pathways, targets immune response pathways, directly drives an immune response to cancer cells, or targets disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells.
  • targeting of other oncogenic signaling pathways comprises administration of inhibitors of MEK/ERK pathway signaling, PI3K/AKT pathway signaling, JAK/STAT pathway signaling, or WNT/p-catenin pathway signaling.
  • targeting of immune response pathways comprises PD-1/PD-L1 checkpoint inhibition.
  • directly driving an immune response to cancer cells comprises bispecific T cell engagers or chimeric antigen receptor expressing T cells.
  • targeting disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells comprises administering seno lytic agents to a subject.
  • the additional therapy comprises administering fluorouracil, FOLFIRI, irinotecan, FOLFOX, gemcitabine, or cisplatin, irinotecan, oxiplatin, fluoropyrimidine to the subject.
  • the method further comprises forming a ternary complex between the peptide complex, the target molecule, and the cellular receptor.
  • formation of the ternary complex increases, facilitates, or stabilizes recycling or turnover of the cellular receptor, the target molecule, or both.
  • formation of the ternary complex increases, facilitates, or stabilizes binding of the target molecule to the cellular receptor.
  • the peptide complex binds at higher levels to cells that overexpress the target molecule and the cellular receptor than to cells that have lower levels of the target molecule or the cellular receptor or both.
  • the peptide complex has a larger, longer, or wider therapeutic window as compared to an alternative therapy.
  • the alternative therapy is not recycled to the cell surface.
  • the alternative therapy is a lysosomal targeting therapy, a ubiquitin-proteosome system (UPS) targeting therapy, a non-selective therapeutic agent, an existing biologic, or a lysosomal delivery molecule.
  • the peptide complex or the EGFR-binding peptide is administered at lower molar dosage than alternative therapies.
  • the peptide complex or the EGFR-binding peptide binds at higher levels to cancer cells than to normal cells.
  • the peptide complex or the EGFR-binding peptide has a higher antiproliferative effect, a higher target molecule depletion effect, or a higher viability effect on cancer cells than on normal cells in vitro or in vivo.
  • the peptide complex or the EGFR-binding peptide has a larger, longer, or wider therapeutic window than an anti-EGFR antibody or a TKI.
  • the peptide complex or the EGFR-binding peptide has lower toxicity on skin or on keratinocytes than an anti-EGFR antibody or a TKI.
  • the method further comprises causing remission in, reducing, ameliorating, or ablating the disease or condition. In some aspects, the method further comprises causing remission in, reducing, ameliorating, or ablating the cancer.
  • the present disclosure provides an EGFR-binding peptide comprising a sequence having at least 70% sequence identity to SEQ ID NO: 317 and comprising at least one mutation relative to SEQ ID NO: 317.
  • the EGFR-binding peptide comprises a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue; wherein the EGFR-binding peptide comprises: seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and eight amino acid residues between the fifth cysteine amino acid residue and the sixth cysteine amino acid residue.
  • the first cysteine amino acid residue is at position 6 of the EGFR- binding peptide
  • the second cysteine amino acid residue is at position 14 of the EGFR-binding peptide
  • the third cysteine amino acid residue is at position 20 of the EGFR-binding peptide
  • the fourth cysteine amino acid residue is at position 31 of the EGFR-binding peptide
  • the fifth cysteine amino acid residue is at position 33 of the EGFR-binding peptide
  • the sixth cysteine amino acid residue is at position 42 of the EGFR-binding peptide.
  • the at least one mutation comprises an amino acid substitution of DI 1R, I23S, V35E, S51P, L52E, R53E, M21R, A30W, I38D, W49R, V34S, Q43I, Q43V, Q43W, Q43Y, K48N, K48T, K48A, K48L, E51S, E51H, L52H, R53H, or a combination thereof.
  • the at least one mutation comprises an amino acid substitution of M21R, A30W, 138D, W49R, or a combination thereof.
  • the at least one mutation comprises an amino acid substitution of DI 1R, I23S, V35E, S51P, L52E, R53E, or a combination thereof. In some aspects, the at least one mutation comprises an amino acid substitution of E51H, L52H, R53H, or a combination thereof.
  • the present disclosure provides an EGFR-binding peptide comprising a sequence of SEQ ID NO: 314.
  • the present disclosure provides a n EGFR-binding peptide comprising a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • the EGFR-binding peptide comprises a sequence having at least 90% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • the EGFR-binding peptide is capable of binding to EGFR without activating the EGFR.
  • the EGFR-binding peptide blocks binding of EGF to EGFR when the EGFR-binding peptide is bound to the EGFR.
  • the EGFR-binding peptide inhibits EGFR when the EGFR-binding peptide is bound to the EGFR.
  • the EGFR-binding peptide prevents dimerization of EGFR when the EGFR- binding peptide is bound to the EGFR.
  • the present disclosure provides a peptide complex comprising: a) a cellular receptor-binding peptide; and b) a target-binding peptide complexed with the cellular receptor-binding peptide, wherein the target-binding peptide has affinity for a target molecule, and wherein the target-binding peptide comprises the EGFR-binding peptide as described herein.
  • the present disclosure provides a peptide complex comprising: a) a cellular receptor-binding peptide; and b) a target-binding peptide complexed with the cellular receptor-binding peptide, wherein the target-binding peptide has affinity for a target molecule, and wherein the target-binding peptide comprises a sequence of SEQ ID NO: 314 or a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • the affinity of the target-binding peptide for the target molecule, the affinity of the cellular receptor binding peptide for the cellular receptor, or both is pH- independent. In some aspects, the affinity of the target-binding peptide for the target molecule, the affinity of the cellular receptor binding peptide for the cellular receptor, or both is pH dependent. In some aspects, the affinity of the target-binding peptide for the target molecule, the affinity of the cellular receptor-binding peptide for the cellular receptor, or both is ionic strength dependent.
  • the target binding peptide comprises a sequence having at least 90% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494. In some aspects, the target binding peptide comprises a sequence of any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • the cellular receptor-binding peptide is a transferrin receptor-binding peptide or a PD-L1 -binding peptide. In some aspects, the cellular receptor is a transferrin receptor or PD-L1. In some aspects, the cellular receptor is a cation-independent mannose 6 phosphate receptor (CI-M6PR), an asialoglycoprotein receptor (ASGPR), CXCR7, folate receptor, or Fc receptor (including but not limited to neonatal Fc receptor (FcRn) or FcyRIIb).
  • CI-M6PR mannose 6 phosphate receptor
  • ASGPR asialoglycoprotein receptor
  • CXCR7 CXCR7
  • folate receptor folate receptor
  • Fc receptor including but not limited to neonatal Fc receptor (FcRn) or FcyRIIb.
  • the cellular receptor-binding peptide binds to the cellular receptor at a pH of from pH 4.5 to pH 7.4, from pH 5.5 to pH 7.4, from pH 5.8 to pH 7.4, or from pH 6.5 to pH 7.4.
  • the cellular receptor-binding peptide is capable of binding the cellular receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • the cellular receptor-binding peptide is capable of binding the cellular receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • the cellular receptor-binding peptide is capable of binding the cellular receptor with a dissociation rate constant (k o ff or kd) of no more than 1 s' 1 , no more than 5x1 O' 1 s' 1 , no more than 2x1 O' 1 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 5x1 O' 2 s' 1 , no more than 2x1 O' 2 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 5x1 O' 3 s' 1 , no more than 2x1 O' 3 s' 1 , no more than 1x1 O' 3 s' 1 , no more than 5x1 O' 4 s' 1 , or no more than 2x1 O' 4 s' 1 at pH 5.5.
  • k o ff or kd dissociation rate constant
  • the affinity of the cellular receptor-binding peptide for the cellular receptor is pH-independent. In some aspects, the affinity of the target-binding peptide for the target molecule is pH-dependent. In some aspects, the affinity of the target-binding peptide for the target molecule is pH-independent.
  • the affinity of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of the cellular receptorbinding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of the cellular receptor-binding peptide for the cellular receptor is pH dependent. In some aspects, the affinity of the cellular receptor-binding peptide for the cellular receptor decreases as pH decreases. In some aspects, the affinity of the cellular receptor-binding peptide for the cellular receptor is higher at pH 7.4 than at pH 5.5. In some aspects, the affinity of the cellular receptor-binding peptide for the cellular receptor is higher at pH 7.4 than at pH 5.8. In some aspects, the affinity of the target-binding peptide for the target molecule is pH dependent. In some aspects, the affinity of the target-binding peptide for the target molecule decreases as pH decreases.
  • the affinity of the target-binding peptide for the target molecule is higher at a higher pH than at a lower pH.
  • the higher pH is pH 7.4, pH 7.2, pH 7.0, or pH 6.8.
  • the lower pH is pH 6.5, pH 6.0, pH 5.8, pH 5.5, pH 5.0, or pH 4.5.
  • the affinity of the target-binding peptide for the target molecule is higher at pH 7.4 than at pH 6.0.
  • the affinity of the targetbinding peptide for the target molecule is higher at pH 7.4 than at pH 5.5.
  • the affinity of the target-binding peptide for the target molecule is higher at pH 7.4 than at pH 5.8.
  • the target-binding peptide is capable of binding the target molecule with an equilibrium dissociation constant (KD) of no more than 500 nM, no more than 200 nM, 100 nM, no more than 50 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, no more than 1 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • the target-binding peptide is capable of binding the target molecule with a dissociation rate constant (koff or kd) of no more than 1x10' 1 s’ 1 , 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , no more than 2x1 O’ 4 s’ 1 , no more than 1x1 O’ 4 s’ 1 , no more than 5x10’ 5 s’ 1 , or no more than 2x10’ 5 s’ 1 at pH 7.4.
  • koff or kd dissociation rate constant
  • the target-binding peptide is capable of binding the target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 5.5.
  • koff or kd dissociation rate constant
  • the target-binding peptide is capable of binding the target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 5.8.
  • koff or kd dissociation rate constant
  • the dissociation rate constant (koff or kd) for target-binding peptide binding the target molecule is at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.5 than at pH 7.4.
  • the dissociation rate constant (koff or kd) for target-binding peptide binding the target molecule is at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.8 than at pH 7.4.
  • the target-binding peptide is capable of binding the target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • the target-binding peptide is capable of binding the target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 5.8.
  • KD equilibrium dissociation constant
  • the affinity of the target-binding peptide for the target molecule at pH 7.4 is at least 1.5-fold, 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the target-binding peptide for the target molecule at pH 5.5.
  • the affinity of the target-binding peptide for the target molecule at pH 7.4 is at least 1.5- fold, at least 2-fold, at least 3 -fold, at least 4-fold, at least 5 -fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the target-binding peptide for the target molecule at pH 5.8.
  • the affinity of the target-binding peptide for the target molecule at pH 7.4 is less than 0.5-fold, less than 1-fold, less than, 1.5-fold, less than 2-fold, less than 3-fold, or less than 10-fold, greater than the affinity of the target-binding peptide for the target molecule at pH 5.8.
  • the target-binding peptide comprises one or more histidine amino acid residues. In some aspects, the affinity of the target-binding peptide for the target molecule decreases as ionic strength increases. In some aspects, the target-binding peptide comprises one or more polar or charged amino acid residues capable of forming polar or charge-charge interactions with the target molecule.
  • the cellular receptor-binding peptide is fused to, linked to, complexed with, or conjugated to the target-binding peptide. In some aspects, the cellular receptor-binding peptide is fused to, linked to, complexed with, or conjugated to the target-binding peptide via a polymer linker.
  • the polymer linker is a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer comprising proline, alanine, serine, or a combination thereof, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, a palmitic acid, an albumin, or an albumin binding molecule.
  • the cellular receptor-binding peptide and the target-binding peptide form a single polypeptide chain.
  • the peptide complex comprises a dimer dimerized via a dimerization domain.
  • the distance between the cellular receptor-binding peptide and the target-binding peptide is at least 1 nm, at least 2 nm, at least 5 nm, at least 10 nm, at least 20 nm, at least 50 nm, or at least 100 nm.
  • the dimerization domain comprises an Fc domain.
  • the dimer is a homodimer dimerized via a homodimerization domain.
  • the homodimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 535, SEQ ID NO: 706, or SEQ ID NO: 246.
  • the dimer is a heterodimer dimerized via a first hetero dimerization domain and a second heterodimerization domain.
  • the first heterodimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 536, SEQ ID NO: 707, or SEQ ID NO: 709.
  • the second heterodimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 537, SEQ ID NO: 708, or SEQ ID NO: 710.
  • the target-binding peptide is linked to the dimerization domain via a peptide linker.
  • the cellular receptor-binding peptide is linked to the dimerization domain via a peptide linker.
  • the cellular receptor-binding peptide is linked to the target-binding peptide via a peptide linker.
  • the peptide linker has a length of from 1 to 50 amino acid residues, from 2 to 40 amino acid residues, from 3 to 20 amino acid residues, or from 3 to 10 amino acid residues.
  • the peptide linker comprises glycine and serine amino acids.
  • the peptide linker has a persistence length of no more than 6 A, no more than 8 A, no more than 10 A, no more than 12 A, no more than 15 A, no more than 20 A, no more than 25 A, no more than 30 A, no more than 40 A, no more than 50 A, no more than 75 A, no more than 100 A, no more than 150 A, no more than 200 A, no more than 250 A, or no more than 300 A.
  • the peptide linker is derived from an immunoglobulin peptide. In some aspects, the peptide linker is derived from a double- knot toxin peptide.
  • the peptide linker comprises a sequence of any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 223 - SEQ ID NO: 223 - SEQ ID NO: 227, SEQ ID NO: 194, SEQ ID NO: 391, SEQ ID NO: 538, or SEQ ID NO: 540 - SEQ ID NO: 541.
  • the cellular receptor-binding peptide, the target-binding peptide, peptide complex, or a combination thereof comprises a miniprotein, a nanobody, an antibody, an antibody fragment, an scFv, a DARPin, or an affibody.
  • the antibody comprises an IgG, or wherein the antibody fragment comprises a Fab, a F(ab)2, an scFv, or an (scFv)2.
  • the miniprotein comprises a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • the cellular receptor-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the target-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the peptide complex comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the cellular receptorbinding peptide comprises at least six cysteine residues. In some aspects, the at least six cysteine residues are positioned at amino acid positions 4, 8, 18, 32, 42, and 46 of the cellular receptorbinding peptide. In some aspects, the at least six cysteine residues form at least three disulfide bonds.
  • the cellular receptor-binding peptide comprises a sequence of any one of SEQ ID NO: 148 - SEQ ID NO: 177. In some aspects, the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of
  • the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 96, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 96.
  • the cellular receptor-binding peptide comprises a sequence of SEQ ID NO: 96.
  • the cellular receptor-binding peptide comprises a sequence of any one of SEQ ID NO: 392 - SEQ ID NO: 399. In some aspects, the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241.
  • the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 187, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 400, or SEQ ID NO: 401 or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 187.
  • the cellular receptorbinding peptide comprises a sequence of SEQ ID NO: 187.
  • the fragment comprises at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, or at least 50 amino acid residues.
  • the cellular receptor-binding peptide comprises one or more histidine residues at a cellular receptor-binding interface.
  • the target-binding peptide comprises one or more histidine residues at a target-binding interface.
  • the target-binding peptide is an EGFR-binding peptide.
  • the target molecule comprises an EGFR.
  • the EGFR is wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, EGFR mutant T790M, or a combination thereof.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • an off rate of the cellular receptor-binding peptide from the cellular receptor is slower than a recycling rate of the cellular receptor.
  • a half-life of dissociation of the cellular receptor-binding peptide from the cellular receptor is no faster than 1 minute, no faster than 2 minutes, no faster than 3 minutes, no faster than 4 minutes, no faster than 5 minutes, no faster than 7 minutes, no faster than 10 minutes, no faster than 15 minutes, no faster than 20 minutes, no faster than 30 minutes, no faster than 45 minutes, no faster than 60 minutes, no faster than 90 minutes, or no faster than 120 minutes.
  • a rate of dissociation of the target-binding peptide from the target molecule is faster than a recycling rate of the cellular receptor.
  • a half-life of dissociation of the target binding-binding peptide from the target molecule is less than 10 seconds, less than 20 seconds, less than 30 seconds, less than 1 minute, less than 2 minutes, less than 5 minutes, less than 10 minutes, less than 20 minutes, less than 30 minutes, less than 45 minutes, or less than 60 minutes in endosomal conditions.
  • the peptide complex is capable of being endocytosed via receptor- mediated endocytosis.
  • the receptor-mediated endocytosis is transferrin receptor-mediated endocytosis.
  • the receptor-mediated endocytosis is PD-L1- mediated endocytosis.
  • the cellular receptor-binding peptide remains bound to the cellular receptor inside an endocytic vesicle.
  • the peptide complex is recycled to the cell surface when the cellular receptor-binding peptide is bound to the cellular receptor and the cellular receptor is recycled.
  • the target molecule is released or dissociated from the target-binding peptide after the peptide complex is endocytosed via receptor-mediated endocytosis.
  • the target molecule is an extracellular protein, a circulating protein, or a soluble protein. In some aspects, the target molecule is a cell surface protein. In some aspects, the target molecule is a transmembrane protein.
  • the peptide complex further comprises a half-life modifying agent coupled to the cellular receptor-binding peptide, the target-binding peptide, or both.
  • the half-life modifying agent is a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, an albumin, or a molecule that binds to albumin.
  • PEG polyethylene glycol
  • a hydroxyethyl starch polyvinyl alcohol
  • a water soluble polymer a zwitterionic water soluble polymer
  • a water soluble poly(amino acid) a water
  • the molecule that binds to albumin is a serum albumin-binding peptide.
  • the serum albumin-binding peptide comprises a sequence of any one of SEQ ID NO: 178, SEQ ID NO: 179, or SEQ ID NO: 193.
  • the cellular receptor-binding peptide, the target-binding peptide, or both is recombinantly expressed.
  • the target-binding peptide is configured to dissociate from the target molecule at pH 6.5, pH 6.0, pH 5.8, pH 5.5, pH 5.0, or pH 4.5.
  • the cellular receptor-binding peptide is configured to dissociate from the cellular receptor at pH 6.5, pH 6.0, pH 5.5, pH 5.0, or pH 4.5.
  • the peptide complex comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 499 - SEQ ID NO: 501, SEQ ID NO: 504, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 508, or SEQ ID NO: 511 - SEQ ID NO: 526.
  • the peptide complex comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 495 - SEQ ID NO: 497, SEQ ID NO: 503, or SEQ ID NO: 506.
  • the present disclosure provides a peptide-active agent complex comprising a peptide complexed to an active agent, wherein the peptide comprises the EGFR- binding peptide as described herein or the peptide complex as described herein.
  • the active agent comprises a peptide, a peptidomimetic, an oligonucleotide, a DNA, an RNA, an antibody, a single chain variable fragment (scFv), an antibody fragment, an aptamer, or a small molecule.
  • the DNA comprises cDNA, ssDNA, or dsDNA.
  • the RNA comprises RNAi, microRNA, snRNA, dsRNA, or an antisense oligonucleotide.
  • the active agent is a therapeutic agent or a detectable agent.
  • the detectable agent comprises a dye, a fhiorophore, a fluorescent biotin compound, a luminescent compound, a chemiluminescent compound, a radioisotope, nanopartide, a paramagnetic metal ion, or a combination thereof.
  • the therapeutic agent is an anti-cancer agent.
  • the anti-cancer agent comprises a radionuclide, radioisotope, a chemotherapeutic agent, a platinum therapeutic, a toxin, an enzyme, a sensitizing drug, an anti-angiogenic agent, cisplatin, an anti-metabolite, an anti- metabolic therapeutic, a mitotic inhibitor, a growth factor inhibitor, paclitaxel, temozolomide, topotecan, fluorouracil, vincristine, vinblastine, procarbazine, decarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubicin, plicamycin, mitomycin
  • the anti-cancer agent targets other oncogenic signaling pathways, targets immune response pathways, directly drives an immune response to cancer cells, or targets disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells.
  • the present disclosure provides a pharmaceutical composition comprising the EGFR-binding peptide as described herein and a pharmaceutically acceptable excipient or diluent.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising the peptide complex as described herein or the peptide-active agent complex as described herein and a pharmaceutically acceptable excipient or diluent.
  • the present disclosure provides a method of inhibiting EGFR in a subject, the method comprising administering to the subject a composition comprising the EGFR-binding peptide as described herein and delivering the EGFR-binding peptide to a cell of the subject that expresses EGFR, wherein the EGFR-binding peptide binds to EGFR on the cell of the subject and inhibits activation of the EGFR.
  • the EGFR-binding peptide inhibits activation of the EGFR by disrupting multimerization, dimerization, or heterodimerization of the EGFR on the cell of the subject that expresses EGFR.
  • the present disclosure provides a method of selectively depleting a target molecule, the method comprising: a) contacting the peptide complex as described herein to a cell expressing a cellular receptor; b) binding the target-binding peptide to the target molecule under extracellular conditions; c) binding the cellular receptor-binding peptide to the cellular receptor under extracellular conditions; and d) endocytosing the peptide complex, the target molecule, and the cellular receptor into an endocytic or lysosomal compartment, thereby depleting the target molecule.
  • the method further comprises: e) dissociating the target-binding peptide from the target molecule, the cellular-receptor-binding peptide from the cellular receptor, or both under endosomal or lysosomal conditions. In some aspects, the method further comprises: f) degrading the target molecule, thereby further depleting the target molecule. In some aspects, the method further comprises recycling the peptide complex and the cellular receptor to the cell surface.
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject the EGFR-binding peptide as described herein or the pharmaceutical composition as described herein and delivering the EGFR-binding peptide to a cell of the subject that expresses EGFR, wherein the EGFR-binding peptide inhibits the EGFR on the cell of the subject, thereby treating the disease or condition.
  • the EGFR comprises wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, EGFR mutant T790M, a cetuximab-resistant EGFR, or a panitumumab- resistant EGFR.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising: a) administering to the subject the EGFR-binding peptide as described herein, the peptide complex as described herein, the peptide-active agent complex as described herein, or the pharmaceutical composition as described herein; b) binding the target-binding peptide under extracellular conditions to a target molecule associated with the disease or condition on a cell of the subject expressing the target molecule and a cellular receptor; c) binding the cellular receptor-binding peptide under extracellular conditions to the cellular receptor on the cell of the subject; and d) endocytosing the peptide complex, the target molecule, and the cellular receptor.
  • the method further comprises: e) dissociating the target-binding peptide from the target molecule, the cellular-receptor-binding peptide from the cellular receptor, or both under endosomal conditions.
  • the method further comprises: f) degrading the target molecule.
  • the target molecule comprises an EGFR.
  • the EGFR comprises wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, or EGFR mutant T790M.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • the disease or condition is a cancer.
  • the cancer expresses EGFR, overexpresses EGFR, or contains mutant EGFR.
  • the cancer is breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin lymphoma, myeloma, blood-cell-derived cancer, lung cancer, sarcoma, stomach cancer, a gastrointestinal cancer, glioblastoma, head and neck cancer, squamous head and neck cancer, non-small-cell lung cancer, squamous non-small cell lung cancer, pancreatic cancer, ovarian cancer, endometrial cancer, blood cancer, skin cancer, liver cancer, kidney cancer, or colorectal cancer.
  • the cancer is TKI-resistant, cetuximab-resistant, necitumumab-resistant, or panitumumab-resistant.
  • the cancer has one or more of the following: overexpresses EGFR, KRAS mutation, KRAS G12S mutation, KRAS G12C mutation, PTEN loss, EGFR exonl9 deletion, EGFR L858R mutation, EGFR T790M mutation, a cetuximabresistant EGFR, a panitumumab-resistant EGFR, PIK3CA mutation, TP53 R273H mutation, PIK3CA amplification, PIK3CA G118D, TP53 R273H, EGFR C797X mutation, EGFR G724S mutation, EGFR L718Q mutation, EGFR S768I mutation, an EGFR mutation, or a combination thereof.
  • the cancer expresses or has upregulated c-MET, Her2, Her3 that heterodimerizes with EGFR.
  • the cancer is a primary cancer, an advanced cancer, a metastatic cancer, a metastatic cancer in the central nervous system, a primary cancer in the central nervous system, metastatic colorectal cancer, metastatic head and neck cancer, metastatic non-small-cell lung cancer, metastatic breast cancer, metastatic skin cancer, a refractory cancer, a KRAS wild type cancer, a KRAS mutant cancer, or an exon20 mutant non- small-cell lung cancer.
  • the method further comprises administering an additional therapy to the subject.
  • the additional therapy is adjuvant, first-line, or combination therapy.
  • the additional therapy targets other oncogenic signaling pathways, targets immune response pathways, directly drives an immune response to cancer cells, or targets disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells.
  • targeting of other oncogenic signaling pathways comprises administration of inhibitors of MEK/ERK pathway signaling, PI3K/AKT pathway signaling, JAK/STAT pathway signaling, or WNT/p-catenin pathway signaling.
  • targeting of immune response pathways comprises PD-1/PD-L1 checkpoint inhibition.
  • directly driving an immune response to cancer cells comprises bispecific T cell engagers or chimeric antigen receptor expressing T cells.
  • the targeting disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells comprises administering senolytic agents to a subject.
  • the additional therapy comprises administering fluorouracil, FOLFIRI, irinotecan, FOLFOX, gemcitabine, or cisplatin, irinotecan, oxiplatin, fluoropyrimidine to the subject.
  • the method further comprises forming a ternary complex between the selective depletion complex, the target molecule, and the cellular receptor.
  • formation of the ternary complex increases, facilitates, or stabilizes recycling or turnover of the cellular receptor, the target molecule, or both.
  • formation of the ternary complex increases, facilitates, or stabilizes binding of the target molecule to the cellular receptor.
  • the peptide complex binds at higher levels to cells that overexpress the target molecule and the cellular receptor than to cells that have lower levels of the target molecule or the cellular receptor or both.
  • the peptide complex has a larger, longer, or wider therapeutic window as compared to an alternative therapy.
  • the alternative therapy is not recycled to the cell surface.
  • the alternative therapy is a lysosomal targeting therapy, a ubiquitin-proteosome system (UPS) targeting therapy, a non-selective therapeutic agent, an existing biologic, or a lysosomal delivery molecule.
  • the peptide complex or the EGFR-binding peptide is administered at lower molar dosage than alternative therapies.
  • the peptide complex or the EGFR-binding peptide binds at higher levels to cancer cells than to normal cells.
  • the peptide complex or the EGFR-binding peptide has a higher antiproliferative effect, a higher target molecule depletion effect, or a higher viability effect on cancer cells than on normal cells in vitro or in vivo.
  • the peptide complex or the EGFR-binding peptide has a larger, longer, or wider therapeutic window than an anti-EGFR antibody or a TKI.
  • the peptide complex or the EGFR-binding peptide has lower toxicity on skin or on keratinocytes than an anti-EGFR antibody or a TKI.
  • the present disclosure provides a method of administering a peptide complex or an EGFR-binding peptide to a subject, the method comprising administering the EGFR-binding peptide as described herein, the peptide complex as described herein, the peptide-active agent complex as described herein, or the pharmaceutical composition as described herein.
  • the present disclosure provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject the EGFR-binding peptide as described herein, the peptide complex as described herein, the peptide-active agent complex as described herein, or the pharmaceutical composition as described herein, thereby treating the disease or condition.
  • FIG. 1 is an image illustrating domain binding in an EGF:EGFR complex.
  • This crystal structure publicly available and deposited into the RCSB as PDB ID: 1IVO, represents the ectodomains of an active EGFR homodimer (tetrameric due to the presence of two EGF molecules).
  • EGF binding to both EGFR Domain I and Domain III brings Domain II away from Domain IV and into a conformation capable of association with another Domain II.
  • EGFR is dimerized and activated, leading to phosphorylation and activation of various pathways such as MEK/ERK and PI3K/AKT which leads to intracellular signaling and promote growth of cells, including promoting oncogenic potential and growth of cancer cells.
  • EGF variants herein bind EGFR, they also disrupt the dimerization of EGFR, and hence disrupt, or reduce, or ablate the promotion of growth and hence disrupt, or reduce, or ablate the oncogenic potential of the EGFR on cells.
  • EGF variants herein can be used to kill target cancer cells through such disruption or via other means as described herein.
  • FIG. 2 illustrates a bar chart showing flow cytometry data for biotinylated soluble EGFR ectodomain and soluble full-length EGFR bound to the surface of a cell expressing wild type EGF (SEQ ID NO: 317), using fluorescent (647 nm excitation) streptavidin as a co-stain.
  • the chart shows that the wild type soluble EGFRvIII ectodomain (i.e., isolated EGFR Domain III, hereafter referred to simply as “EGFRvIII” when describing flow cytometry experiments) does not significantly interact with cell-surface-displayed wild type human EGF, while soluble full- length EGFR ectodomain (hereafter referred to simply as "full-length EGFR” when describing flow cytometry experiments) shows binding.
  • This experiment shows the wild type EGFRvIII ectodomain does not bind to the EGF.
  • FIG. 3 illustrates a stepwise flow chart for engineering showing the high-level modification of EGF into a cell growth disrupting variant that binds EGFR but does not signal on the receptor that would also be ready for SDC incorporation or use as a direct EGFR inhibitor.
  • This methodology is a general roadmap to select properties on variant or modified EGF that would be useful alone or in the context of an SDC without describing specific variants themselves. Specific EGF variants are described herein.
  • FIG. 4 illustrates the EGF:EGFR interface contacting residues subject to Rosetta design (Domain III) or intentional mutational disruption (Domain I).
  • the publicly available crystal structure of EGFR deposited into the RCSB as PDB ID: 1IVO, was used to analyze interactions between EGF and EGFR, which reveals EGF residues closely contacting either Domain I (grey font) or Domain III (black font) which are suitable for mutating in order to improve EGF:EGFR Domain III binding strength and/or disrupt EGF:EGFR Domain I binding strength.
  • Specific residues used on the to improve EGF:EGFR Domain III binding strength and/or disrupt EGF:EGFR Domain I binding are depicted using single letter amino acid code. This methodology is a general roadmap to select properties on variant or modified EGF that would be useful alone or in the context of an SDC without describing specific variants themselves. Specific EGF variants are described herein.
  • FIG. 5 illustrates cells expressing pooled EGF variants screened for GFP fluorescence-x axis (EGF variant expression) and APC channel fluorescence-y-axis (biotinylated target protein + fluorescent streptavidin binding) using flow cytometry.
  • the inset box in each graph shows that the EGF library has a high proportion of full-length EGFR binding variants ( ⁇ 23% of GFP+ cells), with a much smaller proportion capable of showing appreciable binding to Domain III alone (EGFRvIII, ⁇ 2% of GFP+ cells), whereas control protein does not show appreciable APC channel fluorescence.
  • FIG. 6 illustrates successive enrichment or increase in cells expressing EGF variants capable of binding EGFRvIII using flow cytometry.
  • Cells expressing EGF variants were stained with biotinylated EGFRvIII and streptavidin that fluoresces in the APC channel (approximately 647 nm excitation) at 100 nM each for 15 minutes on ice.
  • GFP fluorescence (EGF variant expression) and APC channel fluorescence (target protein + streptavidin binding) were used to identify GFP+ cells with APC channel fluorescence above background levels, which were flow sorted and collected for further enrichment.
  • the middle and bottom panels show same staining and flow sorting for a further two rounds of flow sorting enrichment.
  • FIG. 7 illustrates showing surface displayed EGF variant expression (x axis) and biotinylated EGFRvIII + fluorescent streptavidin binding (y-axis) in cells expressing a single EGF variant, including SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 319, SEQ ID NO: 387, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 369, SEQ ID NO: 372, and SEQ ID NO: 383 measured using flow cytometry.
  • FIG. 8 illustrates amino acid sequences of several isolated EGF variants with demonstrable EGFRvIII binding and Domain 1 contact residues (depicted by “X”) identifying mutations (shaded) to Domain I-adjacent residues that do not eliminate binding to Domain III.
  • Four such mutations are the EGF variants depicted as M21R (present in SEQ ID NO: 378), A30W (present in SEQ ID NO: 371), I38D (present in SEQ ID NO: 376), and W49R (present in SEQ ID NO: 383, SEQ ID NO: 384, and SEQ ID NO: 385).
  • FIG. 9 illustrates the EGF:[EGFR Domain I] interface from public crystallography data (deposited in the RCSB as PDB ID: 1IVO), with a focus on four proposed mutations M21R (present in SEQ ID NO: 378), A30W (present in SEQ ID NO: 371), I38D (present in SEQ ID NO: 376), and W49R (present in SEQ ID NO: 383, SEQ ID NO: 384, and SEQ ID NO: 385), and demonstrates their disruption of Domain I binding at specific residues in EGFR Domain I.
  • the original EGF residue is in black labeled with black font
  • the modeled mutation is in grey labeled in grey font, depicting disrupting hydrophobic interactions strengthening the interaction with Domain 1 or disrupting Domain 1 though steric hindrance.
  • FIG. 10 illustrates flow cytometry data from surface-displayed EGF variants that exhibit EGFRvIII binding despite incorporation of one or more Domain I disrupting mutations (x-axis) and their EGFRvIII-binding capability (y-axis).
  • FIG. 10 demonstrates maintenance of EGFR Domain III binding despite incorporation of one or more Domain I disrupting mutations.
  • Variants of the lead EGFRvIII-binding EGF variant SEQ ID NO: 319) were transfected individually into 293F cells and stained with 50 nM each biotinylated EGFRvIII and streptavidin that fluoresces in the APC channel (approximately 647 nm excitation). A subpopulation of cells with defined GFP expression was gated and fluorescence in these cells was measured. EGFRvIII binding was observed for all five variants, with the highest staining seen by EGF84v9 (SEQ ID NO: 458).
  • FIG. 11 illustrates a comparison of the wild type EGF and an EGF variant binding characteristics on full length EGFR and EGFRvIII (Domain III only).
  • Human EGF (SEQ ID NO: 317) and EGF84v9 (SEQ ID NO: 458) were transfected individually into wells of 293F cells and stained with either 50 nM biotinylated full-length EGFR + fluorescent streptavidin, or 50 nM EGFRvIII + fluorescent streptavidin. A subpopulation of cells with defined GFP expression was gated and fluorescence in these cells was measured.
  • the variant EGF (SEQ ID NO: 458) could still bind to the full length EGFR in spite of its Domain 1 disruption but demonstrated much stronger binding to EGFRvIII (isolated EGFR Domain III), suggesting Domain I disruption was successful.
  • FIG. 12 illustrates, in tabular form, enrichment scores of mutations in a library of EGF84v9 (SEQ ID NO: 458) variants that have high EGFRvIII staining (high DAPI stain) but that lose this binding upon pH 5.5 incubation (low APC stain). Variant abundances were normalized to that of both EGF84v9 (SEQ ID NO: 458) itself and to the variant’s abundance in the initial pre-sort library, enabling evaluation of both overall enrichment/depletion and enrichment/depletion compared to the parent sequence.
  • This double-normalized abundance is log2 -transformed and defined as the variant’s enrichment score; a negative enrichment score represents depletion from the population, while a positive enrichment score represents enrichment, the latter being a byproduct of improved EGFRvIII binding and a high degree of pH 5.5 release.
  • the table shows these enrichment scores, rounded to the nearest integer.
  • Figure discloses SEQ ID NO: 713.
  • FIG. 13 illustrates affinity maturation using EGFRvIII binding of EGF84v9 singleton variants analyzed by flow cytometry. While all of the matured variants demonstrated improved EGFRvIII staining compared to SEQ ID NO: 458, four EGF variants were selected for further analysis due to high EGFRvIII staining, including SEQ ID NO: 477, SEQ ID NO: 481, SEQ ID NO: 493, and SEQ ID NO: 494. [0144] FIG.
  • FIG. 15 illustrates EGF variant-based EGFR selective depletion complex (SDC) candidates. All seven molecules contain an Fc domain (homodimeric or heterodimeric knob- and-hole) and one or two domains constituting EGF variant SEQ ID NO: 494. Six also contain one or two domains constituting TfR-binding CDPs of SEQ ID NO: 96, making EGFR SDC candidate molecules (SEQ ID NO: 495, SEQ ID NO: 496, SEQ ID NO: 497, SEQ ID NO: 503 paired with SEQ ID NO: 504, SEQ ID NO: 503 paired with SEQ ID NO: 505, and SEQ ID NO: 504 paired with SEQ ID NO: 506).
  • SDC EGF variant-based EGFR selective depletion complex
  • SDC candidate molecules The differences between these SDC candidate molecules are the linker between the TfR-binding domain and the EGF variant domain, and also the variations in valence of EGFR or TfR binding capabilities.
  • a control SDC without TfR-binding capabilities was also designed (SEQ ID NO: 498). Though the control SDC of SEQ ID NO: 498 does not have TfR binding capabilities and should therefore not drive TfR-cycling-dependent EGFR uptake, it does have EGFR binding capabilities and is predicted to bind EGFR without facilitating growth-signal-driving dimerization, which could render SEQ ID NO: 498 into an effective EGFR inhibitor.
  • Ovals marked “N” and “C” represent homodimerization domains of SEQ ID NO: 535; ovals containing a convex or concave semicircular notch and marked “N” and “C” represent heterodimerization domains of SEQ ID NO: 536 and SEQ ID NO: 537, respectively; circles represent TfR-binding variants of SEQ ID NO: 96; 7-pointed stars represent EGF variants of SEQ ID NO: 494; curved and wavey lines represent linkers of SEQ ID NO: 223, SEQ ID NO: 540, SEQ ID NO: 541, or SEQ ID NO: 538.
  • FIG. 16 illustrates EGF variant-based EGFR selective depletion complex (SDC) candidates that use PD-L1 as the cellular receptor. All six molecules contain an Fc domain (homodimeric or heterodimeric knob-and-hole), one or two domains constituting EGF variant SEQ ID NO: 494, and one or two domains constituting PD-Ll-binding CDPs of SEQ ID NO: 187, making EGFR SDC candidate molecules (SEQ ID NO: 511, SEQ ID NO: 515, SEQ ID NO: 513, SEQ ID NO: 515 paired with SEQ ID NO: 516, SEQ ID NO: 515 paired with SEQ ID NO: 505, and SEQ ID NO: 506 paired with SEQ ID NO: 516).
  • SDC EGF variant-based EGFR selective depletion complex
  • SDC candidate molecules The differences between these SDC candidate molecules are the linker between the PD-L1 -binding domain and the EGF variant domain, and also the variations in valence of EGFR or PD-L1 binding capabilities.
  • Ovals marked “N” and “C” represent homodimerization domains of SEQ ID NO: 535; ovals containing a convex or concave semicircular notch and marked “N” and “C” represent heterodimerization domains of SEQ ID NO: 536 and SEQ ID NO: 537, respectively; circles represent PD-Ll-binding variants of SEQ ID NO: 187; 7-ponited stars represent EGF variants of SEQ ID NO: 494; curved and wavey lines represent linkers of SEQ ID NO: 223, SEQ ID NO: 540, SEQ ID NO: 541, or SEQ ID NO: 538.
  • FIG. 17A-B illustrates the extent and duration of elimination of surface EGFR in the cells by selective depletion complexes (SDC) under different SDC concentrations and treatment regimens.
  • FIG. 17A illustrates the extent of elimination of surface EGFR in cells by a selective depletion complex (SDC) of SEQ ID NO: 495 evaluated by analyzing samples by flow cytometry to measure the surface EGFR under different SDC concentrations.
  • SDC selective depletion complex
  • FIG. 17B illustrates the extent and duration of elimination of surface EGFR in the cells by a selective depletion complex (SDC) evaluated by analyzing samples by flow cytometry to measure the surface EGFR under different SDC treatment regimens.
  • SDC selective depletion complex
  • FIG. 18 illustrates the uptake of soluble EGFR into the cells evaluated by analyzing samples by flow cytometry to measure the soluble EGFR uptake under different SDC treatment regimens.
  • Hl 975 cancer cells were grown until approximately 40% confluence in RPMI media with 10% FBS and antibiotic/antimycotic supplementation. After this point, cells underwent one of three treatments to assess uptake of soluble biotinylated EGFRvIII (sEGFR; SEQ ID NO: 527). Each of the three treatments are summarized in the table in FIG. 18.
  • Treatment (1) referred to as “No SDC”, incubated the cells for two hours in media with 20 nM sEGFR and 20 nM unlabeled monovalent streptavidin.
  • Treatment (2) referred to as “SEQ ID NO: 495 Pre-treat”, incubated the cells for 2 hours in media with 20 nM sEGFR, 20 nM unlabeled monovalent strepatavidin, and 5 nM of the SDC comprising SEQ ID NO: 495.
  • This treatment first exposed cells to sEGFR-saturated SDC molecules.
  • Treatment (3) referred to as “SEQ ID NO: 495 24 hr”, was the same treatment as “SEQ ID NO: 495 Pre-treat”, except the second incubation (24 hours with 10 nM sEGFR and 10 nM fluorescent streptavidin) also included 5 nM SDC comprising SEQ ID NO: 495.
  • FIG. 19 illustrates the assessment of disruption of EGFR signaling by an EGF -variant selective depletion complex (SDC) as well as the absence of EGFR activation by molecules that incorporate the EGF variant (designed to bind EGFR but not activate it) analyzed by Western blot.
  • SDC EGF -variant selective depletion complex
  • EGF EGF
  • BCA bicinchoninic acid
  • PVDF polyvinylidine difluoride
  • a fluorescent secondary antibody provides signal that can be read on a scanner.
  • compositions and methods for selective depletion of an EGFR target molecule using cellular endocytic pathways e.g., transferrin receptor-mediated endocytosis.
  • Epidermal growth factor receptor EGFR
  • EGFR signaling regulates cell growth and survival, and upregulation of EGFR is implicated in many types of cancer.
  • EGFR proteins are regularly cycled through production, use, and degradation, and their degradation is typically within the endosomal-lysosomal pathway.
  • endocytic vesicles containing material taken up from extracellular space as well as embedded membrane proteins become acidified and fuse with or enter lysosomes containing enzymes that degrade such proteins.
  • Selective removal of certain cell proteins such as EGFR proteins either from circulation or disease-associated tissues, such as by removing the proteins from the cell surface or from soluble forms, optionally with selective delivery to the lysosome, can be used to treat disease conditions, including diseases resulting from over-expression or mutations in EGFR.
  • the peptide complexes described herein for selective depletion of a target molecule can be used to deliver an administered therapeutic drug to a cell or an endosomal or lysosomal compartment in cells or tissues with increased EGFR expression, for example to treat lysosomal storage diseases like Gaucher’s Disease (deficiency of glucocerebrosidase) or Pompe Disease (deficiency of a-glucosidase) or a disease associated with EGFR (e.g., a cancer).
  • Gaucher’s Disease deficiency of glucocerebrosidase
  • Pompe Disease deficiency of a-glucosidase
  • a disease associated with EGFR e.g., a cancer
  • a therapeutic molecule e.g., a lysosomal enzyme for an enzyme replacement therapy or a chemotherapeutic agent
  • a selective depletion complex comprising a target-binding peptide that binds the therapeutic molecule, thereby delivering the therapeutic molecule to the endosome or lysosome.
  • a selective depletion construct can function as a selective delivery complex and facilitate delivery of active enzymes to an endosome or lysosome.
  • a lysosomal enzyme can be delivered using a selective depletion complex and can retain enzymatic activity in the endosome or lysosome.
  • lysosomal enzyme in combination with a selective depletion complex comprising a targetbinding peptide that binds the lysosomal enzyme can increase the therapeutic response per dose of enzyme administered relative to administration of the lysosomal enzyme alone.
  • lysosomal delivery could be accomplished by taking advantage of existing protein uptake and recycling mechanisms, and engineering of pH-dependent binding domains into target-binding molecules.
  • TfR transferrin receptor
  • TfR transferrin receptor
  • Transferrin is known as a serum chaperone for iron ions destined for redox sensitive intracellular enzymes.
  • Iron-loaded transferrin holo-transferrin
  • the TfR:transferrin complex is natively recycled back to the cell surface, exposing transferrin to neutral pH conditions. Transferrin unbound by iron (apo-transferrin) no longer has TfR affinity under neutral pH conditions at the cell surface and is released back into circulation to pick up more iron, and repeat the process, in what is essentially a catalytic process for iron delivery to cells.
  • compositions and methods of this disclosure exploit the transferrin receptor endocytic and recycling pathways to selectively deplete target molecules (e.g., EGFR) from the cell surface, disrupt EGFR multimerization, and/or to selectively deplete and deliver target molecules (e.g., EGFR) to endocytic vesicles for lysosomal degradation.
  • target molecules e.g., EGFR
  • the compositions and methods of this disclosure can be used to selectively deplete or degrade EGFR target receptor proteins or over-expressed in disease via this pathway.
  • the compositions and methods described effectively reduce, diminish, eliminate, or deplete the target receptors from the cell surface which has many applications in medicine as described herein.
  • Selective depletion complexes of the present disclosure comprising a TfR-binding peptide (e.g., a TfR-binding cystine-dense peptide) coupled to a target-binding peptide (e.g., a target-binding EGF variant) can recruit a target molecule to the TfR by binding to both the TfR (via the TfR-binding peptide) and to the target molecule (via the target-binding peptide). Upon endocytosis, the TfR can carry the selective depletion complex and the target molecule into the endocytic vesicle.
  • a TfR-binding peptide e.g., a TfR-binding cystine-dense peptide
  • a target-binding peptide e.g., a target-binding EGF variant
  • the TfR-binding peptide of the selective depletion complex can have high affinity for TfR at extracellular pH (about pH 7.4) to maturing endosomal pH (about pH 5.5), inclusive.
  • the TfR-binding peptide can maintain its affinity for TfR upon internalization and as the endosomal compartment acidifies.
  • the target-binding peptide of the selective depletion complex can have higher affinity for the target molecule at extracellular pH and lower affinity for the target molecule at a lower endosomal pH.
  • the selective depletion complex can remain bound to TfR and release the target molecule upon acidification of the endosome.
  • the selective depletion complex can remain bound to TfR while TfR is recycled to the cell surface to be reloaded with another target molecule, and the target molecule can remain in the endosome and in some embodiments the target molecule is further delivered to a lysosome and degraded.
  • the TfR-binding peptide of the selective depletion complex can have higher affinity for TfR at extracellular pH and lower affinity for the target molecule at a lower endosomal pH.
  • the selective depletion complex can release from TfR upon acidification of the endosome.
  • the dissociation rate of the selective depletion complex from the target while in the endosome is faster than the rate of endosome recycling back to the cell surface.
  • the target may be released from the selective depletion complex regardless of any or no variation in affinity to the target as a function of pH.
  • the methods of the present disclosure can comprise contacting a cell (e.g., a cell expressing TfR) with a selective depletion complex (e.g., a molecule comprising a TfR-binding peptide and a target-binding peptide).
  • a selective depletion complex e.g., a molecule comprising a TfR-binding peptide and a target-binding peptide.
  • the selective depletion complex can recruit target molecules into endocytic vesicles via transferrin receptor-mediated (TfR-mediated) endocytosis.
  • TfR-mediated transferrin receptor-mediated
  • the target molecule can be released in the endocytic vesicle, and it may be further delivered to the lysosome and degraded.
  • the selective depletion complex can remain bound to the TfR and can remain bound to TfR as TfR is recycled to the cell surface.
  • Such methods can be used to deplete a target molecule (e.g., EGFR), such as a molecule associated with a disease or a condition (e.g., associated with cancer).
  • a target molecule e.g., EGFR
  • the methods of the present disclosure can be used to selectively deplete EGFR that is over-expressed, contains a disease-associated mutation (e.g., a mutation causing constitutive activity, resistance to treatment, or dominant negative activity), or accumulates in a disease or a condition.
  • a disease-associated mutation e.g., a mutation causing constitutive activity, resistance to treatment, or dominant negative activity
  • selective depletion of a target molecule includes the depletion of the selected target from the cell surface or soluble target in circulation, each of which could result in a therapeutic effect of the selective depletion complex.
  • the presently described selective depletion complex can comprise peptide conjugates, peptide complexes, peptide constructs, fusion peptides, or fusion molecules such as linked by chemical conjugation of any molecule type, such as small molecules, peptides, or proteins, or by recombinant fusions of peptides or proteins, respectively (e.g., a peptide construct or a peptide complex).
  • fusion peptide and “peptide fusion” are used interchangeably herein.
  • the peptide constructs or peptide complexes can be produced biologically or synthetically.
  • a selective depletion complex can comprise a TfR-binding peptide domain linked to another molecule or group of molecules such as small molecules, peptides, or proteins or other macromolecules such as nanoparticles.
  • the presently described selective depletion complexes can be peptide complexes comprising one or more TfR-binding peptides as described herein conjugated to, linked to, or fused to. or complexed with one or more target-binding peptides (e.g., one or more EGFR-binding peptides), one or more active agents (e.g., therapeutic agents, detectable agents, or combinations thereof), or combinations thereof.
  • target-binding peptides e.g., one or more EGFR-binding peptides
  • active agents e.g., therapeutic agents, detectable agents, or combinations thereof
  • Selective depletion complexes as described herein can include chemical conjugates and recombinant fusion molecules.
  • a chemical conjugate can comprise a TfR-binding peptide as described herein that is chemically conjugated to or linked to another peptide (e.g., an EGFR target-binding peptide), a molecule, an agent, or a combination thereof.
  • Molecules can include small molecules, peptides, polypeptides, proteins, or other macromolecules (e.g., nanoparticles) and polymers (e.g., nucleic acids, polylysine, or polyethylene glycol).
  • a TfR-binding peptide of the present disclosure is conjugated to another peptide or a molecule via a linker.
  • Linker moieties can include cleavable (e.g., pH sensitive or enzyme-labile linkers) or stable linkers.
  • a peptide complex is a fusion molecule (e.g., a fusion peptide or fusion protein) that can be recombinantly expressed, and wherein the fusion molecule can comprise one or more TfR-binding peptides fused to one or more other molecules peptides, polypeptides, proteins, or other macromolecules that can be recombinantly expressed.
  • the selective depletion complexes of this disclosure can have a therapeutic effect at a lower dose or a longer lasting therapeutic effect as compared to lysosomal delivery molecules that are degraded and not recycled to the cell surface. Rather than being degraded in the lysosome, the selective depletion complexes of this disclosure can be recycled back to the cell surface to “reload” with the target molecule, meaning that the potential for one selective depletion complex of this disclosure can drive the degradation of multiple target molecules with a potentially catalytic effect.
  • the selective depletion complex may also continue to have depletion activity even when the selective depletion complex is no longer present in serum but is present on or in a cell.
  • a lysosomal delivery molecule that is not recycled to the cell surface can itself be degraded or can accumulate in the lysosome without being re-used or “reloaded”.
  • the selective depletion complexes of this disclosure can have a larger (e.g., longer or wider) therapeutic window (i.e., the dosage above which a therapeutic pharmacodynamic response is observed but below which toxicity is observed) or a higher potency or a longer duration of effect as compared to lysosomal delivery molecules that are not recycled to the cell surface.
  • the therapeutic window of a drug e.g., a selective depletion complex of the present disclosure
  • the therapeutic window of a drug is the dose range at which the drug is effective without having unacceptable toxic effects.
  • the selective depletion complexes of this disclosure can be used with less risk of toxicity.
  • the selective depletion complexes of this disclosure e.g., complexes comprising a receptor-binding peptide and an EGFR target-binding peptide
  • the selective depletion complexes of this disclosure are advantageously not depleted as rapidly as non-recyclable delivery compositions targeted to lysosomes which are depleted as they are used.
  • the selective depletion complexes can be more concentrated on tissues that express the receptor, such as TfR, or the target (such as EGFR) at higher levels than other tissues; as such, the selective depletion complexes and their effects can be more concentrated on diseased tissues that overexpress the applicable receptor or the target or both compared to normal or healthy tissues.
  • TfR tumor necrosis factor receptor
  • Many solid tumors express TfR at high levels and thus selective depletion complexes that bind TfR may be more concentrated on solid tumor tissues, concentrating their depletion effect on the tumor tissues.
  • Many human tumors express EGFR at high levels (e.g., the lung, head and neck, colon, pancreas, breast, ovary, bladder and kidney, and in glioma) and thus selective depletion complexes that bind EGFR may be more concentrated on such tumor tissues, concentrating their depletion effect on the tumor tissues.
  • selective depletion complexes of this disclosure e.g., selective depletion complexes comprising a receptor-binding peptide and an EGFR target-binding peptide
  • therapeutic agents are advantageously less toxic than non-selective therapeutic agents. This is particularly advantageous for applications in cancer, where therapeutic agents can be non-selective and highly toxic and exhibit detrimental side effects on normal cells, organs, and tissues, or require lower than effective therapeutic doses less able to reduce, cure, ablate disease.
  • a selective depletion complex can bind the PD-L1 receptor, rather than TfR, to enable uptake of the target and recycling of the selective depletion complex.
  • PD-L1 is expressed by cells such as solid tumor cells, pancreatic beta cells, and certain cells of the immune system. PD-L1 can be taken up by endosomes, and then recycled back up to the cell surface. PD-L1 can co-localize with CMTM6 in recycling endosomes, where CMTM6 prevents PD-L1 from being targeted for lysosomal degradation.
  • a selective depletion complex can bind to PD-L1 and to a target, such as EGFR, that is targeted for depletion.
  • the target When PD-L1 is endocytosed into the cell, the target can be depleted from the cell surface.
  • the selective depletion complex may recycle back up to the cell surface along with PD-L1 and the target may remain in the endosome and may proceed to the lysosome and be degraded.
  • Selective depletion complexes that use PD-L1 for uptake have the potential to function in all the ways that selective depletion complexes that use TfR for uptake may function.
  • PD-L1 as a selective depletion complex receptor may permit selective targeting of selective depletion complexes to solid tumor cells, as PD-L1 is expressed in high levels on some solid tumors but is otherwise not commonly expressed in adult tissues except for some specific cell populations (e.g., certain cells of the immune system or pancreatic beta cells).
  • the selective depletion complexes of this disclosure can have less immunogenicity than an alternative therapy (e.g., a lysosomal delivery molecule) that contains sugars, glycans, polymers containing sugar-like molecules, or other derivatives.
  • an alternative therapy e.g., a lysosomal delivery molecule
  • a selective depletion complex of this disclosure can have less immunogenicity than an alternative therapy (e.g., a lysosomal delivery molecule) that targets the mannose-6-phosphate receptor, folate receptor, or the asialoglycoprotein receptor (ASGPR).
  • a selective depletion complex of this disclosure can be manufactured by a single recombinant expression and can have improved manufacturing yield, purity, cost, or manufacturing time than a molecule that has multiple synthetic steps to generate a ligand for mannose-6-phosphate receptor, folate receptor, or the asialoglycoprotein receptor (ASGPR).
  • a selective depletion complex of this disclosure can have a greater therapeutic effect or a lower therapeutic dose due to the ability to design the linker for maximal ability to bind for the receptor (e.g., TfR) and the target molecule (e.g., EGFR) at the same time, including of the target molecule is bound in the cell surface.
  • the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of this disclosure can have fewer epitopes to trigger an adaptive immune response, resulting in reduced immunogenicity as compared to TfR-binding antibody-based therapeutics.
  • the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of this disclosure can exhibit more facile and less disruptive incorporation of active agents into protein fusion complexes as compared to TfR-binding antibody-based therapeutics.
  • the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of this disclosure can have a smaller surface area, resulting in lower risk for off-target-binding, as compared to TfR-binding antibody-based therapeutics.
  • the TfR- binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of this disclosure can be formulated at a higher molar concentration than TfR-binding antibody-based therapeutics due to their lower molecule weight, lower hydrodynamic radius, or lower molar solution viscosity.
  • the selective depletion complexes of this disclosure can, in some embodiments, cross the blood brain barrier.
  • the selective depletion complexes of this disclosure may be able to transcytose across endothelial cells of the blood-brain barrier and thereby reach the central nervous system (CNS), brain, and associated cells.
  • CNS central nervous system
  • the selective depletion complexes of this disclosure may be able to deplete targets that are in the CNS including tumors that are present in the brain.
  • the selective depletion complexes of this disclosure can function with a wide range of linker lengths.
  • Selective depletion complexes of this disclosure can have a range of short to long linkers between the receptor-binding portion and the target binding portion of the SDC. and the structure of the SDC does not necessarily require close association of the target and the receptor in order cause depletion of the target so long as it forms a ternary complex with the receptor and target that is endocytosed when the receptor is endocytosed.
  • E3 ligases Because the ubiquitination domain of cell surface E3 ligases is on the intracellular portion of the ligase, it is unable to ubiquitinate extracellular soluble targets and thus the use of E3 ligases does not facilitate ubiquitin-mediated depletion of soluble targets for depletion.
  • the selective depletion complexes of this disclosure do not require such proximity constraints and have been demonstrated to promote the cellular uptake of soluble targets (e.g., soluble EGFRvIII) and hence are an improvement on such prior systems.
  • the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of this disclosure exhibit lower on- target toxicity than an anti-TfR antibody or other therapeutic agents when administered to a subject at the same molar dose or at a similarly effective dose. In some embodiments, the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides exhibit lower off-target toxicity than an antibody or other therapeutic agent when administered to a subject at the same molar dose or a similarly effective dose.
  • the TfR-binding peptides, TfR-binding peptide conjugates, or TfR- binding fusion peptides of this disclosure can be administered to a subject at about 1-fold, 2- fold, 3-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold higher molar dose than an antibody while providing similar or lower observed toxicity.
  • the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of this disclosure exhibit higher efficacy than an anti-TfR antibody or other therapeutic agent when administered to a subject at the same dose by weight as the anti-TfR antibody or other therapeutic agent.
  • the TfR-binding peptides of the present disclosure when fused to a half-life extending moiety (e.g., Fc, SA21, PEG), can be delivered at even lower doses while preserving activity and efficacy and, thus, is far superior to administering an anti-TfR antibody or other therapeutic agent.
  • the present disclosure provides peptides (e.g., CDPs, knotted peptides, or hitchins), chemical conjugates (e.g., comprising one or more TfR-binding peptides and one or more active agents), or recombinantly expressed fusion molecules (e.g., comprising one or more TfR-binding peptides and one or more active agents) that bind to TfR, PD-L1, other receptors, or the target.
  • the TfR-binding peptides can be cystine-dense peptides (CDPs).
  • TfR-binding peptides are used interchangeably herein.
  • the binding of peptides described in the present disclosure to TfR can facilitate transcytosis of the selective depletion complex, peptide, peptide complex or peptide construct (e.g., fusion protein, or peptide conjugated to, linked to, complexed with, or fused to an agent) across a cell barrier (e.g., the BBB).
  • a cell barrier e.g., the BBB
  • the binding of peptides described in the present disclosure to TfR can facilitate endocytosis of the selective depletion complex, peptide, or peptide complex in any cell that expresses TfR, or in cell that express TfR at higher levels, including some cancer cells, hepatic cells, spleen cells, and bone marrow cells. Also disclosed herein is the use of a mammalian surface display screening platform to screen a diverse library of CDPs and identify CDPs that specifically bind to human TfR.
  • Such identified peptides can be modified to improve binding to TfR and used in selective depletion complexes as the peptide or peptide complex that binds TfR and is recycled to the cell surface (e.g., the pH-independent TFR-binding CDP). Also disclosed herein is the use of a mammalian surface display screening platform to screen a diverse library of CDPs and identify CDPs that specifically bind to a target molecule that is desired to be degraded.
  • Such identified peptides can be optimized for binding to a selected target molecule and used in selective depletion complexes as the peptide or peptide complex that binds such selected target molecule and is released in the endosome for degradation within the cell (e.g., the pH-dependent target-binding EGF variant as shown in FIG. 14). Further affinity maturation can be subsequently implemented to produce an allelic series of TfR-binding CDPs or target-binding CDPs as appropriate with varying affinities. In some embodiments, TfR-binding CDPs or target-binding CDPs are identified, and binding can be determined by crystallography or other methods. Peptides of the present disclosure can have cross-reactivity across species.
  • the peptides disclosed herein in some cases, bind to human and murine TfR.
  • Peptides disclosed herein can accumulate in the CNS and can penetrated the BBB via engagement of the TfR, following intravenous administration.
  • TfR-binding CDPs for use as therapeutic delivery agents in oncology, autoimmune disease, acute and chronic neurodegeneration, and pain management. Delivery of active or pharmaceutical agents via TfR-binding CDP can be advantageous over conventional anti-TfR antibodies due to simpler manufacturing (peptides can be made via biologic or synthetic means), improved stability, improved therapeutic window (e.g., a larger, longer, or wider therapeutic window), and smaller size (less potential for steric hindrance of cargo activity).
  • the methods and compositions of the present disclosure can provide a solution to the problem of effectively transporting cargo molecules (e.g., therapeutic and/or diagnostic small molecules, peptides or proteins) into the CNS (e.g., the brain).
  • cargo molecules e.g., therapeutic and/or diagnostic small molecules, peptides or proteins
  • the peptides of the present disclosure aid in drug delivery to tumors located in the brain.
  • a diverse library of CDPs, knotted peptides, hitchins, or peptides derived from knotted peptides or hitchins can be used in combination with a mammalian surface display screening platform is used to identify peptides that specifically bind to human TfR or PD-L1 or other receptors desired for recycling or to a target molecule desired for degradation.
  • a mammalian surface display screening platform is used to identify peptides that specifically bind to human TfR or PD-L1 or other receptors desired for recycling or to a target molecule desired for degradation.
  • a diverse library of CDPs, knotted peptides, hitchins, or peptides derived from knotted peptides or hitchins is mutagenized from endogenous peptide sequences to provide novel peptide sequences.
  • affinity maturation e.g., site-saturation mutagenesis
  • allelic series of binders with varying (e.g., improved) affinities for TfR or a target molecule can be performed to produce an allelic series of binders with varying (e.g., improved) affinities for TfR or a target molecule.
  • peptides of the present disclosure are developed to bind human TfR.
  • the engineered peptides of the present disclosure can have a high target-binding affinity at physiologic extracellular pH (e.g., a pH from about pH 7.2 to about pH 7.5, a pH of from about pH 6.5 to about 7.5, or a pH of from about pH 6.5 to about pH 6.9) but a significantly reduced binding affinity at lower pH levels such as endosomal pH of about 6.5, about 6.0, about 5.8, or about 5.5.
  • Extracellular pH can be, for example pH 7.4. Extracellular pH can also be lower, including in the tumor microenvironment, such as pH 7.2, 7.0, or 6.8.
  • extracellular pH can be from about pH 6.5 to about pH 6.9.
  • endocytosis the endosome undergoes a decrease in pH.
  • Endosomal pH can decrease by the action of proton pumps or by merging with other vesicles with lower pH. The pH can decrease to 7.0, and then to 6.5, and then to 6.0, and then to 5.8, and then to 5.5 or lower.
  • Some endosomes are called early endosomes and can have a pH around 6.5. Some of these endosomes become recycling endosomes.
  • Some endosomes are called late endosomes and can have a pH around 5.5.
  • the target-binding peptides release in the endosome at about pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • the target-binding peptide may release at any point during the endosomal maturation process upon a decrease in pH following endocytosis.
  • histidine scans and comparative binding experiments can be performed to develop and screen for such peptides.
  • an amino acid residue in a peptide of the present disclosure is substituted with a different amino acid residue to alter a pH-dependent binding affinity to the target molecule or to TfR or other receptors.
  • the amino acid substitution can increase a binding affinity at low pH, increase a binding affinity at high pH, decrease a binding affinity at low pH, decrease a binding affinity at high pH, or a combination thereof.
  • a peptide that has high affinity to TfR and used in selective depletion complexes as the peptide or peptide complex that binds TfR for recycling to the cell surface can be a pH-independent TfR-binding peptide (e.g., a pH-independent TfR- binding CDP) such that it is not released in the endosome.
  • the TfR- binding peptide can remain bound to TfR as the ionic strength of the endosomal compartment increases upon acidification of the endosome.
  • the TfR-binding peptides are stable at endosomal pH, and do not release in the endosome for example under acidic conditions, such as pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • acidic conditions such as pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • a peptide that has high affinity for binding to a selected target molecule and used in selective depletion complexes as the peptide or peptide complex that binds such selected target molecule and is released in the endosome for degradation within the cell can be a pH-dependent target-binding CDP such that it is released in the endosome.
  • a target-binding peptide can release the target molecule as the ionic strength of the endosomal compartment increases upon acidification of the endosome.
  • the target-binding peptides are less stable at endosomal pH, and release wholly or in part in the endosome for example under acidic conditions, such as pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • acidic conditions such as pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH
  • the TfR-binding peptides of the present disclosure can be optimized for improved intra- vesicular (e.g., intra-endosomal) function while retaining high TfR binding capabilities.
  • the target-binding peptide may not release at any point during the endosomal maturation process, for example using designs that are not pH-sensitive (i.e., are pH-independent) to release the target molecule in the endosome or lysosome, but the selective depletion complex still results in selective depletion of the target molecule from the cell surface or soluble target molecule in circulation.
  • TfR-binding peptides of the present disclosure are shown in TABLE 1 with amino acid sequences comprising SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • a protein or molecule of interest such as TfR
  • bind to a target molecule for depletion or both.
  • the methods and compositions as described herein can provide peptides with improved TfR-binding capabilities, or peptides that exhibit improved transport capabilities across the BBB, or any combination thereof.
  • the presently described peptides efficiently transport cargo molecules (e.g., target-binding molecules) across endothelial cell layers (e.g., the BBB) or epithelial layers.
  • cargo molecules e.g., target-binding molecules
  • the TfR- binding peptides of the present disclosure bind to a TfR and promote vesicular transcytosis.
  • the TfR-binding peptides of the present disclosure bind to a cell that overexpress a TfR (e.g., a cancer cell) and promotes uptake of the peptide by the cell.
  • a TfR binding peptide or peptide complexes as described herein promotes vesicular transcytosis and uptake by a TfR-overexpressing cell such as a cancer, or a combination thereof.
  • the TfR-binding peptides of the present disclosure facilitate TfR-mediated endocytosis of a selective depletion complex and a target molecule.
  • the TfR-binding peptides of the present disclosure can bind TfR of different species including human, monkey, mouse, and rat TfR. In some cases, variations or mutations in any of the amino acid residues of a TfR-binding peptide can influence cross-reactivity. In some cases, variations or mutations in any of the amino acid residues of a TfR-binding peptide that interact with the bindings site of TfR can influence cross-reactivity.
  • peptides including, but not limited to, designed or engineered peptides, recombinant peptides, and cystine-dense peptides (CDPs)/small disulfide-knotted peptides (e.g., knotted peptides, hitchins, and peptides derived therefrom), that can be large enough to carry a cargo molecule while retaining the ability to bind a target protein with high affinity (e.g., TfR), but yet small enough to access cellular tissues, such as the center of cell agglomerates (e.g., solid tumors).
  • the peptides as described herein carry cargo molecules across the BBB into the CNS (e.g., the parenchyma) via vascular transcytosis.
  • the transcytosis is TfR-mediated.
  • peptide-receptor interactions e.g., using X-ray crystallography
  • CNS e.g., brain
  • peptides described herein have the ability to target molecule and accumulate in tumor cells. In some cases, the tumor cells overexpress TfR, EGFR, or both.
  • the peptides of the present disclosure have high in vivo stabilities, e.g., high protease stability, high tolerability of reducing agents such as glutathione (GSH), and tolerate elevated temperatures (e.g., up to 95 °C).
  • high in vivo stabilities e.g., high protease stability, high tolerability of reducing agents such as glutathione (GSH), and tolerate elevated temperatures (e.g., up to 95 °C).
  • the present disclosure provides, in some embodiments, a peptide or protein design approach based on the 3D protein or receptor structure for identifying peptides or proteins capable of binding such receptor.
  • the receptor is a transferrin receptor.
  • Xaa can indicate any amino acid.
  • X can be asparagine (N), glutamine (Q), hist
  • Some embodiments of the disclosure contemplate D-amino acid residues of any standard or non-standard amino acid or analogue thereof.
  • an amino acid sequence is represented as a series of three-letter or one-letter amino acid abbreviations, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy terminal direction, in accordance with standard usage and convention.
  • peptide can be used interchangeably herein to refer to a polymer of amino acid residues.
  • peptides”, polypeptides”, and “proteins” can be chains of amino acids whose alpha carbons are linked through peptide bonds.
  • the terminal amino acid at one end of the chain e.g., amino terminal, or N-terminal
  • the terminal amino acid at the other end of the chain e.g., carboxy terminal, or C-terminal
  • the terminal amino acid at the other end of the chain e.g., carboxy terminal, or C-terminal
  • amino terminus can refer to the free a-amino group on an amino acid at the amino terminal of a peptide or to the a-amino group (e.g., imino group when participating in a peptide bond) of an amino acid at any other location within the peptide.
  • carboxy terminus can refer to the free carboxyl group on the carboxy terminus of a peptide or the carboxyl group of an amino acid at any other location within the peptide.
  • Peptides also include essentially any polyamino acid including, but not limited to, peptide mimetics such as amino acids joined by an ether or thioether as opposed to an amide bond.
  • the term “peptide construct” can refer to a molecule comprising one or more peptides of the present disclosure that can be conjugated to, linked to (including by complexation), or fused to one or more peptides or cargo molecules.
  • cargo molecules are active agents.
  • the term “active agent” can refer to any molecule, e.g., any molecule that is capable of eliciting a biological effect and/or a physical effect (e.g., emission of radiation) which can allow the localization, detection, or visualization of the respective peptide construct.
  • the term “active agent” refers to a therapeutic and/or diagnostic agent.
  • a peptide construct of the present disclosure can comprise a TfR-b inding peptide that is linked to one or more active agents via one or more linker moieties (e.g., cleavable or stable linker) as described herein.
  • the term “peptide complex” can refer to one or more peptides of the present disclosure that are fused, linked, conjugated, or otherwise connected to form a complex.
  • the one or more peptides can comprise a TfR-b inding peptide, a target-binding peptide, a half-life modifying peptide, a peptide that modifies pharmacodynamics and/or pharmacokinetic properties, or combinations thereof.
  • a peptide complex comprising a TfR-b inding peptide and a target-binding peptide can be referred to herein as a selective depletion complex.
  • the terms “comprising” and “having” can be used interchangeably.
  • the terms “a peptide comprising an amino acid sequence of SEQ ID NO: 32” and “a peptide having an amino acid sequence of SEQ ID NO: 32” can be used interchangeably.
  • TfR or “transferrin receptor” is a class of protein used herein and can refer to a transferrin receptor from any species (e.g., human or murine TfR or any human or non-human animal TfR).
  • TfR or “transferrin receptor” refers to human TfR (hTfR) and can include TfR or any of the known TfR homologs or orthologs, including TfRl, TfR2, soluble TfR, or any combination or fragment (e.g., ectodomain) thereof.
  • endosome As used herein, the terms “endosome,” “endosomal,” “endosomal compartment,” or “endocytic pathway” can be used interchangeably and may refer to any one or more components of the intracellular endosomal network or trans-Golgi network (TGN) that allows for the vesicular transcytosis or trafficking and transfer of peptides and cargoes between distinct membrane-bound compartments within a cell, including lysosomal degradation as well as recycling to the cell surface.
  • TGN trans-Golgi network
  • vesicles commonly referred to as transport vesicles or early endosomes to late endosomes to lysosomes, and that endosomal compartment acidity increases upon acidification of the endosome throughout the maturation process.
  • Lysosomes serving as the last vesicle in the matured endocytic pathway typically contain hydrolytic enzymes which digest the contents of the late endosomes.
  • Other endosomes continue to a pathway of recycling endosomes, where the contents are recycled back to the cell surface.
  • pH-independent when used in reference to a molecule or moiety, refer means that as the endosomal compartment is acidified, the binding affinity of the molecule or moiety to its target molecule does not change sufficiently to enable dissociation in the endosome with the target molecule.
  • the referenced molecule or moiety has the same or similar affinity to its target molecule at extracellular pH and at an endosomal pH.
  • pH-independent molecules or moieties do not include pH-dependent molecules or moieties, since the binding affinity of pH-dependent molecules or moieties to its target molecule changes as it enters and proceeds through the endosomal pathway, for example, to enable dissociation in the endosome with the target molecule to some degree, or the referenced molecule or moiety has a different affinity at extracellular pH and at an endosomal pH.
  • engineered when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences and is in a form suitable for use within genetically engineered protein production systems.
  • engineered molecules are those that are separated from their natural environment and include cDNA and genomic clones (i.e., a prokaryotic or eukaryotic cell with a vector containing a fragment of DNA from a different organism).
  • Engineered DNA molecules of the present invention are free of other genes with which they are ordinarily associated but can include naturally occurring or non-naturally occurring 5 ’and 3’ untranslated regions such as enhancers, promoters, and terminators.
  • An “engineered” polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue.
  • the engineered polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, e.g., greater than 90% pure, greater than 95% pure, more preferably greater than 98% pure or greater than 99% pure.
  • engineered does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers, heterodimers and multimers, heteromultimers, or alternatively glycosylated, carboxylated, modified, or derivatized forms.
  • An “engineered” peptide or protein is a polypeptide that is distinct from a naturally occurring polypeptide structure, sequence, or composition.
  • Engineered peptides include non- naturally occurring, artificial, isolated, synthetic, designed, modified, or recombinantly expressed peptides.
  • Provided herein are engineered TfR-binding peptides, variants, or fragments thereof. These engineered TfR-binding peptides can be further linked to a target-binding moiety or a half-life extending moiety, or can be further linked to an active agent or detectable agent, or any combination of the foregoing.
  • Polypeptides of the disclosure include polypeptides that have been modified in any way, for example, to: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, (5) alter binding affinity at certain pH values, and (6) confer or modify other physicochemical or functional properties.
  • single or multiple amino acid substitutions e.g., conservative amino acid substitutions
  • a “conservative amino acid substitution” can refer to the substitution in a polypeptide of an amino acid with a functionally similar amino acid.
  • a conserved amino acid substitution can comprise a non-natural amino acid. For example, substitution of an amino acid for a non-natural derivative of the same amino acid can be a conserved substitution.
  • polypeptide fragment and “truncated polypeptide” as used herein can refer to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion as compared to a corresponding full-length peptide or protein.
  • fragments are at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 600, at least 700, at least 800, at least 900 or at least 1000 amino acids in length.
  • fragments can also be, e.g., at most 1000, at most 900, at most 800, at most 700, at most 600, at most 500, at most 450, at most 400, at most 350, at most 300, at most 250, at most 200, at most 150, at most 100, at most 50, at most 45, at most 40, at most 35, at most 30, at most 25, at most 20, at most 15, at most 10, or at most 5 amino acids in length.
  • a fragment can further comprise, at either or both of its ends, one or more additional amino acids, for example, a sequence of amino acids from a different naturally-occurring protein (e.g., an Fc or leucine zipper domain) or an artificial amino acid sequence (e.g., an artificial linker sequence).
  • peptide or “polypeptide” in conjunction with “variant”, “mutant”, or “enriched mutant”, or “permuted enriched mutant” can refer to a peptide or polypeptide that can comprise an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and/or substituted into the amino acid sequence relative to another polypeptide sequence.
  • the number of amino acid residues to be inserted, deleted, or substituted is at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 225, at least 250, at least 275, at least 300, at least 350, at least 400, at least 450 or at least 500 amino acids in length.
  • Variants of the present disclosure include peptide conjugates or fusion molecules (e.g., peptide constructs or peptide complexes).
  • a “derivative” of a peptide or polypeptide can be a peptide or polypeptide that can have been chemically modified, e.g., conjugation to another chemical moiety such as, for example, polyethylene glycol, albumin (e.g., human serum albumin), phosphorylation, and glycosylation.
  • % sequence identity can be used interchangeably herein with the term “% identity” and can refer to the level of amino acid sequence identity between two or more peptide sequences or the level of nucleotide sequence identity between two or more nucleotide sequences, when aligned using a sequence alignment program.
  • 80% identity means the same thing as 80% sequence identity determined by a defined algorithm, and means that a given sequence is at least 80% identical to another length of another sequence.
  • the % identity is selected from, e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99% or more up to 100% sequence identity to a given sequence.
  • the % identity is in the range of, e.g., about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
  • the terms “% sequence homology” or “percent sequence homology” or “percent sequence identity” can be used interchangeably herein with the terms “% homology,” “% sequence identity,” or “% identity” and can refer to the level of amino acid sequence homology between two or more peptide sequences or the level of nucleotide sequence homology between two or more nucleotide sequences, when aligned using a sequence alignment program.
  • 80% homology means the same thing as 80% sequence homology determined by a defined algorithm, and accordingly a homologue of a given sequence has greater than 80% sequence homology over a length of the given sequence.
  • the % homology is selected from, e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or more up to 100% sequence homology to a given sequence.
  • the % homology is in the range of, e.g., about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
  • a protein or polypeptide can be “substantially pure,” “substantially homogeneous”, or “substantially purified” when at least about 60% to 75% of a sample exhibits a single species of polypeptide.
  • the polypeptide or protein can be monomeric or multimeric.
  • a substantially pure polypeptide or protein can typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and e.g., will be over 98% or 99% pure.
  • Protein purity or homogeneity can be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well known in the art.
  • higher resolution is provided by using high-pressure liquid chromatography (e.g., HPLC) or other high-resolution analytical techniques (e.g., LC-mass spectrometry).
  • the term “pharmaceutical composition” can generally refer to a composition suitable for pharmaceutical use in a subject such as an animal (e.g., human or mouse).
  • a pharmaceutical composition can comprise a pharmacologically effective amount of an active agent and a pharmaceutically acceptable carrier.
  • pharmacologically effective amount can refer to that amount of an agent effective to produce the intended biological or pharmacological result.
  • the term “pharmaceutically acceptable carrier” can refer to any of the standard pharmaceutical carriers, vehicles, buffers, and excipients, such as a phosphate buffered saline solution, or a buffered saline solution, 5% aqueous solution of dextrose, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents and/or adjuvants.
  • Suitable pharmaceutical carriers and formulations are described in Remington's Pharmaceutical Sciences, 21st Ed. 2005, Mack Publishing Co, Easton.
  • a “pharmaceutically acceptable salt” can be a salt that can be formulated into a compound for pharmaceutical use including, e.g., metal salts (sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
  • metal salts sodium, potassium, magnesium, calcium, etc.
  • salts of ammonia or organic amines can be formulated into a compound for pharmaceutical use including, e.g., metal salts (sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
  • the terms “treat”, “treating” and “treatment” can refer to a method of alleviating or abrogating a biological disorder and/or at least one of its attendant symptoms.
  • to “alleviate” a disease, disorder or condition for example, means reducing the severity and/or occurrence frequency of the symptoms of the disease, disorder, or condition.
  • references herein to “treatment” can include references to curative, palliative, and prophylactic or diagnostic treatment.
  • a cell of the present disclosure can be a eukaryotic cell or a prokaryotic cell.
  • a cell can be an epithelial cell.
  • a cell can be a microorganism, bacterial, yeast, fungal or algae cell.
  • a cell can be an animal cell or a plant cell.
  • An animal cell can include a cell from a marine invertebrate, fish, insects, amphibian, reptile, or mammal.
  • a mammalian cell can be obtained from a primate, ape, equine, bovine, porcine, canine, feline, or rodent.
  • a mammal can be a primate, ape, dog, cat, rabbit, ferret, or the like.
  • a rodent can be a mouse, rat, hamster, gerbil, hamster, chinchilla, or guinea pig.
  • a bird cell can be from a canary, parakeet, or parrots.
  • a reptile cell can be from a turtles, lizard, or snake.
  • a fish cell can be from a tropical fish.
  • the fish cell can be from a zebrafish (e.g., Danino rerid).
  • a worm cell can be from a nematode (e.g., C. elegans).
  • An amphibian cell can be from a frog.
  • An arthropod cell can be from a tarantula or hermit crab.
  • a mammalian cell can also include cells obtained from a primate (e.g., a human or a non-human primate).
  • a mammalian cell can include a blood cell, a stem cell, an epithelial cell, connective tissue cell, hormone secreting cell, a nerve cell, a skeletal muscle cell, or an immune system cell.
  • the term “vector,” generally refers to a DNA molecule capable of replication in a host cell and/or to which another DNA segment can be operatively linked so as to bring about replication of the attached segment.
  • a plasmid is an exemplary vector.
  • the term “subject,” generally refers to a human or to another animal. A subject can be of any age, for example, a subject can be prenatal, newborn, an infant, a toddler, a child, a pre-adolescent, an adolescent, an adult, or an elderly individual.
  • Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are in relation to the other endpoint, and independently of the other endpoint. The term “about” as used herein refers to a range that is 15% plus or minus from a stated numerical value within the context of the particular usage. For example, about 10 can include a range from 8.5 to 11.5.
  • the selective depletion complexes of the present disclosure can comprise one or more peptides.
  • a selective depletion complex of the present disclosure can comprise a receptor-binding peptide (e.g., a TfR-binding peptide or a PD-L1 -binding peptide) and a targetbinding peptide (e.g., a target-binding EGF variant).
  • a receptor-binding peptide e.g., a TfR-binding peptide or a PD-L1 -binding peptide
  • a targetbinding peptide e.g., a target-binding EGF variant
  • two or more peptides can be connected via a linker.
  • the peptides of the present disclosure can be used in a method of selectively depleting a target molecule.
  • the peptides of the present disclosure e.g., TfR-binding peptide, an EGFR target-binding peptide, or a peptide comprising a TfR-binding peptide linked to an EGFR target-binding peptide
  • a peptide as disclosed herein can contain only one lysine residue, or no lysine residues. In some instances, one or more or all of the lysine residues in the peptide are replaced with arginine residues. In some instances, one or more or all of the methionine residues in the peptide are replaced by leucine or isoleucine. One or more or all of the tryptophan residues in the peptide can be replaced by phenylalanine or tyrosine. In some instances, one or more or all of the asparagine residues in the peptide are replaced by glutamine.
  • one or more or all of the aspartic acid residues can be replaced by glutamic acid residues. In some instances, one or more or all of the lysine residues in the peptide are replaced by alanine or arginine.
  • the N-terminus of the peptide is blocked or protected, such as by an acetyl group or a te/7-butyloxycarbonyl group. Alternatively or in combination, the C-terminus of the peptide can be blocked or protected, such as by an amide group or by the formation of an ester (e.g., a butyl or a benzyl ester).
  • the peptide is modified by methylation on free amines. For example, full methylation is accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
  • the peptide comprises an amino acid sequence SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • a dipeptide GS can be added as the first two N-terminal amino acids, for example as shown in SEQ ID NO: 1 - SEQ ID NO: 64, or such N-terminal dipeptide GS can be absent as shown in SEQ ID NO: 96 and SEQ ID NO: 65 - SEQ ID NO: 128 or can be substituted by any other one or two amino acids.
  • a dipeptide comprising GS is used as a linker or used to couple to a linker to form a peptide conjugate or fusion molecules such as a peptide construct or peptide complex.
  • the peptide comprising the amino acid sequence of any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241 can also comprise a dipeptide comprising GS used as a linker or used to couple to a linker to form a peptide conjugate or fusion molecules such as a peptide construct or peptide complex.
  • the linker comprises a G x S y (SEQ ID NO: 130) peptide, wherein x and y independently are any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 and the G and S residues are arranged in any order.
  • the peptide linker comprises (GS)x (SEQ ID NO: 131), wherein x can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
  • the peptide linker comprises GGSSG (SEQ ID NO: 132), GGGGG (SEQ ID NO: 133), GSGSGSGS (SEQ ID NO: 134), GSGG (SEQ ID NO: 135), GGGGS (SEQ ID NO: 136), GGGS (SEQ ID NO: 129), GGS (SEQ ID NO: 137), GGGSGGGSGGGS (SEQ ID NO: 138), or a variant or fragment thereof or any number of repeats and combinations thereof.
  • KKYKPYVPVTTN (SEQ ID NO: 139) from DkTx
  • EPKSSDKTHT (SEQ ID NO: 140) from human IgG3
  • the peptide linker comprises GGGSGGSGGGS (SEQ ID NO: 141) or a variant or fragment thereof or any number of repeats and combinations thereof. It is understood that any of the foregoing linkers or a variant or fragment thereof can be used with any number of repeats or any combinations thereof. It is also understood that other peptide linkers in the art or a variant or fragment thereof can be used with any number of repeats or any combinations thereof.
  • the linker between the TfR- binding and target-binding peptides (e.g., EGFR-b inding peptides) within the selective depletion complex is at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36 at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50
  • a peptide or peptide complex as described herein comprises a TfR-b inding peptide comprising an amino acid sequence set forth in any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • a TfR-binding peptide as disclosed herein can be a fragment comprising a contiguous fragment of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 that is at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36 at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46,
  • the peptides as described herein that are capable of targeting and binding to a TfR comprise no more than 80 amino acids in length, or no more than 70, no more than 60, no more than 40, no more than 35, no more than 30, no more than 25, no more than 20, no more than 15, or no more than 10 amino acids in length.
  • the peptides as described herein that are capable of targeting and binding to a target molecule comprise no more than 80 amino acids in length, or no more than 70, no more than 60, no more than 50, no more than 40, no more than 35, no more than 30, no more than 25, no more than 24, no more than 23, no more than 22, no more than 21, no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, or no more than 10 amino acids in length.
  • peptides can be conjugated to, linked to, or fused to a carrier or a molecule with targeting or homing function for a cell of interest or a target cell.
  • peptides can be conjugated to, linked to, or fused to a molecule that extends halflife or modifies the pharmacodynamic and/or pharmacokinetic properties of the peptides, or any combination thereof.
  • a peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues, such as Arg or Lys, or any combination thereof.
  • one or more lysine residues in the peptide are replaced with arginine residues.
  • peptides comprise one or more Arg patches.
  • a peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 histidine residues.
  • the peptides of the present disclosure can further comprise neutral amino acid residues.
  • the peptide has 35 or fewer neutral amino acid residues.
  • the peptide has 81 or fewer neutral amino acid residues, 70 or fewer neutral amino acid residues, 60 or fewer neutral amino acid residues, 50 or fewer neutral amino acid residues, 40 or fewer neutral amino acid residues, 36 or fewer neutral amino acid residues, 33 or fewer neutral amino acid residues, 30 or fewer neutral amino acid residues, 25 or fewer neutral amino acid residues, or 10 or fewer neutral amino acid residues.
  • the peptides of the present disclosure can further comprise negative amino acid residues.
  • the peptide has 6 or fewer negative amino acid residues, 5 or fewer negative amino acid residues, 4 or fewer negative amino acid residues, 3 or fewer negative amino acid residues, 2 or fewer negative amino acid residues, or 1 or fewer negative amino acid residues.
  • negative amino acid residues can be selected from any negatively charged amino acid residues, in some embodiments, the negative amino acid residues are either E, or D, or a combination of both E and D.
  • a three-dimensional or tertiary structure of a peptide is primarily comprised of beta-sheets and/or alpha-helix structures.
  • designed or engineered TfR-b inding peptides or target-binding of the present disclosure are small, compact peptides or polypeptides stabilized by intra-chain disulfide bonds (e.g., mediated by cysteines) to form cystine and a hydrophobic core.
  • engineered TfR-b inding peptides have structures comprising helical bundles with at least one disulfide bridge between each of the alpha helices, thereby stabilizing the peptides.
  • the engineered TfR-b inding peptides or target-binding peptides comprise structures with three alpha helices and three intra-chain disulfide bonds, one between each of the three alpha helices in the bundle of alpha helices.
  • peptide sequences capable of binding to a receptor (e.g., a transferrin receptor or PD-L1 (also known as programmed death-ligand 1)).
  • a receptor e.g., a transferrin receptor or PD-L1 (also known as programmed death-ligand 1)
  • the peptide capable of binding a receptor may be referred to as a receptor-binding peptide.
  • a receptor-binding peptide may bind to a recycled receptor that undergoes recycling via a recycling pathway.
  • the depletion of a selected target (e.g., EGFR) by the SDCs described herein is dependent on the normal trafficking and cycling behavior of the recycling receptor in cells to which the recycling receptor-binding peptide the in the SDC is bound.
  • the recycled receptor may be endocytosed into an early endosome and packaged into a recycling endosome prior to maturation of the early endosome into a late endosome.
  • the recycling endosome containing the recycled receptor may fuse with a cell membrane and return the recycled receptor to the cell surface.
  • a receptor-binding peptide of the present disclosure may remain bound to the receptor during the recycling process, thereby recycling the receptor-binding peptide as well.
  • a receptor-binding peptide examples include transferrin receptor, programmed death-ligand 1, cation-independent mannose 6 phosphate receptor (CI-M6PR), asialoglycoprotein receptor (ASGPR), CXCR7, folate receptor, or Fc receptors (including but not limited to neonatal Fc receptor (FcRn) or FcyRIIb).
  • a receptorbinding peptide of the present disclosure may comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, an scFv, an (scFv)2, a DARPin, or an affibody.
  • receptor binding can be achieved by engineering an Fc domain for improved binding to an existing Fc receptor, e.g., FcRn or FcyRIIb, or for novel binding to a non-native receptor, e.g., TfR.
  • the receptor-binding peptide may comprise a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • receptor binding can be achieved by conjugation of a target-binding peptide or peptide complex with a sugar or other small molecule that is bound by the cellular receptor (e.g., mannose-6-phosphonate or N-acetylgalactosamine that bind with CI-M6PR and ASGPR, respectively).
  • a target-binding peptide or peptide complex with a sugar or other small molecule that is bound by the cellular receptor (e.g., mannose-6-phosphonate or N-acetylgalactosamine that bind with CI-M6PR and ASGPR, respectively).
  • a receptor-binding peptide of the present disclosure can bind to the receptor (e.g., a recycled receptor) with an affinity that is pH-independent.
  • a receptor-binding peptide can bind the receptor at an extracellular pH (about pH 7.4) with an affinity that is substantially the same the binding affinity at an endocytic pH (such as about pH 5.5 or about pH 6.5).
  • a receptor-binding peptide can bind the receptor at an extracellular pH (about pH 7.4) with an affinity that is lower than the binding affinity at an endocytic pH (such as about pH 5.5 or about pH 6.5).
  • a receptor-binding peptide can bind the receptor at an extracellular pH (about pH 7.4) with an affinity that is higher than the binding affinity at an endocytic pH (such as about pH 5.5 or about pH 6.5).
  • the binding affinity of a receptor-binding peptide for the receptor at extracellular pH (about pH 7.4) and the binding affinity of a receptor-binding peptide for the receptor at endocytic pH (about pH 5.5) can differ by no more than about 1%, no more than about 2%, no more than about 3%, no more than about 4%, no more than about 5%, no more than about 6%, no more than about 7%, no more than about 8%, no more than about 9%, no more than about 10%, no more than about 12%, no more than about 15%, no more than about 17%, no more than about 20%, no more than about 25%, no more than about 30%, no more than about 35%, no more than about 40%, no more than about 45%, or no more than about
  • the affinity of the receptor-binding peptide for the receptor at pH 7.4 and at pH 5.5 can differ by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15 -fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40- fold, or no more than 50-fold.
  • a receptor-binding peptide e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, SEQ ID NO: 1 - SEQ ID NO: 64, SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241) can be modified to remove one or more histidine amino acids in the receptor-binding interface, thereby reducing the pH-dependence of the binding affinity of the receptor-binding peptide for the receptor.
  • a receptor-binding peptide e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, SEQ ID NO: 1 - SEQ ID NO: 64, SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241) can lack histidine amino acids in the receptor-binding interface.
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at extracellular pH (about pH 7.4).
  • KD equilibrium dissociation constant
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at endosomal pH (about pH 5.5).
  • KD equilibrium dissociation constant
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at endosomal pH (about pH 5.8).
  • KD equilibrium dissociation constant
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • a receptor-binding peptide with pH- independent binding can bind to the receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • a receptorbinding peptide with pH-independent binding can bind to the receptor with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.8.
  • KD equilibrium dissociation constant
  • the affinity of the receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of the receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with a dissociation rate constant (k o ff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 7.4.
  • k o ff or kd dissociation rate constant
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ no more than 5xl0’ 4 s’ 1 , or no more than 2xl0’ 4 s’ 1 at pH 5.5.
  • koff or kd dissociation rate constant
  • a receptor-binding peptide with pH-independent binding can bind to the receptor with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 5.8.
  • koff or kd dissociation rate constant
  • the dissociation rate constant (k o ff or kd) of the receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25- fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of the receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the receptor-binding peptide can bind to the receptor with an affinity that is pH-dependent.
  • the receptor-binding molecule can bind to the receptor with higher affinity at extracellular pH (about pH 7.4) and with lower affinity at endosomal pH (about pH 5.5), thereby releasing the selective depletion complex from receptor upon internalization and acidification of the endosomal compartment.
  • the recycling receptor may be TfR.
  • a peptide capable of binding transferrin receptor may bind TfR or any of the known TfR homologs, including TfRl, TfR2, soluble TfR, or any combination or fragment (e.g., ectodomain) thereof.
  • a peptide capable of binding a transferrin receptor or a TfR homolog can be referred to herein as a transferrin receptor-binding peptide or a TfR-binding peptide.
  • peptides disclosed herein can penetrate, cross, or enter target cells in a TfR-mediated manner.
  • These cell layers or cells can include TfR-expressing endothelial cells, epithelial cells, and TfR-expressing cells of various tissues or organs such as tumor cells, brain cells, cancerous or tumor cells, liver cells (e.g., hepatocytes (HCs), hepatic stellate cells (HSCs), Kupffer cells (KCs), or liver sinusoidal endothelial cells (LSECs)), pancreas cells, colon cells, ovarian cells, breast cells, spleen cells, bone marrow cells, and/or lung cells, or any combination thereof.
  • liver cells e.g., hepatocytes (HCs), hepatic stellate cells (HSCs), Kupffer cells (KCs), or liver sinusoidal endothelial cells (LSECs)
  • pancreas cells colon cells, ovarian cells, breast cells, spleen cells, bone marrow cells, and/or lung cells, or any combination thereof.
  • a TfR-binding peptide of the present disclosure may comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, an scFv, an (scFv)2, a DARPin, or an affibody.
  • the TfR-binding peptide may comprise a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • the peptides as discloses herein can cross cellular layers or barriers (e.g., BBB) or cell membranes via, for example, TfR-mediated vesicular transcytosis and TfR-mediated endocytosis, respectively.
  • BBB cellular layers or barriers
  • the peptides of the present disclosure can also bind to additional target proteins on cells such as cancer cells.
  • a peptide is a peptide or peptide complex comprising a TfR-binding peptide conjugated to, linked to, or fused to a targeting moiety or an active agent (e.g., a therapeutic or diagnostic agent) such as a small molecule or a peptide that has an affinity for an additional target protein (e.g., receptor or enzyme).
  • an active agent e.g., a therapeutic or diagnostic agent
  • the TfR-binding peptide is linked to a target-binding peptide and enables or promotes TfR-mediated transcytosis of the target-binding peptide across the BBB or TfR-mediated endocytosis into a cell.
  • a peptide complex comprising the TfR-binding peptide and a target-binding peptide can target a specific cell or tissue in the CNS and exert a biological effect (e.g., binding a target protein) upon reaching said cell or tissue.
  • a peptide complex of the present disclosure exerts a biological effect that is mediated by the TfR-binding peptide, the target-binding peptide, an active agent, or a combination thereof.
  • a TfR-binding peptide complex of the present disclosure comprising one target-binding peptides can transport and/or deliver target molecules into cells that express TfR (e.g., deliver target molecules into endosomes).
  • the TfR-binding peptide accumulates in tissues in the CNS. In some cases, off-target effects are reduced due to CNS-specific accumulation. In some cases, the TfR-binding peptide accumulates in tissue outside of the CNS (e.g., liver, kidney, spleen, or skin).
  • the cells expressing TfR are tumor cells and the TfR-binding peptide complex delivers anti-tumor agents to these tumor cells.
  • the anti-tumor agents alone show no or only very limited therapeutic efficacy against the tumor cells; however, when the anti -tumor agents are combined with the TfR-binding peptides of the present disclosure as, for example, a peptide complex, the therapeutic efficacy of these anti-tumor agents is significantly improved.
  • the TfR-binding peptides of the present disclosure can induce a biologically relevant response.
  • a TfR-binding peptide conjugated to a target-binding peptide can selectively deplete a soluble target molecule or a cell surface target molecule.
  • the biologically relevant response can be induced after intravenous, subcutaneous, peritoneal, intracranial, or intramuscular dose, and in some embodiments, after a single intravenous, subcutaneous, peritoneal, intracranial, or intramuscular dose.
  • the TfR-binding peptides can be used in combination with various other classes of therapeutic compounds used to treat and/or prevent pain, neuropathic pain or other neurological disorders such as neurodegenerative disorders, infectious diseases, immunological disorders (e.g., autoimmune diseases) or lysosomal storage diseases.
  • Binding of the herein described peptides and peptide complexes e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes
  • TfR a cell layer or barrier
  • BBB e.g., via TfR-mediated vesicular transcytosis
  • a cell membrane e.g., via TfR-mediated endocytosis
  • diseases associated with mutations e.g., mutations causing constitutive activity, resistance to treatment, or dominant negative activity in soluble or surface proteins in a subject (e.g., a human).
  • Binding of the herein described peptides and peptide complexes e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes
  • TfR a cell layer or barrier
  • BBB e.g., via vesicular transcytosis
  • a cell membrane e.g., via endocytosis
  • TfR-binding peptides of the present disclosure can bind to any of the known TfR homologs, including TfRl, TfR2, soluble TfR, or any combination or fragment (e.g., ectodomain) thereof.
  • TfR can refer to any known homolog, derivative, fragment, or member of the TfR family including TfRl, TfR2, and a soluble TfR.
  • peptides are capable of binding to one, one or more, or all TfR homologs.
  • peptides of the present disclosure can bind to a TfR and promote a particular biological effect such as vesicular transcytosis.
  • TfR-binding peptides of the present disclosure including peptides and peptide complexes with amino acid sequences set forth in SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, and SEQ ID NO: 1 - SEQ ID NO: 64, and any derivatives or variant thereof, prevent or decrease the binding of endogenous TfR binders (e.g., transferrin or any derivatives such as apo-transferrin or holo-transferrin) to TfR.
  • endogenous TfR binders e.g., transferrin or any derivatives such as apo-transferrin or
  • peptides or peptide complexes of the present disclosure comprise derivatives and variants with at least 40% homology, at least 50% homology, at least 60% homology, at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to amino acid sequences set forth in SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, and SEQ ID NO: 1 - SEQ ID NO: 64.
  • the interface residues of the TfR-binding peptides of the present disclosure can be divided between two largely helical domains of the peptide.
  • the interface residues can comprise residues corresponding to residues 5-25 (e.g., and comprising corresponding residues G5, A7, S8, Ml 1, N14, L17, E18, and E21), with reference to SEQ ID NO: 32, or corresponding to residues 35-51 (e.g., and comprising corresponding residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51), with reference to SEQ ID NO: 32, or both.
  • residues corresponding to residues 5-25 e.g., and comprising corresponding residues G5, A7, S8, Ml 1, N14, L17, E18, and E21
  • residues 35-51 e.g., and comprising corresponding residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51
  • the interface residues can comprise residues corresponding to residues 5-25 (e.g., and comprising corresponding residues G5, A7, S8, Mi l, N14, L17, E18, and E21), with reference to SEQ ID NO: 32, or corresponding to residues 35-51 (e.g., and comprising corresponding residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51), with reference to SEQ ID NO: 32.
  • residues corresponding to residues 5-25 e.g., and comprising corresponding residues G5, A7, S8, Mi l, N14, L17, E18, and E21
  • residues 35-51 e.g., and comprising corresponding residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51
  • a TfR-binding peptide can comprise a fragment of a peptide provided herein, wherein the fragment comprises the minimum interface residues for binding, for example residues corresponding to residues 5-25 (e.g., and comprising corresponding residues G5, A7, S8, Ml 1, N14, L17, E18, and E21), with reference to SEQ ID NO: 32, or corresponding to residues 35-51 (e.g., and comprising corresponding residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51), with reference to SEQ ID NO: 32.
  • residues corresponding to residues 5-25 e.g., and comprising corresponding residues G5, A7, S8, Ml 1, N14, L17, E18, and E21
  • residues 35-51 e.g., and comprising corresponding residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51
  • the TfR-binding peptide is a peptide having the sequence set forth in SEQ ID NO: 32 comprising the TfR-binding residues corresponding to residues G5, A7, S8, Mi l, N14, L17, E18, and E21 of the domain and corresponding to residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51 of the second domain, with reference to SEQ ID NO: 32.
  • TfR-binding peptides bind to TfR with equal, similar, or greater affinity (e.g., lower equilibrium dissociation constant KD) as compared to endogenous molecules (e.g., transferrin, holotransferrin (iron-bound transferrin), apotransferrin (transferrin not bound to iron), or any other endogenous TfR ligands) or other exogenous molecules.
  • endogenous molecules e.g., transferrin, holotransferrin (iron-bound transferrin), apotransferrin (transferrin not bound to iron), or any other endogenous TfR ligands
  • the peptide can have an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM.
  • KD equilibrium dissociation constant
  • the peptide can have an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM.
  • KD equilibrium dissociation constant
  • the peptide can have a dissociation rate constant (k o ff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 .
  • k o ff or kd dissociation rate constant
  • peptide transport by TfR is improved by having a lower affinity (e.g., a higher equilibrium dissociation constant KD) as compared to endogenous molecules. In some embodiments, peptide transport by TfR is improved by having a faster off rate or higher k o ff than endogenous molecules. In some embodiments, the dissociation rate constant (kd or koff) is similar to that of transferrin. In some embodiments, peptide transport is improved by having a faster on rate or a higher k on , optionally such as higher than that of transferrin.
  • one or more conserved residues at the transferrin (Tf)-TfR- binding interface are also present in the amino acid sequences of the peptides described herein.
  • a TfR-binding peptide has an off rate that is slower than the recycling rate of TfR, such that the TfR-binding peptide is likely to remain bound to TfR during the recycling process.
  • the TfR-binding peptide may have a half-life of dissociation that is no faster than 1 minute, no faster than 2 minutes, no faster than 3 minutes, no faster than 4 minutes, no faster than 5 minutes, no faster than 7 minutes, no faster than 10 minutes, no faster than 15 minutes, or no faster than 20 minutes, no faster than 30 minutes, no faster than 45 minutes, no faster than 60 minutes, no faster than 90 minutes, or no faster than 120 minutes.
  • the TfR-binding peptide may have a half-life of dissociation that is from about 1 minute to about 20 minutes, from about 2 minutes to about 15 minutes, from about 2 minutes to about 10 minutes, or from about 5 minutes to about 10 minutes.
  • a rate of dissociation of the target-binding peptide from the target molecule is faster than a recycling rate of the cellular receptor.
  • a half-life of dissociation of the target molecule binding-binding peptide from the target molecule is less than 10 seconds, less than 20 seconds, less than 30 seconds, less than 1 minute, less than 2 minutes, less than 5 minutes, less than 10 minutes, less than 20 minutes, less than 30 minutes, less than 45 minutes, or less than 60 minutes in endosomal conditions.
  • TfR-binding peptides that exhibit an improved TfR receptor binding show improved transcytosis function, improved endocytosis function, improved recycling, or combinations thereof. In some embodiments, TfR-binding peptides that exhibit an improved TfR receptor binding show no or small changes in transcytosis function, endocytosis function, recycling, or combinations thereof. In some embodiments, TfR-binding peptides that exhibit an improved TfR receptor binding show reduced transcytosis function, reduced endocytosis function, reduced recycling, or combinations thereof.
  • the TfR-b inding peptide binds at a site of high homology between human and murine TfR, including one or more, or all, of the amino acid domains corresponding to residues 506-510, 523-531, and 611-662 of the human TfR (SEQ ID NO: 190, MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVT KPKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGEDFPA ARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVENQFREF KLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLV HANFGTKKDFEDLYTPVNGSIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNA ELS
  • the regions of TfR to which the peptides disclosed herein or variants thereof bind all or in part to such TfR domains.
  • the peptides disclosed herein bind to any one, any two, or all three of the TfR regions of high homology including the amino acid domains corresponding to residues 506-510, 523-531, and 611-662 of the human TfR (SEQ ID NO: 190).
  • the peptides disclosed herein bind at least to the domain corresponding to residues 611-662 of the human TfR.
  • the KA and KD values of a TfR-binding peptide can be modulated and optimized (e.g., via amino acid substitutions) to provide an optimal ratio of TfR-binding affinity and efficient transcytosis function.
  • peptides disclosed herein or variants thereof bind to TfR at residues found in the binding interface (e.g., the binding domain or the binding pocket) of TfR with other exogenous or endogenous ligands (e.g., transferrin (Tf), Tf derivatives, or Tf-like peptides or proteins).
  • Tf transferrin
  • Tf derivatives Tf derivatives
  • Tf-like peptides or proteins Tf-like peptides or proteins
  • a peptide disclosed herein or a variant thereof, which binds to TfR comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to a sequence that binds residues of TfR, which makeup the binding pocket.
  • a peptide disclosed herein or a variant thereof, which binds to TfR comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to an endogenous or exogenous polypeptide known to bind TfR, for example, endogenous Transferrin or any one of the peptides listed in TABLE 1.
  • a peptide described herein binds to a protein of interest, which comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to TfR, a fragment, homolog, or a variant thereof.
  • peptides disclosed herein or variants thereof bind regions of TfR that comprise the amino acid residues corresponding to residues 506-510, 523-531, and 611-662 (the numbering of these amino acid residues is based on the following Uniprot reference protein sequence of endogenous human TFRC UniProtKB - P02786 (SEQ ID NO: 190, TFR1 HUMAN)).
  • the regions of TfR to which the peptides disclosed herein or variants thereof bind overlap with those of Tf, a fragment, homolog, or a variant thereof.
  • a nucleic acid, vector, plasmid, or donor DNA comprises a sequence that encodes a peptide, peptide construct, a peptide complex, or variant or functional fragment thereof, as described in the present disclosure.
  • TfR-binding motifs e.g., conserved binding motifs
  • certain parts or fragments of TfR-binding motifs can be grafted onto a peptide or peptide complex with a sequence of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • peptides can cause TfR to be degraded, prevent TfR from localizing to a cell’s nucleus, or prevent TfR from interacting with transferrin or transferrin-like proteins.
  • a peptide can be selected for further testing or use based upon its ability to bind to the certain amino acid residue or motif of amino acid residues.
  • the certain amino acid residue or motif of amino acid residues in TfR can be identified an amino acid residue or sequence of amino acid residues that are involved in the binding of TfR to Tf.
  • a certain amino acid residue or motif of amino acid residues can be identified from a crystal structure of the TfR:Tf complex.
  • peptides e.g., CDPs
  • the peptides, peptide complexes e.g., peptide conjugates or fusion peptides
  • selective delivery complexes comprising one or more of the amino acid sequences set forth in SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 can bind to a protein of interest.
  • the protein of interest is a TfR.
  • the peptides and peptide complexes that bind to a TfR comprise at least one of the amino acid sequences set forth in SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • peptides, peptide complexes (e.g., peptide conjugates and fusion molecules) of the present disclosure that bind to a TfR comprise peptide derivatives or variants having at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to amino acid sequences set forth in SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • peptides or peptide complexes that bind to a TfR can comprise peptide derivatives or variants having at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to the amino acid sequence set forth in SEQ ID NO: 96.
  • peptides or peptide complexes that bind to a TfR can comprise peptide derivatives or variants having at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to the amino acid sequence set forth in SEQ ID NO: 66.
  • peptides or peptide complexes that bind to a TfR can comprise peptide derivatives or variants having at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to the amino acid sequence set forth in SEQ ID NO: 65.
  • TABLE 1 lists exemplary peptide sequences according to the methods and compositions of the present disclosure.
  • a TfR-binding peptide disclosed herein comprises REGCAX1RCX2KYX4DEX2X3KCX3ARMMSMSNTEEDCEQEX2EDX2X2YCX2X3X5CX5X1 X 4 (SEQ ID NO: 167) or
  • GSREGCAX1RCX2KYX4DEX2X3KCX3ARMMSMSNTEEDCEQEX2EDX2X2YCX2X3X5CX5 X1X4 (SEQ ID NO: 148), wherein Xi can be independently selected from S, T, D, or N, X2 can be independently selected from A, M, I, L, or V, X3 can be independently selected from D, E, N, Q, S, or T, X 4 can be independently selected from D, E, H, K, R, N, Q, S, or T, and X5 can be independently selected from H, K, R, N, Q, S, or T.
  • a TfR-binding peptide disclosed herein comprises REXICX2X3RCX4KYX5DEX6X 7 KCX 8 ARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 168) or
  • GSREX1CX2X3RCX4KYX 5 DEX6X7KCX 8 ARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 149), wherein Xi, X2, X3, X4, X5, Xe, X7 and X 8 are TfR binding interface residues and can independently be any amino acid.
  • a TfR-binding peptide disclosed herein comprises REGCASRCMKYNDELEKCEARMMSMSNTEEDCEQEXIEDX2X3YCX4X5X6CX 7 X 8 X9 (SEQ ID NO: 169) or
  • GSREGCASRCMKYNDELEKCEARMMSMSNTEEDCEQEXIEDX2X3YCX4X5X6CX 7 X 8 X9 (SEQ ID NO: 150), wherein Xi, X2, X3, X4, X5, Xe, X 7 , X 8 , and X9 are TfR binding interface residues and can independently be any amino acid.
  • a TfR-binding peptide disclosed herein comprises REX1CX2X3RCX4KYX5DEX6X7KCX8ARMMSMSNTEEDCEQEX9EDX10X11YCX12X13X13C Xi 5 Xi 6 Xi7 (SEQ ID NO: 170) or GSREX1CX2X3RCX4KYX5DEX6X7KCX8ARMMSMSNTEEDCEQEX9EDX10X11YCX12X13X1 3 CX1 5 X16X17 (SEQ ID NO: 151), wherein Xi, X 2 , X3, X 4 , X 5 , X6, X 7 , Xs, X 9 , X10, Xn, Xi 2 , Xi 3 , X14, X15, Xi6 and X17 are TfR binding interface residues and can independently be any amino acid.
  • a TfR-binding peptide disclosed herein comprises REGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 96) or GSREGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 32).
  • a TfR-binding peptide disclosed herein comprises REGCASRCTKYNAELEKCEARVMSMSNTEEDCEQELEDLLHCLDHCHSQ (SEQ ID NO: 66) or GSREGCASRCTKYNAELEKCEARVMSMSNTEEDCEQELEDLLHCLDHCHSQ (SEQ ID NO: 2).
  • a TfR-binding peptide disclosed herein comprises REGCASRCTKYNAELEKCEARVSSMSNTEETCVQELFDLLHCVDHCVSQ (SEQ ID NO: 65) or GSREGCASRCTKYNAELEKCEARVSSMSNTEETCVQELFDLLHCVDHCVSQ (SEQ ID NO: 1).
  • a TfR-binding peptide disclosed herein comprises X1X2X3X4GX5ASX6X7MX8X9NX10X11LEX12X13EX14X15X16X17X18X19X20X21X22X23X24X25X26 X27X28X29X30X31X32X33X34X35X36X37X38X39X40X41X42X43 (SEQ ID NO: 152), wherein Xi, X 2 , X3, X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X10, Xn, X12, X13, X14,X15, X16, X17, X18, X19,X 2 0, X21, X 2 2, X23, X 24 , X25, X26, X27, X28, X29, X30,
  • a TfR-binding peptide disclosed herein comprises XlX2X3X4X 5 X6X7X8X 9 XloXl 1X12X13X14X15X16X17X18X19X20X21X22X23X24X25X26X27X28X29X30 X31X32X33X34X35X36X37LX38X39LLX40X41LDHX42HSQ (SEQ ID NO: 153), wherein Xi, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X10, X11, X12,X13, X14, X15, X16, X17, X18,X19, X 2 0, X21,X 2 2, X23, X24, X25, X26, X27, X28, X29, X30
  • a TfR-binding peptide disclosed herein comprises
  • X27X28X29LX30X31LLX32X33LDHX34HSQ (SEQ ID NO: 154), wherein Xi, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20,X21, X 2 2, X 2 3, X 2 4, X 25 , X 2 6, X 2 7, X 2 8, X29, X30, X31, X32, X33, and X34 can independently be any amino acid.
  • a TfR-binding peptide or peptide complex disclosed herein comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence homology to any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO:
  • a TfR- binding peptide or peptide complex disclosed herein comprises any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64, or any variant, homolog, or functional fragment thereof.
  • a peptide that binds to a TfR comprises the amino acid sequence set forth in SEQ ID NO: 96 or SEQ ID NO: 32.
  • a peptide that binds to a TfR comprises the amino acid sequence set forth in SEQ ID NO: 66 or SEQ ID NO: 2. In some embodiments, a peptide that binds to a TfR comprises the amino acid sequence set forth in SEQ ID NO: 65 or SEQ ID NO: 1.
  • a TfR-binding peptide comprises canonical amino acid residues as surface interface residues at any one of the corresponding positions 5, 7, 8, 14, 17, 18, 21, 38, 42, 45, 46, 47, 50, 51, with reference to SEQ ID NO: 32 or a combination thereof.
  • a TfR-binding peptide comprises canonical amino acid residues as surface interface residues at any one of the corresponding positions G5, A7, S8, N14, L17, E18, E21, L38, L42, L45, D46, H47, S50, Q51, with reference to SEQ ID NO: 32 or a combination thereof.
  • the peptide or peptide complex of the present disclosure comprises at least one or more of these corresponding residues in SEQ ID NO: 96, SEQ ID NO:
  • Such peptides can accordingly be engineered with enhanced binding to TfR.
  • a TfR-binding peptide disclosed herein comprises XlX2X3X4GX 5 ASX6X7X 8 X9X10NXllX12LEX13X14EXl 5 X16X17Xl 8 X19X20X21X22X23X24X25X26X 2 7X2 8 X29X3OLX3IX32X33LX34X3 5 LDHX36X37SQ (SEQ ID NO: 155), wherein Xi, X2, X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X10, Xu, X12, X13, X14, X15, X16, X17, Xi 8 , X19, X20, X21, X22, X23, X 24 , X 25 , X 26 , X27, x 28 , X29,
  • a peptide as disclosed herein comprises a hydrophilic amino acid residue at any one of the corresponding positions 3, 4, 9, 11, 15, 16, 19, 23, 26, 28, 29, 30, 31, 32, 33, 35, 36, 37, 39, 40, with reference to SEQ ID NO: 32, or any combination thereof.
  • a peptide of the present disclosure comprises hydrophilic amino acid residues at the following corresponding positions: R3, E4, R9, K12, D15, E16, K19, R23, S26, S28, N29, T30, E31, E32, D33, E35, Q36, E37, E39, D40, with reference to SEQ ID NO: 32, or any combination thereof.
  • any one of or any combination of corresponding positions R3, E4, R9, K12, D15, E16, K19, R23, S26, S28, N29, T30, E31, E32, D33, E35, Q36, E37, E39, D40 with reference to SEQ ID NO: 32, can be mutated to another hydrophilic residue without significantly impacting solubility or TfR-binding.
  • a TfR-binding peptide disclosed herein comprises
  • a TfR-binding peptide disclosed herein comprises XiX2GCASX3CMX4YNX 5 X6LEX7CEAX8MMX9MXioXiiXi2Xi3Xi4Xi 5 CXi6Xi7Xi8LXi9X2oL LYCLDHCHSQ (SEQ ID NO: 171) or GSXiX2GCASX3CMX4YNX 5 X6LEX7CEAX8MMX9MXioXiiXi2Xi3Xi4Xi 5 CXi6Xi7Xi8LXi9X2 oLLYCLDHCHSQ (SEQ ID NO: 157), wherein Xi, X 2 , X3, X 4 , X 5 , X6, X 7 , X 8 , X 9 , Xio, Xn, Xi 2 , X13, X14, X15,
  • a peptide of the present disclosure comprises cysteine amino acid residues at corresponding positions 4, 8, 18, 32, 42, and 46 with reference to SEQ ID NO: 96. In some embodiments, a peptide of the present disclosure comprises cysteine amino acid residues at corresponding positions 6, 10, 20, 34, 44, and 48 with reference to SEQ ID NO: 32. In some embodiments, a peptide of the present disclosure comprises hydrophilic residues (e.g., D, E, H, K, R, N, Q, S, or T) at corresponding positions 15, 35, 39, 49, with reference to SEQ ID NO: 32, or any combination thereof.
  • hydrophilic residues e.g., D, E, H, K, R, N, Q, S, or T
  • a peptide of the present disclosure comprises hydrophilic amino acid residues at the following corresponding positions: D15, E35, E39, H49, with reference to SEQ ID NO: 32, or any combination thereof. In some embodiments, any one of or any combination of corresponding positions D15, E35, E39, H49 with reference to SEQ ID NO: 32, can be mutated to another hydrophilic residue without significantly impacting solubility or TfR-binding. In some embodiments, a TfR-binding peptide disclosed herein comprises. In some embodiments, a TfR-binding peptide disclosed herein comprises
  • GSREGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 159), wherein Xi, X2, X3, and X4 can be independently selected from D, E, H, K, R, N, Q, S, or T.
  • a peptide of the present disclosure comprises hydrophobic residues (e.g., A, M, I, L, V, F, W, or Y) at corresponding positions 15, 35, 39, 49, with reference to SEQ ID NO: 32, or any combination thereof.
  • hydrophobic residues e.g., A, M, I, L, V, F, W, or Y
  • a TfR-binding peptide disclosed herein comprises REGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 173) or GSREGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 160), wherein Xi, X2, X3, and X4 can be independently selected from A, M, I, L, V, F, W, or Y.
  • hydrophilic amino acid residues at any one of the corresponding positions 15, 35, 39, and 49, with reference to SEQ ID NO: 32 are associated with higher binding affinity for TfR (e.g., target engagement) and higher solubility.
  • mutation of an amino acid residue at any one of the corresponding positions 15, 35, 39, and 49, with reference to SEQ ID NO: 32, from a hydrophobic to a hydrophilic residue can lead to higher binding affinity for TfR (e.g., target engagement) and higher solubility.
  • a peptide of the present disclosure comprises hydrophobic residues (e.g., A, M, I, L, V, F, W, or Y) at corresponding positions 11, 25, 27, with reference to SEQ ID NO: 32, or any combination thereof.
  • a peptide of the present disclosure comprises hydrophilic residues (e.g., D, E, H, K, R, N, Q, S, or T) at corresponding positions 11, 25, 27, with reference to SEQ ID NO: 32, or any combination thereof.
  • hydrophobic amino acid residues at any one of the corresponding positions 11 , 25, and 27, with reference to SEQ ID NO: 32 are associated with higher binding affinity for TfR (e.g., target engagement) and higher solubility.
  • mutation of an amino acid residue at any one of the corresponding positions 11, 25, and 27, with reference to SEQ ID NO: 32, from a hydrophilic residue to a hydrophobic residue can lead to higher binding affinity for TfR (e.g., target engagement) and higher solubility.
  • a peptide of the present disclosure comprises hydrophobic amino acid residues at the corresponding positions Mi l, M25, M27, with reference to SEQ ID NO: 32, or any combination thereof.
  • a peptide comprises the hydrophobic amino acid residues at the corresponding positions Mi l, M25, and M27, with reference to SEQ ID NO: 32.
  • any combination of the corresponding positions Mi l, M25, and M27, with reference to SEQ ID NO: 32 can be mutated to another hydrophobic residue without significantly impacting solubility or TfR-binding.
  • a TfR-binding peptide disclosed herein comprises X1X2X3X4X 5 X6X7X 8 X9X1OMX11X12X13X14X1 5 X16X17X1 8 X19X2OX21X22X23MX24MX25X26X27X 2 8 X29X30X31X32X33X34X35X36X37X3 8 X39X40X41X42X43X44X45X46X47X 48 (SEQ ID NO: 161), wherein Xi, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , Xio, Xu , X12, X13, Xi 4 , X15, Xi 6 ,Xi 7 , Xi 8 , X19, X20, X21, X22, X23, X24,
  • a TfR-binding peptide disclosed herein comprises REGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 174) or GSREGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 162), wherein Xi, X 2 , and X3 can be independently selected from A, M, I, L, V, F, W, or Y.
  • a TfR-binding peptide disclosed herein comprises REGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 175) or GSREGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 163), wherein Xi, X2, and X3 can be independently selected from D, E, H, K, R, N, Q, S, or T.
  • a peptide of the present disclosure comprises an aliphatic amino acid residue (e.g., A, M, I, L, or V) at corresponding position 45, with reference to SEQ ID NO: 32.
  • a peptide of the present disclosure comprises an aromatic amino acid residue (e.g., F, W, or Y) at corresponding position 45, with reference to SEQ ID NO: 32.
  • an aliphatic amino acid residue at corresponding position 45, with reference to SEQ ID NO: 32 is associated with higher binding affinity to TfR.
  • a peptide comprises the aliphatic amino acid residue corresponding to L45, with reference to SEQ ID NO: 32.
  • mutation of an amino acid residue at corresponding position 45 from an aromatic residue to an aliphatic reside can lead to higher binding affinity for TfR (e.g., target engagement) and higher solubility.
  • mutating corresponding position L45, with reference to SEQ ID NO: 32, to another aliphatic residue may not significantly impact solubility or TfR-binding.
  • a TfR-binding peptide disclosed herein comprises
  • a TfR-binding peptide disclosed herein comprises GSREGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCXiDHCHSQ (SEQ ID NO: 165) or REGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCXiDHCHSQ (SEQ ID NO: 176), wherein Xi can be independently selected from A, M, I, L, or V.
  • a peptide of the present disclosure comprises GSREGCASRCMX1YNDELEX2CEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 166) or REGCASRCMX1YNDELEX2CEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 177), wherein Xi and X2 can be independently selected from K or R. In some embodiments, these residues at corresponding position 12 and 19, with reference to SEQ ID NO: 32, can be used for chemical conjugation to another molecule (e.g., an active or a detectable agent). In some embodiments, Xi and X2 are both R and chemical conjugation occurs at the N-terminus of the peptide.
  • a receptor-binding peptide may be derived from an antibody or antibody fragment.
  • a receptor-binding peptide may be derived from a single chain antibody fragment (scFv).
  • scFv single chain antibody fragment
  • TfR-binding peptides that may be incorporated into a selective depletion complex of the present disclosure include SEQ ID NO: 220
  • TfR-binding peptide may have a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 220 - SEQ ID NO: 222, or a fragment thereof.
  • a peptide of SEQ ID NO: 220 or SEQ ID NO: 221 may function as a pH- independent TfR-binding peptide.
  • a peptide of SEQ ID NO: 222 may function as a pH-dependent TfR-binding peptide.
  • mutations in any one or more of the amino acid residues of a peptide of the present disclosure can improve binding affinity of the peptide to TfR.
  • mutations in 5-80% of amino acid residues of a peptide of the present disclosure improve the binding affinity of the peptide to TfR.
  • mutations in 1-100%, 5-100%, or 5-50% of amino acid residues of a peptide of the present disclosure improve binding affinity of the peptide to TfR.
  • mutations in 15-50% of amino acid residues of a peptide of the present disclosure improve binding affinity of the peptide to TfR.
  • mutations in 15-30% of amino acid residues of a peptide of the present disclosure improve binding affinity of the peptide to TfR. In some embodiments, mutations in 25-30% of amino acid residues of a peptide of the present disclosure improve binding affinity of the peptide to TfR. For example, mutations in 14 of the 51 amino acid residues (27.5%) of a peptide having a sequence of SEQ ID NO: 32 can improve binding affinity of the peptide to TfR.
  • mutations in any one or more of the amino acid residues of a peptide of the present disclosure can lie at the binding interface of TfR.
  • a mutation to a peptide can improve binding affinity, which can be beneficial to binding and transcytosis of a peptide or peptide complex disclosed herein.
  • the peptides provided herein can have many mutations or few mutations to obtain optimal activity, wherein optimal activity is sufficient binding for engagement of the TfR, but not necessarily binding that is so strong as to preclude release of the peptide and/or peptide complex after transcytosis.
  • peptides of the present disclosure can comprise a number of mutations (also referred to as % mutated amino acid residues) that tune binding affinity and off rate to obtain optimal binding, function (e.g., transcytosis, BBB-penetration, cell membrane penetration, transport across a biological barrier, endocytosis, recycling, or combinations thereof), and release of the peptide or peptide complex.
  • mutations that result in the highest possible affinity may not necessarily correlate to a superior peptide having optimal binding and transcytosis.
  • 1-100% or 5-100% of amino acid residues of a peptide of the present disclosure lie at the binding interface of TfR. In some embodiments, 10-90% of amino acid residues of a peptide of the present disclosure lie at the binding interface of TfR. In some embodiments, 20-80% of amino acid residues of a peptide of the present disclosure lie at the binding interface of TfR. In some embodiments, 30-70% of amino acid residues of a peptide of the present disclosure lie at the binding interface of TfR. In some embodiments, 40-60% of amino acid residues of a peptide of the present disclosure lie at the binding interface of TfR.
  • 30-35% of amino acid residues of a peptide of the present disclosure lie at the binding interface of TfR.
  • 17 of the 51 amino acid residues (33%) of a peptide having a sequence of SEQ ID NO: 32 can lie at the binding interface of TfR.
  • mutations in any one or more of the amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR can improve binding affinity of the peptide to TfR.
  • mutations in 1-100% or 5-100% of amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 5-80% of amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 10-70% of amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR improve binding affinity of the peptide to TfR. In some embodiments, mutations in 15-60% of amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR improve binding affinity of the peptide to TfR. In some embodiments, mutations in 20-50% of amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 25-30% of amino acid residues of a peptide of the present disclosure that lie at the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in any one or more of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR. In some embodiments, 1-100% or 5-100% of amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR. In some embodiments, 10-90% of amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR. In some embodiments, 20-80% of amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR. In some embodiments, 30-70% of amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR.
  • 40- 60% of amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR. In some embodiments, 65-70% of amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR. For example, 34 of the 51 amino acid residues (66%) of a peptide having a sequence of SEQ ID NO: 32 can lie at the binding interface of TfR.
  • mutations in any one or more of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 1-100% or 5-100% of amino acid residues of a peptide of the present disclosure that are distal to the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 5-80% of amino acid residues of a peptide of the present disclosure that are distal to the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 10- 70% of amino acid residues of a peptide of the present disclosure that are distal to the binding interface of TfR improve binding affinity of the peptide to TfR. In some embodiments, mutations in 15-60% of amino acid residues of a peptide of the present disclosure that are distal to the binding interface of TfR improve binding affinity of the peptide to TfR. In some embodiments, mutations in 20-50% of amino acid residues of a peptide of the present disclosure that are distal to the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 25-30% of amino acid residues of a peptide of the present disclosure that are distal to the binding interface of TfR improve binding affinity of the peptide to TfR.
  • mutations in 5 of the 17 amino acid residues that are distal to the binding interface of TfR can improve binding affinity of the peptide to TfR.
  • mutations in 9 of the 34 amino acid residues (26.5%) of a peptide having a sequence of SEQ ID NO: 32 that are distal to the binding interface of TfR can improve binding affinity of the peptide to TfR.
  • one or more mutations in the amino acid residues of the peptide that are distal to the binding interface of TfR can improve protein folding, enhance protein solubility, and/or alter the backbone geometry that can improve binding through an optimized interface shape complementarity.
  • the mutations and amino acid substitutions comprise at least one or more of the corresponding residues in SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • a receptor-binding peptide of the present disclosure may be a PD- L1 -binding peptide.
  • the PD-L1 -binding peptide may be incorporated into a selective depletion complex of the present disclosure to facilitate selective depletion of a target molecule via PD- Ll-mediated endocytosis.
  • the PD-Ll-binding peptide that is a receptorbinding peptide may bind PD-L1 with an affinity that is pH-independent (for example, a similar affinity at extracellular pH and at an endosomal pH) or may bind PD-L1 with an affinity that is pH-dependent (for example, a higher affinity at extracellular pH and a lower affinity at an endosomal pH).
  • pH-independent for example, a similar affinity at extracellular pH and at an endosomal pH
  • pH-dependent for example, a higher affinity at extracellular pH and a lower affinity at an endosomal pH
  • a PD-L1 -binding peptide disclosed herein comprises a sequence of X 1 X 2 X 3 CX 4 X 5 X 6 CX 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 CX 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 C X 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 CX 38 X 39 X 40 CX 41 X 42 X 43 (SEQ ID NO: 392), wherein X 1 can independently be selected from E, M, V, or W; X 2 can independently be selected from G, E, L, or F; X 3 can independently be selected from D, E, or S; X 4 can independently be selected from K, R, or V; X 5 can independently be selected from E, Q, S, M, L, or
  • a binding peptide disclosed herein comprises a sequence of EEDCKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 CX 1 EX 1 X 4 X 1 X 1 X 1 X 1 X 1 X 1 AX 1 CX 1 GX 1 X 5 FX 6 VFX 6 CLX 'X'CX'X'X 1 (SEQ ID NO: 393), wherein X 1 can independently be selected from any noncysteine amino acid; X 2 can independently be selected from M, I, L, or V; X 3 can independently be selected from Y, A, H, K, R, N, Q, S, or T; X 4 can independently be selected from D, E, N, Q, or P; X 5 can independently be selected from K or P; and X 6 can independently be selected from D or K.
  • a PD-L1 -binding peptide may comprise a PD-L1 -binding motif that forms part or all of a binding interface with PD-L1.
  • One or more residues of a PD-L1 -binding motif may interact with one or more residues of PD-L1 at the binding interface between the PD-L1 -binding peptide and PD-L1.
  • multiple PD-L1 -binding motifs may be present in a PD-L1- binding peptide.
  • a PD-L1 -binding motif may comprise a sequence of CX 1 X 2 X 3 CX 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 C (SEQ ID NO: 394), wherein X 1 can independently be selected from K, R, or V; X 2 can independently be selected from E, Q, S, M, L, or V; X 3 can independently be selected from D, E, H, K, R, N, Q, S, or Y; X 4 can independently be selected from D, M, or V; X 5 can independently be selected from A, K, R, Q, S, or T; X 6 can independently be selected from A, D, E, H, Q, S, T, M, I, L, V, or W; X 7 can independently be selected from A, E, R, Q, S, T, W, or P; X 8 can independently be selected from A, E, K, R, N, Q, T, M, I, L, V, or
  • a PD-Ll-binding motif may comprise a sequence of CKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 C (SEQ ID NO: 396), wherein X 1 can independently be selected from any non-cysteine amino acid; X 2 can independently be selected from M, I, L, or V; and X 3 can independently be selected from Y, A, H, K, R, N, Q, S, or T.
  • a PD-Ll-binding motif may comprise a sequence of CKVHCVKEWMAGKAC (SEQ ID NO: 398).
  • a PD-Ll-binding motif may comprise at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% identity to SEQ ID NO: 398.
  • a PD-Ll-binding motif may comprise a sequence of X 1 X 2 X 3 X 4 X 5 X 6 CX 7 X 8 X 9 C (SEQ ID NO: 395), wherein X 1 can independently be selected from D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 2 can independently be selected from G, E, Q, or F; X 3 can independently be selected from D or K; X 4 can independently be selected from G, V, or P; X 5 can independently be selected from G, H, R, V, F, W, or P; X 6 can independently be selected from A, D, or K; X 7 can independently be selected from E, H, Q, L, or F; X 8 can independently be selected from D, E, R, S, T, M, L, or F; and X 9 can independently be selected from G, A, D, E, H, K, R, M, L, or P.
  • a PD-Ll-binding motif may comprise a sequence of X 1 FX 2 VFX 2 CLX 3 X 3 C (SEQ ID NO: 397), wherein X 1 can independently be selected from K or P; X 2 can independently be selected from D or K; and X 3 can independently be selected from any noncysteine amino acid.
  • a PD-Ll-binding motif may comprise a sequence of KFDVFKCLDHC (SEQ ID NO: 399).
  • a PD-L1 -binding motif may comprise at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% identity to SEQ ID NO: 399.
  • a PD-Ll-binding peptide (e.g., any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241, or a pH-independent variant thereof) with high affinity PD-Ll-binding at endosomal pH may be complexed with a target-binding peptide as described herein to form a selective depletion complex for selective depletion of the target molecule.
  • the selective depletion complex can be used to selectively deliver a target molecule across a cellular layer or membrane.
  • the selective depletion complex can be used to selectively deliver the target molecule to an endocytic compartment via PD-L1 -mediated endocytosis.
  • the target molecule can be selectively depleted upon binding to the target-binding peptide of the selective depletion complex and endocytosis via PD-L1 -mediated endocytosis as described.
  • Selective depletion of a target molecule using PD-L1 -mediated endocytosis may be used to selectively deplete the target molecule specifically in tissues that express PD-L1.
  • a selective depletion complex comprising a receptor-binding peptide that binds PD-L1 may be used to selectively deplete a target molecule in a PD-L1 positive cancer, a lung tissue, a pancreatic islet tissue, a lymphoid tissue, an immune cell, a gastrointestinal tissue, a bone marrow tissue, a reproductive tissue, a muscle tissue, an adipose tissue, or any other PD-L1 positive tissue.
  • a selective depletion complex comprising a PD-Ll-binding peptide and an ACE2-binding peptide may be used to selectively deplete ACE2 in lung tissue to prevent a viral infection (e.g., a SARS-CoV-2 infection).
  • a selective depletion complex comprising a PD-Ll-binding peptide and an HLA-b inding peptide may be used to selectively deplete HLA in pancreatic islet cells to prevent T-cell attack of insulin-expressing cells in type I diabetes.
  • Peptides, peptide complexes, or selective depletion complexes of the present disclosure can comprise a target-binding peptide (e.g., a target-binding EGF variant).
  • the target-binding peptide can be capable of binding a target molecule (e.g., EGFR).
  • the target-binding peptide can bind to the target molecule with an affinity that is pH-dependent.
  • the target-binding peptide can bind the target molecule with a higher affinity at an extracellular pH (such as about pH 7.4) than at an endosomal pH (such as about pH 5.5).
  • a target-binding peptide can be conjugated to a receptor-binding peptide of the present disclosure (e.g., a TfR-binding peptide any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 or a PD-Ll-binding peptide of any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 241) to form a selective depletion complex.
  • a receptor-binding peptide of the present disclosure e.g., a TfR-binding peptide any one of SEQ ID NO: 96, SEQ
  • the selective depletion complex can be used to selectively deliver a target molecule across a cellular layer or membrane (e.g., BBB or cell membrane).
  • the selective depletion complex can be used to selectively deliver the target molecule (e.g., EGFR) to an endocytic compartment via receptor-mediated endocytosis (e.g., PD-L1 -mediated endocytosis or TfR-mediated endocytosis).
  • the target molecule e.g., EGFR
  • the target molecule can be selectively depleted upon binding to the target-binding peptide of the selective depletion complex and endocytosis via receptor-mediated endocytosis.
  • the target molecule can be an EGFR protein.
  • a selective depletion complex of the present disclosure can comprise two or more target-binding peptides to promote dimerization of a target molecule. Promoting dimerization can increase internalization of the target molecule, resulting in selective depletion of the target molecule.
  • a selective depletion complex comprising two copies of a target-binding peptide can promote homodimerization of the target molecule.
  • the EGF variant peptide of the present disclosure may further comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, an scFv, an (scFv)2, a DARPin, or an affibody.
  • the target-binding peptide may comprise a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • an EGF variant peptide can further comprise an antibody (e.g., IgG or other antibody), an antibody fragment, (e.g., scFv, scFv2, Fab, F(ab)2, or other antibody fragment), or a nanobody (e.g., a VHH-domain nanobody or VNAR-domain nanobody from camelids or sharks), which can be stable at a low pH.
  • an antibody e.g., IgG or other antibody
  • an antibody fragment e.g., scFv, scFv2, Fab, F(ab)2, or other antibody fragment
  • a nanobody e.g., a VHH-domain nanobody or VNAR-domain nanobody from camelids or sharks
  • a target-binding peptide of the present disclosure can bind to the target molecule (e.g., EGFR) with an affinity that is pH- dependent.
  • the target-binding peptide can bind the target molecule at an extracellular pH (such as about pH 7.4) with an affinity that is higher than the binding affinity at an endocytic pH (such as about pH 7.0, pH 6.5, pH 6.0, pH 5.8, or pH 5.5).
  • the binding affinity of the target-binding peptide for the target molecule at an extracellular pH can be at least about 1.1 -fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5- fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45- fold, at least about 50-fold, at least about 60-fold, at least about 70-fold,
  • the affinity of the target-binding peptide for the target at pH 6.5 or pH 5.5 is no greater than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, or about 50% the affinity of the target-binding peptide for the target at pH 7.4.
  • the affinity of the target-binding peptide for the target at pH 7.4 is at least 2-fold, at least 3 -fold, at least 4-fold, at least 5 -fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the target-binding peptide for the target molecule at pH 6.5 or pH 5.5 [0263]
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3
  • KD equilibrium dissociation
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 20 nM, at least 50 nM, at least 100 nM, at least 200 nM, at least 500 nM, at least 1 pM, at least 2 pM, at least 5 pM, at least 10 pM, at least 20 pM, at least 50 pM, at least 100 pM, at least 500 pM, at least 1 mM, at least 2 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 50 mM, at least 100 mM, at least 200 mM, at least 500 mM, or at least 1 M at endosomal pH (about pH 5.5 or about pH 6.5).
  • KD equilibrium dissociation constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 20 nM, at least 50 nM, at least 100 nM, at least 200 nM, at least 500 nM, at least 1 pM, at least 2 pM, at least 5 pM, at least 10 pM, at least 20 pM, at least 50 pM, at least 100 pM, at least 500 pM, at least 1 mM, at least 2 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 50 mM, at least 100 mM, at least 200 mM, at least 500 mM, or at least 1 M at endosomal pH (about pH 5.8).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH- dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no less than 0.1 nM, no less than 0.5 nM, 1 nM, no less than 2 nM, no less than 5 nM, no less than 10 nM, no less than 20 nM, no less than 50 nM, no less than 100 nM, no less than 200 nM, or no less than 500 nM, or no less than 1000 nM at pH 5.8.
  • KD equilibrium dissociation constant
  • the affinity of the target-binding peptide with pH-dependent binding to the target molecule at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25- fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of the target-binding peptide with pH-dependent binding to the target molecule at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH- dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 6.5.
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (k o ff or kd) of no more than 1x10' 1 s’ 1 , 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , no more than 2x1 O’ 4 s’ 1 , no more than 1x1 O’ 4 s’ 1 , no more than 5xl0’ 5 s’ 1 , or no more than 2xl0’ 5 s’ 1 at pH of 7.4.
  • k o ff or kd dissociation rate constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 1x10’ 1 s’ 1 , 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , no more than 2x1 O’ 4 s’ 1 , no more than 1x1 O’ 4 s’ 1 , no more than 5xl0’ 5 s’ 1 , or no more than 2xl0’ 5 s’ 1 at pH 6.5.
  • koff or kd dissociation rate constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ or no more than 2xl0’ 4 s’ 1 at pH 5.5.
  • koff or kd dissociation rate constant
  • a target-binding peptide with pH- dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 5.8.
  • koff or kd dissociation rate constant
  • the dissociation rate constant (koff or kd) of the target-binding peptide with pH-dependent binding to the target molecule at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of the target-binding peptide with pH-dependent binding to the target molecule at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (k o ff or kd) of the target-binding peptide with pH-dependent binding to the target molecule at pH 7.4 and at pH 5.5 at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.5 than at pH 7.4.
  • the target-binding molecule can release the target molecule upon internalization into an endosomal compartment and acidification of the endosome.
  • Such release the target molecule upon acidification of the endosome can occur at about pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • release of the target molecule can occur at a pH of from about pH 7.0 to about pH 4.5, from about pH 6.5 to about pH 5.0, or from about pH 6.0 to about pH 5.5 or lower.
  • Target-binding peptides with pH-dependent binding affinity can be engineered by selective integration of histidine (His) amino acid residues in the target-binding interface.
  • a target-binding peptide with pH-dependent binding affinity comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 histidine residues in the target-binding interface.
  • a target-binding peptide can be stable at low pH (e.g., at endosomal pH).
  • release of the target molecule by the target-binding peptide upon internalization into an endosomal compartment can be affected by differences in the ionic strength between the extracellular physiologic environment and endosomal cellular compartments.
  • the ionic strength of the endosomal compartment is higher than the ionic strength of the extracellular physiologic environment.
  • Ionic strength which varies with salt concentration, may depend on the concentrations of various electrolytes in solution, for example hydrogen (H + ), hydroxide (OH’), hydronium (H 3 O + ), sodium (Na + ), potassium (K + ), calcium (Ca 2+ ), magnesium (Mg 2+ ), manganese (Mn 2+ ), chloride (Cl’), carbonate (CO 3 2 ’), cobalt (Co 2+ ), phosphate (PCU 3 '), or nitrate (NO,-).
  • targetbinding peptides with salt-dependent or ionic strength-dependent binding affinity can be engineered by selective integration of salt labile moieties (e.g., polar or charged amino acid side chains) in the target-binding interface that would enable dissociation of the target-binding molecule in the endosome.
  • salt labile moieties e.g., polar or charged amino acid side chains
  • the target-binding interface of the target-binding peptide may form one or more polar or charge-charge interactions with the target-binding peptide that can be disrupted as the ionic strength of the environment increases.
  • a target-binding peptide with a binding affinity dependent on ionic strength could dissociate over a range of ionic strengths, for example ionic strengths from about 30 mM to about 1 M.
  • an ionic strength-dependent target-binding peptide with a binding affinity dependent on ionic strength could dissociate at an ionic strength of from about 50 mM to about from about 50 mM to about 1 M, from about 60 mM to about 950 mM, from about 70 mM to about 900 mM, from about 80 mM to about 850 mM, from about 90 mM to about 800 mM, from about 100 mM to about 750 mM, from about 110 mM to about 700 mM, from about 120 mM to about 650 mM, from about 130 mM to about 600 mM, from about 140 mM to about 550 mM, from about 150 mM to about 500 mM, from about 160 mM to about 450 mM, from about 170 mM to about 400 mM, from about 180 mM to about 350 mM, from about 190 mM to about 300 mM, or from about 200
  • the ionic strength-dependent target-binding peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 polar or charge-charge interactions in the target-binding interface (e.g., the interface between EGFR and the EGFR-b inding peptide).
  • the target-binding interface e.g., the interface between EGFR and the EGFR-b inding peptide.
  • a target-binding peptide of the present disclosure may bind to a target (e.g., a target molecule), such as EGFR, EGFRvIII, or TKI-resistant EGFR.
  • a target e.g., a target molecule
  • the target molecule e.g., EGFR, EGFRvIII, or TKI-resistant EGFR
  • the amino acid sequence of soluble EGFRvIII ectodomain (EGFRvIII) is provided as follows:
  • soluble EGFRvIII may also comprise a labelling or affinity tag.
  • soluble EGFRvIII e.g., SEQ ID NO: 527) may comprise one or more of a G4S spacer (e.g., SEQ ID NO: 136), a poly-His tag (e.g., SEQ ID NO: 142), a biotinylation tag (e.g., SEQ ID NO: 543), or any combination thereof.
  • soluble EGFRvIII e.g., SEQ ID NO: 527) may be in a biotinylated form.
  • soluble EGFRvIII e.g., SEQ ID NO: 527) may comprise a biotinylation tag (e.g., SEQ ID NO: 543) and undergo biotinylation by a BirA enzyme.
  • a target-binding peptide of the present disclosure may bind to a target molecule, such as a target molecule with clinical relevance.
  • a target molecule may be a protein that is over-expressed or over-activated in a disease or condition.
  • a target molecule may be an EGFR transmembrane protein involved in oncogenic signaling.
  • the target molecule e.g., EGFR
  • EGFR may be endocytosed and degraded upon binding to the target-binding peptide of a selective depletion complex.
  • a target molecule may be a transmembrane protein, such as a receptor tyrosine kinase.
  • a transmembrane protein such as a receptor tyrosine kinase.
  • receptor tyrosine kinases that may be targeted using a selective depletion complex include EGF receptor, or ErbB.
  • the receptor tyrosine kinase may be EGFR. Targeting the transmembrane protein using a selective depletion complex may lead to internalization and degradation of the transmembrane protein
  • Endocytosis and subsequent degradation of the target molecule may treat (e.g., eliminate, reduce, slow progression of, or treat symptoms of) a disease or condition associated with the target molecule.
  • the degradation of the target molecule may cause remission in, reduce, ameliorate, or ablate a disease or condition (e.g., a cancer).
  • the degradation of the target molecule may cause remission in, reduce, ameliorate, or ablate a cancer.
  • targeting and degradation of a receptor tyrosine kinase with a selective depletion complex may be beneficial in treating a variant of cancers.
  • targeting and degrading EGFR with a selective depletion complex comprising an EGFR-binding peptide may be beneficial in treating cancers, such as non-small- cell lung cancer, primary non-small-cell lung cancer, metastatic non-small-cell lung cancer, head and neck cancer, head and neck squamous cell carcinoma, glioblastoma, brain cancer, metastatic brain cancer, colorectal cancer, colon cancer, tyrosine kinase inhibitor (TKI)-resistant cancer, cetuximab-resistant cancer, necitumumab-resistant cancer, panitumumab-resistant cancer, local cancer, regionally advanced cancer, recurrent cancer, metastatic cancer, refractory cancer, KRAS wildtype cancer, KRAS mutant cancers, or exon20 mutant non-small-cell lung cancer.
  • cancers such as non-small- cell lung cancer, primary non-small-cell lung cancer, metastatic non-small-cell lung cancer, head and neck cancer, head and neck squamous cell carcinoma,
  • the selective depletion complexes of the present disclosure may be well- suited for treatment of CNS-associated disorders such as EGFR-driven brain cancers due to the ability of the selective depletion complexes to penetrate the blood-brain barrier (BBB) and access the CNS via TfR-binding.
  • a selective depletion complex e.g., comprising a TfR-binding peptide may facilitate higher BBB penetration.
  • binding and subsequently depleting a target molecule using a selective depletion complex of the present disclosure comprising a target-binding peptide may be used to treat a disease or condition wherein the target molecule is a cell-based or soluble moiety associated with a disease or condition and is expressed or present in diseased tissues or cells.
  • depletion of the target molecule may be cell type or tissue dependent.
  • depletion of a target molecule may be specific to cells or tissues expressing both the target molecule targeted by the target-binding peptide of the selective depletion complex and the cell surface receptor targeted by the receptor-binding peptide of the selective depletion complex.
  • the degradation and depletion and of the target molecule using a selective depletion complex may prevent, treat, or ameliorate the disease or condition.
  • a target-binding peptide may comprise a sequence of any one of SEQ ID NO: 317 - SEQ ID NO: 390, or SEQ ID NO: 457 - SEQ ID NO: 494.
  • a target-binding peptide may comprise a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 318 - SEQ ID NO: 390, or SEQ ID NO: 457 - SEQ ID NO: 494, or a fragment thereof.
  • a target-binding peptide may comprise a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 318 - SEQ ID NO: 390, or SEQ ID NO: 457 - SEQ ID NO: 494. Examples of target-binding peptides and their corresponding target molecules are provided in TABLE 3.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) may comprise a sequence of any one of SEQ ID NO: 318 - SEQ ID NO: 390, or SEQ ID NO: 457 - SEQ ID NO: 494.
  • a target-binding peptide may comprise a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 318 - SEQ ID NO: 390, or SEQ ID NO: 457 - SEQ ID NO: 494, or a fragment thereof.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 458 - SEQ ID NO: 494, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of any one of SEQ ID NO: 458 - SEQ ID NO: 494.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 458 - SEQ ID NO: 494.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 90% sequence identity with any one of SEQ ID NO: 458 - SEQ ID NO: 494.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 95% sequence identity with SEQ ID NO: 494.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence of any one of SEQ ID NO: 458 - SEQ ID NO: 494.
  • a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 494, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 494.
  • a target-binding peptide (e.g., an EGFR targetbinding peptide) comprises a sequence that has at least 80% sequence identity with SEQ ID NO: 494. In some aspects, a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 90% sequence identity with SEQ ID NO: 494. In some aspects, a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence that has at least 95% sequence identity with SEQ ID NO: 494. In some aspects, a target-binding peptide (e.g., an EGFR target-binding peptide) comprises a sequence of SEQ ID NO: 494.
  • a target-binding peptide disclosed herein comprises a sequence of XlX2X3X4X 5 CX6X7X 8 X9X10XllX12CX13X14Xl 5 GX16CX17YSXl 8 X19LX20X21YX22CNCX23X 2 4G YX25GX26RCQX27X 28 X29X3oX3iX32X33 (SEQ ID NO: 314) wherein Xi is any amino acid; X 2 is any amino acid; X3 is any amino acid; X4 is any of Lys, Ser, He, or Vai; X5 is any of Glu, Lys, or Asn; Xe is Asp or Pro; X7 is any amino acid; X 8 is any of Gly, Ser, or Met; X9 is any of His, Leu, or Trp; X10 is Arg or Va
  • An EGFR-binding peptide of the present disclosure may comprise a configuration (e.g., a cysteine configuration), one or more amino acid substitutions, or a combination thereof, relative to an EGF peptide (e.g., a human EGF peptide of SEQ ID NO: 317), wherein “relative to” the EGF peptide describes the amino acid positions of the EGFR-binding peptide relative to the amino acid positions of the EGF peptide.
  • an EGFR-binding peptide of the present disclosure may comprise 53 amino acids described by positions 1-53 relative to positions 1-53 of SEQ ID NO: 317.
  • an EGFR-binding peptide of the present disclosure may comprise 50 amino acids described by positions 1-50 relative to positions 1-50 of SEQ ID NO: 317.
  • an EGFR-binding peptide may comprise additional amino acid positions on the N terminus of the peptide relative to an EGF peptide (e.g., a human EGF peptide of SEQ ID NO: 317) which can be described as amino acid positions 0 through -n relative to the EGF peptide (e.g., a human EGF peptide of SEQ ID NO: 317).
  • an EGFR-binding peptide may comprise an additional 5 amino acids on the N terminus as compared to an EGF peptide (e.g., a human EGF peptide of SEQ ID NO: 317) that can be described as amino acid positions 0, -1, -2, -3, and -4 relative to the EGF peptide (e.g., a human EGF peptide of SEQ ID NO: 317).
  • EGF peptide e.g., a human EGF peptide of SEQ ID NO: 317
  • an EGFR-binding peptide may comprise additional amino acid positions on the C terminus of the peptide which can be described as amino acid positions of the last position number +1 through the last position number +n (e.g., 54 through 53+n relative to SEQ ID NO: 317) relative to the EGF peptide (e.g., a human EGF peptide of SEQ ID NO: 317).
  • an EGFR-binding peptide may comprise an additional 5 amino acids on the C terminus as compared to an EGF peptide of SEQ ID NO: 317 that can be described as amino acid positions 54, 55, 56, 57, and 58 relative to the EGF peptide of SEQ ID NO: 317.
  • the amino acid positions of an EGFR-binding peptide relative to an EGF variant may describe a position of a specific amino acid (e.g., a position of a cysteine amino acid).
  • the amino acid positions of an EGFR-binding peptide relative to an EGF variant may describe a position of an amino acid substitution using amino acid substitution nomenclature of “(the original amino acid)(the position of the amino acid substitution)(the substituted amino acid).”
  • an EGFR-binding peptide with a DI 1R amino acid substitution relative to a human EGF peptide of SEQ ID NO: 317 describes the amino acid substitution of R in place of D at position 11 of the EGFR-binding peptide.
  • an EGFR target-binding peptide may comprise a cysteine configuration of that of an EGF peptide (e.g., a human EGF peptide).
  • an EGFR target-binding peptide may comprise cysteine amino acids at positions 6, 14, 20, 31, 33, and 42 of the EGFR target-binding peptide, not counting tags, linkers, or other components complexed with the EGFR target-binding peptide.
  • an EGFR target-binding peptide may comprise cysteine residues spaced by 7 amino acid residues between a first cysteine and a second cysteine, 5 amino acid residues between the second cysteine and a third cysteine, 10 amino acid residues between the third cysteine and a fourth cysteine, 1 amino acid residue between the fourth cysteine and a fifth cysteine, and 8 amino acid residues between the fifth cysteine and a sixth cysteine (SEQ ID NO: 711).
  • An EGFR target-binding peptide may comprise a truncation relative to an EGF peptide.
  • an EGFR target-binding peptide may comprise 1, 2, 3, 4, or 5 amino acids truncated from the C-terminus relative to EGF. In some embodiments, an EGFR target-binding peptide may comprise 1, 2, 3, 4, or 5 amino acids truncated from the N-terminus relative to EGF.
  • An EGFR target-binding peptide may comprise at least 70%, at least 75%, at least 77%, at least 80%, at least 82%, at least 85%, at least 87%, at least 90%, at least 92%, at least 94%, or at least 96% sequence identity to an EGF peptide (e.g., a human EGF) and may further comprise at least 1 , at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the EGF peptide.
  • EGF peptide e.g., a human EGF
  • the EGFR target-binding peptide may comprise amino acid substitutions DI 1R, I23S, V35E, S51P, L52E, R53E, M21R, A30W, I38D, W49R, V34S, Q43I, Q43V, Q43W, Q43Y, K48N, K48T, K48A, K48L, E51S, E51H, L52H, R53H, or combinations thereof, relative to human EGF.
  • an EGFR target-binding peptide may comprise substitutions V34S, K48T, E51S, or any combination thereof, relative to human EGF.
  • an EGFR target-binding peptide may comprise substitutions M21R, A30W, I38D, W49R, or combinations thereof, relative to human EGF.
  • an EGFR target-binding peptide may comprise substitutions DI 1R, I23S, V35E, S51P, L52E, R53E, or combinations thereof, relative to human EGF.
  • an EGFR target-binding peptide may comprise substitutions E51H, L52H, R53H, or combinations thereof, relative to human EGF.
  • TfR-binding peptides or PD-Ll-binding peptides or targetbinding peptides (e.g., EGFR target-binding peptides) of the present disclosure comprise one or more Cys, or one or more disulfide bonds.
  • the TfR-binding peptides or the target-binding peptides are derived from cystine-dense peptides (CDPs), knotted peptides, or hitchins.
  • peptide is considered to be interchangeable with the terms “knotted peptide”, “cystine-dense peptide”, “CDP”, and “hitchin”. (See e.g., Correnti et al. Screening, large-scale production, and structure -based classification for cystine-dense peptides. Nat Struct Mol Biol. 2018 Mar; 25(3): 270-278).
  • the TfR-binding peptides of the present disclosure, or derivatives, fragments, or variants thereof can have an affinity and selectively for TfR, or a derivative or analog thereof.
  • the target-binding peptides of the present disclosure can have an affinity and selectively for a target molecule.
  • the TfR-binding peptides of the present disclosure can be engineered using site-saturation mutagenesis (SSM) to exhibit improved TfR-binding properties or promote transcytosis or endocytosis more effectively.
  • the target-binding peptides of the present disclosure can be engineered using site-saturation mutagenesis (SSM) to exhibit improved target-binding properties.
  • the peptides of the present disclosure are cystine-dense peptides (CDPs), related to knotted peptides or hitchin-derived peptides or knottin-derived peptides.
  • CDPs cystine-dense peptides
  • the TfR-binding peptides can be cystine-dense peptides (CDPs).
  • Hitchins can be a subclass of CDPs wherein six cysteine residues form disulfide bonds according to the connectivity [1-4], 2-5, 3-6 indicating that the first cysteine residue forms a disulfide bond with the fourth residue, the second with the fifth, and the third cysteine residue with the sixth.
  • the brackets in this nomenclature indicate cysteine residues form the knotting disulfide bond.
  • Knottins can be a subclass of CDPs wherein six cysteine residues form disulfide bonds according to the connectivity 1-4, 2-5, [3-6].
  • Knottins are a class of peptides, usually ranging from about 20 to about 80 amino acids in length that are often folded into a compact structure.
  • Knottins are typically assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks and can contain beta strands and other secondary structures.
  • the peptides described herein can be derived from knotted peptides.
  • the amino acid sequences of peptides as disclosed herein can comprise a plurality of cysteine residues. In some cases, at least cysteine residues of the plurality of cysteine residues present within the amino acid sequence of a peptide participate in the formation of disulfide bonds. In some cases, all cysteine residues of the plurality of cysteine residues present within the amino acid sequence of a peptide participate in the formation of disulfide bonds.
  • the term “knotted peptide” can be used interchangeably with the terms “cystine-dense peptide”, “CDP”, or “peptide”.
  • CDPs that bind the transferrin receptor and allow selection, optimization and characterization of CDP-TfR binding peptides that can be used in selective depletion complexes, including for use as bioactive molecules at therapeutically relevant concentrations in a subject (e.g., a human or non-human animal).
  • This disclosure demonstrates the utility of CDPs as a diverse scaffold family that can be screened for applicability to modem drug discovery strategies.
  • CDPs comprise alternatives to existing biologies, primarily antibodies, which can bypass some of the liabilities of the immunoglobulin scaffold, including poor tissue permeability, immunogenicity, and long serum half-life that can become problematic if toxicities arise.
  • Peptides of the present disclosure in the 20-80 amino acid range represent medically relevant therapeutics that are midsized, with many of the favorable binding specificity and affinity characteristics of antibodies but with improved stability, reduced immunogenicity, and simpler manufacturing methods.
  • the intramolecular disulfide architecture of CDPs provides particularly high stability metrics, reducing fragmentation and immunogenicity, while their smaller size could improve tissue penetration or cell penetration and facilitate tunable serum half-life.
  • peptides representing candidate peptides that can serve as vehicles for delivering target molecules to endocytic compartments.
  • TfR-binding peptides can be engineered peptides.
  • An engineered peptide can be a peptide that is non-naturally occurring, artificial, isolated, synthetic, designed, or recombinantly expressed.
  • the TfR-binding peptides of the present disclosure comprise one or more properties of CDPs, knotted peptides, or hitchins, such as stability, resistance to proteolysis, resistance to reducing conditions, and/or ability to cross the blood brain barrier.
  • the target-binding peptides of the present disclosure comprise one or more properties of CDPs, knotted peptides, or hitchins, such as stability, resistance to proteolysis, or resistance to reducing conditions.
  • CDPs can be advantageous for delivery to the CNS, as compared to other molecules such as antibodies due to smaller size, greater tissue or cell penetration, lack of Fc function, and quicker clearance from serum, and as compared to smaller peptides due to resistance to proteases (both for stability and for immunogenicity reduction).
  • the TfR-binding peptides or target-binding peptides of the present disclosure e.g., CDPs, knotted peptides, or hitchins
  • selective depletion complexes e.g., comprising one or more TfR-binding peptides and one or more target-binding peptides
  • engineered TfR-binding fusion peptides e.g., comprising one or more TfR-binding peptides and one or more peptides
  • the peptides and complexes described herein can provide superior, deeper, and/or faster tissue or cell penetration to cells and targeted tissues (e.g., brain parenchyma penetration, solid tumor penetration) and faster clearance from non- targeted tissues and serum.
  • the TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of this disclosure can have lower molecular weights than TfR-binding antibodies or targetbinding antibodies.
  • the lower molecular weight can confer advantageous properties on the TfR- binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of this disclosure as compared to TfR-binding antibodies or target-binding antibodies.
  • the TfR-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of this disclosure can penetrate a cell or tissue more readily than an anti-TfR antibody or can have lower molar dose toxicity than an anti-TfR antibody.
  • the TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of this disclosure can be advantageous for lacking the Fc function of an antibody.
  • the TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of this disclosure can be advantageous for allowing higher concentrations, on a molar basis, of formulations.
  • CDPs or knotted peptides can be conjugated to, linked to, or fused to the TfR-binding peptides of the present disclosure, such as those described in TABLE 1, to selectively deliver a target molecule to an endocytic compartment of cell.
  • the cell can be a cancer cell, pancreatic cell, liver cell, colon cell, ovarian cell, breast cell, lung cell, spleen cell, bone marrow cell, or any combination thereof.
  • the cell can be any cell that expresses TfR.
  • An engineered peptide can be a peptide that is non-naturally occurring, artificial, synthetic, designed, or recomb inantly expressed.
  • a TfR-binding peptide of the present disclosure or a complex comprising a TfR-binding peptide (e.g., a selective depletion complex)
  • a TfR-binding peptide of the present disclosure enables TfR-mediated transcytosis and/or cellular endocytosis, and the additional CDP or knotted peptide that is conjugated to, linked to, or fused to TfR-binding peptide can selectively target a molecule (e.g., an enzyme or other protein of interest) in a cell associated with a disease or condition.
  • the cell is a cancer cell.
  • Cancers can include breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, nonHodgkin lymphoma, myeloma, blood-cell-derived cancer, spleen cancer, cancers of the salivary gland, kidney cancer, muscle cancers, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, sarcoma, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, diffuse intrinsic pontine glioma, lung cancer, bone marrow cell cancers, or skin cancer, genitourinary cancer, osteosarcoma, muscle-derived sarcoma, melanoma, head and neck cancer, a neuroblastoma, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymom
  • CDP or knotted peptides are conjugated to, linked to, or fused to TfR- binding peptides and are capable of localizing TfR-binding peptides across the blood brain barrier to deliver TfR-binding peptides to target cells in the central nervous system.
  • CDPs are a class of peptides, usually ranging from about 11 to about 81 amino acids in length that are often folded into a compact structure. Knotted peptides are typically assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks and can contain beta strands, alpha helices, and other secondary structures. The presence of the disulfide bonds gives knotted peptides remarkable environmental stability, allowing them to withstand extremes of temperature and pH and to resist the proteolytic enzymes of the blood stream. The presence of a disulfide knot can provide resistance to reduction by reducing agents.
  • knotted peptides also allows them to bind to targets without paying the “entropic penalty” that a floppy peptide accrues upon binding a target.
  • binding is adversely affected by the loss of entropy that occurs when a peptide binds a target to form a complex. Therefore, “entropic penalty” is the adverse effect on binding, and the greater the entropic loss that occurs upon this binding, the greater the “entropic penalty.”
  • unbound molecules that are flexible lose more entropy when forming a complex than molecules that are rigidly structured, because of the loss of flexibility when bound up in a complex.
  • rigidity in the unbound molecule also generally increases specificity by limiting the number of complexes that molecule can form.
  • the peptides can bind targets with antibody-like affinity, or with nanomolar or picomolar affinity.
  • a wider examination of the sequence structure and sequence identity or homology of knotted peptides reveals that they have arisen by convergent evolution in all kinds of animals and plants. In animals, they are often found in venoms, for example, the venoms of spiders and scorpions and have been implicated in the modulation of ion channels.
  • the knotted proteins of plants can inhibit the proteolytic enzymes of animals or have antimicrobial activity, suggesting that knotted peptides can function in molecular defense systems found in plants.
  • a peptide of the present disclosure can comprise a cysteine amino acid residue.
  • the peptide has at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 cysteine amino acid residues.
  • the peptide has at least 6 cysteine amino acid residues.
  • the peptide has at least 8 cysteine amino acid residues.
  • the peptide has at least 10 cysteine amino acid residues, at least 12 cysteine amino acid residues, at least 14 cysteine amino acid residues or at least 16 cysteine amino acid residues.
  • a knotted peptide can comprise disulfide bridges.
  • a knotted peptide can be a peptide wherein 5% or more of the residues are cysteines forming intramolecular disulfide bonds.
  • a disulfide-linked peptide can be a drug scaffold.
  • the disulfide bridges form a knot.
  • a disulfide bridge can be formed between cysteine residues, for example, between cysteines 1 and 4, 2 and 5, or, 3 and 6.
  • one disulfide bridge passes through a loop formed by the other two disulfide bridges, for example, to form the knot.
  • the disulfide bridges can be formed between any two cysteine residues.
  • the present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides.
  • these scaffolds can be derived from a variety of knotted peptides (such as CDPs or knotted peptides or hitchins).
  • CDPs e.g., knotted peptides or hitchins
  • CDPs are assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks, and optionally contain beta strands and other secondary structures such as an alpha helix.
  • CDPs include, in some embodiments, small disulfide-rich proteins characterized by a disulfide through disulfide knot. This knot can be, e.g., obtained when one disulfide bridge crosses the macrocycle formed by two other disulfides and the interconnecting backbone.
  • the knotted peptides can include growth factor cysteine knots or inhibitor cysteine knots.
  • Other possible peptide structures include peptide having two parallel helices linked by two disulfide bridges without P-sheets (e.g., hefutoxin).
  • Some peptides of the present disclosure can comprise at least one amino acid residue in an L configuration.
  • a peptide can comprise at least one amino acid residue in D configuration. In some embodiments, a peptide is 15-75 amino acid residues long. In other embodiments, a peptide is 11-55 amino acid residues long. In still other embodiments, a peptide is 11-65 amino acid residues long. In further embodiments, a peptide is at least 20 amino acid residues long.
  • Some CDPs e.g., knotted peptides
  • Some CDPs can be derived or isolated from a class of proteins known to be present or associated with toxins or venoms. In some cases, the peptide can be derived from toxins or venoms associated with scorpions or spiders.
  • the peptide can be derived from venoms and toxins of spiders and scorpions of various genus and species.
  • the peptide can be derived from a venom or toxin of the Leiurus quinquestriatus hebraeus, Buthus occitanus tunetanus, Hottentotta judaicus, Mesobuthus eupeus, Buthus occitanus israelis, Hadrurus gertschi, Androctonus australis, Centruroides noxius, Heteroflowers laoticus, Opistophthalmus carinatus, Haplopelma schmidti, Isometrus maculatus, Haplopelma huwenum, Haplopelma hainanum, Haplopelma schmidti, Agelenopsis aperta, Haydronyche versuta, Selenocosmia huwena, Heteropoda venatoria,
  • a peptide of the present disclosure can comprise a sequence having cysteine residues at one or more of corresponding positions 11, 12, 13, 14, 19, 20, 21, 22, 36, 38, 39, 41, for example with reference to SEQ ID NO: 96.
  • a peptide comprises Cys at corresponding positions 11, 12, 19, 20, 36, 39, or any combination thereof.
  • a peptide can comprise a sequence having a cysteine residue at corresponding position 11.
  • a peptide can comprise a sequence having a cysteine residue at corresponding position 12. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 13. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 14. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 19. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 20. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 21. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 22.
  • a peptide can comprise a sequence having a cysteine residue at corresponding position 36. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 38. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 39. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at corresponding position 41.
  • the first cysteine residue in the sequence can be disulfide bonded with the 4th cysteine residue in the sequence
  • the 2nd cysteine residue in the sequence can be disulfide bonded to the 5th cysteine residue in the sequence
  • the 3rd cysteine residue in the sequence can be disulfide bonded to the 6th cysteine residue in the sequence.
  • a peptide can comprise one disulfide bridge that passes through a ring formed by two other disulfide bridges, also known as a “two-and-through” structure system.
  • the peptides disclosed herein can have one or more cysteines mutated to serine.
  • peptides of the present disclosure comprise at least one cysteine residue.
  • peptides of the present disclosure comprise at least two cysteine residues.
  • peptides of the present disclosure comprise at least three cysteine residues.
  • peptides of the present disclosure comprise at least four cysteine residues.
  • peptides of the present disclosure comprise at least five cysteine residues.
  • peptides of the present disclosure comprise at least six cysteine residues.
  • peptides of the present disclosure comprise at least ten cysteine residues. In some embodiments, a peptide of the present disclosure comprises six cysteine residues. In some embodiments, a peptide of the present disclosure comprises seven cysteine residues. In some embodiments, a peptide of the present disclosure comprises eight cysteine residues.
  • a peptide of the present disclosure comprises an amino acid sequence having cysteine residues at one or more positions, for example with reference to SEQ ID NO: 96.
  • the one or more cysteine residues are located at any one of the corresponding amino acid positions 6, 10, 20, 34, 44, 48, or any combination thereof.
  • the one or more cysteine (C) residues participate in disulfide bonds with various pairing patterns (e.g., C10-C20).
  • the corresponding pairing patterns are C6-C48, C10-C44, and C20-C34.
  • the peptides as described herein comprise at least one, at least two, or at least three disulfide bonds. In some embodiments, at least one, at least two, or at least three disulfide bonds are arranged according to the corresponding C6-C48, C10-C44, and C20-C34 pairing patterns, or a combination thereof. In some embodiments, peptides as described herein comprise three disulfide bonds with the corresponding pairing patterns C6-C48, C10-C44, and C20-C34.
  • a peptide (e.g., a TfR-binding peptide, a PD-Ll-binding peptide, a target-binding peptide, or a selective depletion complex) comprises a sequence having a cysteine residue at corresponding position 6.
  • a peptide comprises a sequence having a cysteine residue at corresponding position 10.
  • a peptide comprises a sequence having a cysteine residue at corresponding position 20.
  • a peptide comprises a sequence having a cysteine residue at corresponding position 34.
  • a peptide comprises a sequence having a cysteine residue at corresponding position 44.
  • a peptide comprises a sequence having a cysteine residue at corresponding position 50.
  • the first cysteine residue in the sequence is disulfide bonded with the last cysteine residue in the sequence.
  • the second cysteine residue in the sequence is disulfide bonded with the second to the last cysteine residue in the sequence.
  • the third cysteine residue in the sequence is disulfide bonded with the third to the last cysteine residue in the sequence and so forth.
  • the first cysteine residue in the sequence is disulfide bonded with the 6th cysteine residue in the sequence
  • the 2nd cysteine residue in the sequence is disulfide bonded to the 5th cysteine residue in the sequence
  • the 3rd cysteine residue in the sequence is disulfide bonded to the 4th cysteine residue in the sequence.
  • a peptide can comprise one disulfide bridge that passes through a ring formed by two other disulfide bridges, also known as a “two-and-through” structure system.
  • the peptides disclosed herein have one or more cysteines mutated to serine.
  • a peptide (e.g., a TfR-binding peptide, a PD-Ll-binding peptide, a target-binding peptide, or a selective depletion complex) comprises no cysteine or disulfides.
  • a peptide comprises 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more cysteine or disulfides.
  • 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more cysteine residues have been replaced with serine residues. In some embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more cysteine residues have been replaced with threonine residues.
  • a peptide (e.g., a TfR-binding peptide, a PD-Ll-binding peptide, a target-binding peptide, or a selective depletion complex) comprises no Cys or disulfides.
  • a peptide comprises 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more Cys or disulfides.
  • 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues have been replaced with Ser residues. In some embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues have been replaced with Thr residues.
  • one or more or all of the methionine residues in the peptide are replaced by leucine or isoleucine.
  • one or more or all of the tryptophan residues in the peptide are replaced by phenylalanine or tyrosine.
  • one or more or all of the asparagine residues in the peptide are replaced by glutamine.
  • the N-terminus of the peptide is blocked, such as by an acetyl group.
  • the C-terminus of the peptide is blocked, such as by an amide group.
  • the peptide is modified by methylation on free amines.
  • full methylation can be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
  • the peptides or peptide complexes as described herein target and/or penetrate a TfR-expressing cellular layer or barrier and/or the membrane of a TfR- expressing cell.
  • a peptide targets and/or penetrates a cell membrane of a cell, wherein said cell is located in the CNS such as the brain.
  • a peptide complex comprising a TfR-binding peptide and one or more active agents (e.g., a therapeutic or diagnostic compound) crosses a cellular barrier (e.g., BBB) via vesicular transcytosis, and subsequently targets and/or penetrates the cell membrane of a cell located within the CNS to deliver said one or more active agents to that cell.
  • a cellular barrier e.g., BBB
  • a selective depletion complex comprising a TfR-binding peptide and a target-binding peptide binds a TfR-expressing cell located in the gastrointestinal tract, spleen, liver, kidney, muscle, bone marrow, brain, or skin.
  • the TfR- expressing cell is a tumor cell, an immune cell, an erythrocyte, an erythrocyte precursor cell, a stem cell, a bone marrow cell, or stem cell.
  • the TfR-binding peptide is responsible for targeting the cell, e.g., in cases where the cell is overexpressing a TfR.
  • a peptide complex as described herein comprising a TfR-binding peptide conjugated to, linked to, or fused to a target-binding peptide binds a cell located within various organs such as the spleen, brain, liver, kidney, muscle, bone marrow, gastrointestinal tract, or skin.
  • the target-binding peptides promotes endocytosis of a target molecule.
  • a peptide or peptide complex e.g., peptide conjugate or fusion peptide
  • a selective depletion complex e.g., a complex comprising a TfR-binding peptide and a target-binding peptide
  • a certain biological effect e.g., selective depletion of the target molecule.
  • the peptides of the presented disclosure can be dimerized in numerous ways.
  • a TfR- binding peptide can be dimerized with a target-binding peptide via a peptide linker to form a selective depletion complex.
  • a peptide linker does not disturb the independent folding of peptide domains (e.g., a TfR-binding peptide, a PD-Ll-binding peptide, or an EGFR target-binding peptide).
  • a peptide linker can comprise sufficient length to the peptide complex so as to facilitate contact between a target molecule and a TfR via the peptide complex (e.g., a selective depletion complex).
  • a peptide linker does not negatively impact manufacturability (synthetic or recombinant) of the peptide complex (e.g., the selective depletion complex).
  • a peptide linker does not impair post-synthesis chemical alteration (e.g., conjugation of a fluorophore or albumin-binding chemical group) of the peptide complex (e.g., the selective depletion complex).
  • cellular receptor-binding peptide is conjugated to the target-binding peptide via a polymer linker.
  • the polymer linker is a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer comprising proline, alanine, serine, or a combination thereof, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, a palmitic acid, an albumin, or an albumin binding molecule.
  • PEG polyethylene glycol
  • a hydroxyethyl starch polyvinyl alcohol
  • a water soluble polymer a zwitterionic water soluble polymer
  • a water soluble poly(amino acid) a water soluble poly(amino acid)
  • a water soluble poly(amino acid) a water soluble poly(amino acid)
  • a water soluble polymer comprising
  • a peptide linker can connect the C-terminus of a first peptide (e.g., an EGFR target-binding peptide, a TfR-binding peptide, or a half-life modifying peptide) to the N-terminus of a second peptide (e.g., an EGFR target-binding peptide, a TfR-binding peptide, or a half-life modifying peptide).
  • a first peptide e.g., an EGFR target-binding peptide, a TfR-binding peptide, or a half-life modifying peptide
  • a peptide linker can connect the C-terminus of the second peptide (e.g., an EGFR target-binding peptide, a TfR-binding peptide, or a half-life modifying peptide) to the N-terminus of a third peptide (e.g., an EGFR target-binding peptide, a TfR-binding peptide, or a half-life modifying peptide).
  • a third peptide e.g., an EGFR target-binding peptide, a TfR-binding peptide, or a half-life modifying peptide
  • a linker e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541
  • a target-binding peptide e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494
  • TfR-binding peptide e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO:
  • a linker e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541
  • a linker can connect the C-terminus of a TfR- binding peptide (e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64) to the N-terminus of a target-binding peptide (e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ
  • a linker e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541
  • a linker can connect the C-terminus of a TfR- binding peptide (e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64) to the N-terminus of a half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 192 SEQ ID NO: 245 - SEQ ID NO: 287,
  • a linker e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541
  • a target-binding peptide e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494
  • a half-life extending peptide e.g., SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 192, SEQ ID NO: 245 - SEQ ID NO: 287, SEQ ID NO: 535 - SEQ ID NO: 537, or SEQ ID NO: 706 - SEQ ID NO: 710
  • a second linker e.g., any one
  • a first linker (e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541) can connect the C-terminus of a target-binding peptide (e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494) to the N-terminus of a half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 192, SEQ ID NO: 245 - SEQ ID NO: 287, SEQ ID NO: 535 - SEQ ID NO: 537, or SEQ ID NO: 706 - SEQ ID NO: 710) and a second linker (e.g., any one of S
  • a linker e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541
  • a linker can connect the C-terminus of a half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 192, SEQ ID NO: 245 - SEQ ID NO: 287, SEQ ID NO: 535 - SEQ ID NO: 537, or SEQ ID NO: 706 - SEQ ID NO: 710) to the N- terminus of a target-binding peptide (e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494) and a second linker (e.g.
  • a linker e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541
  • a linker can connect the C-terminus of a half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 192, SEQ ID NO: 245 - SEQ ID NO: 287, SEQ ID NO: 535 - SEQ ID NO: 537, or SEQ ID NO: 706 - SEQ ID NO: 710) to the N-terminus of a TfR-binding peptide (e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO
  • a linker can comprise a Tau-theraphotoxin-Hsla, also known as DkTx (double-knot toxin), extracted from a native knottin-knottin dimer from Haplopelma schmidti (e.g., SEQ ID NO: 139).
  • the linker can lack structural features that would interfere with dimerizing independently functional CDPs (e.g., a TfR-binding CDP and an EGFR target- binding CDP).
  • a linker can comprise a glycine-serine (Gly-Ser or GS) linker (e.g., SEQ ID NO: 129 - SEQ ID NO: 138 or SEQ ID NO: 141 or SEQ ID NO: 195 - SEQ ID NO: 218 or SEQ ID NO: 538).
  • Gly-Ser linkers can have minimal chemical reactivity and can impart flexibility to the linker.
  • Serines can increase the solubility of the linker or the peptide complex, as the hydroxyl on the side chain is hydrophilic.
  • a linker can be derived from a peptide that separates the Fc from the Fv domains in a heavy chain of human immunoglobulin G (e.g., SEQ ID NO: 140).
  • a linker derived from a peptide from the heavy chain of human IgG can comprise a cysteine to serine mutation relative to the native IgG peptide.
  • peptides of the present disclosure can be dimerized using an immunoglobulin heavy chain Fc domain.
  • the half-life of peptides of the present disclosure can be extended using an Fc domain, such Fc domains are described herein and also referred to as a “half-life extender”.
  • an Fc domain can serve as a linker. These Fc domains can be used to dimerize functional domains (e.g., a TfR-binding peptide and a target-binding peptide, or a PD-L1 -binding peptide and a target-binding peptide), either based on antibodies or other otherwise soluble functional domains.
  • dimerization can be homodimeric if the Fc sequences are native. In some embodiments, dimerization can be heterodimeric by mutating the Fc domain to generate a “knob-in-hole” format where one Fc CH3 domain contains novel residues (knob) designed to fit into a cavity (hole) on the other Fc CH3 domain.
  • a first peptide domain e.g., a TfR-binding peptide, a PD- L1 -binding peptide, or an EGFR target-binding peptide
  • a second peptide domain e.g., a TfR-binding peptide, a PD-Ll-binding peptide, or an EGFR target-binding peptide
  • Knob+knob dimers can be highly energetically unfavorable.
  • a purification tag can be added to the “knob” side to remove hole+hole dimers and select for knob+hole dimers.
  • dimerization can be heterodimeric by mutating the Fc domain to generate an “electrostatic steering” effect wherein one Fc CH3 domain (“Chain 1”) contains mutations that manipulate the distribution of charges at the interface, supporting electrostatic interactions with a paired Fc CH3 domain (“Chain 2”) containing mutations creating a reciprocal charge distribution to that of Chain 1.
  • a first peptide domain (e.g., a TfR-binding peptide, a PD-Ll-binding peptide, or an EGFR target-binding peptide) can be coupled to Chain 1 of an engineered pair
  • a second peptide domain e.g., a TfR-binding peptide, a PD-Ll-binding peptide, or an EGFR target-binding peptide
  • Homodimers of Chain 1 or Chain 2 can be highly energetically unfavorable, promoting selective secretion of heterodimers.
  • the peptide peptides of the present disclosure can be linked to another peptide (e.g., a target-binding peptide such as an EGFR target-binding peptide, a TfR- binding peptide, a selective depletion complex, or a half-life modifying peptide) at the N- terminus or C-terminus.
  • a target-binding peptide such as an EGFR target-binding peptide, a TfR- binding peptide, a selective depletion complex, or a half-life modifying peptide
  • one or more peptides can be linked or fused via a peptide linker (e.g., a peptide linker comprising a sequence of any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541).
  • a peptide linker e.g., a peptide linker comprising a sequence of any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541).
  • a TfR-binding peptide can be fused to a target-binding peptide (e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494) via a peptide linker of any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541.
  • a target-binding peptide e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 49
  • a peptide linker (e.g., a linker connecting a TfR-binding peptide, a target-binding peptide, a half-life modifying peptide, or combinations thereof) can have a length of about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 30, about 35, about 40, about 45, or about 50 amino acid residues.
  • a peptide linker (e.g., a linker connecting a TfR-binding peptide, a target-binding peptide such as an EGFR target-binding peptide, a half-life modifying peptide, or combinations thereof) can have a length of from about 2 to about 5, from about 2 to about 10, from about 2 to about 20, from about 3 to about 5, from about 3 to about 10, from about 3 to about 15, from about 3 to about 20, from about 3 to about 25, from about 5 to about 10, from about 5 to about 15, from about 5 to about 20, from about 5 to about 25, from about 10 to about 15, from about 10 to about 20, from about 10 to about 25, from about 15 to about 20, from about 15 to about 25, from about 20 to about 25, from about 20 to about 30, from about 20 to about 35, from about 20 to about 40, from about 20 to about 45, from about 20 to about 50, from about 3 to about 50, from about 3 to about 40, from about 3 to about 30, from about 10 to about 40, from about 10 to about 30, from about 50 to about 100
  • a first peptide e.g., a TfR-binding peptide or a PD-Ll-binding peptide
  • a second peptide e.g., an EGFR target-binding peptide
  • a flexible linker can provide rotational freedom between the first peptide and the second peptide and can allow the first peptide and the second peptide to bind their respective targets (e.g., a transferrin receptor and an EGFR target molecule) with minimal strain.
  • a peptide linker can have a persistence length of no more than 6 A, no more than 7 A, no more than 8 A, no more than 9 A, no more than 10 A, no more than 12 A, no more than 15 A, no more than 20 A, no more than 25 A, no more than 30 A, no more than 40 A, or no more than 50 A.
  • a peptide linker can have a persistence length of no more than 6 A, no more than 7 A, no more than 8 A, no more than 9 A, no more than 10 A, no more than 12 A, no more than 15 A, no more than 20 A, no more than 25 A, no more than 30 A, no more than 40 A, no more than 50 A, no more than 75 A, no more than 100 A, no more than 150 A, no more than 200 A, no more than 250 A, or no more than 300 A.
  • a peptide linker can have a persistence length of from about 4 A to about 100 A, from about 4 A to about 50 A, from about 4 A to about 20 A, from about 4 A to about 10 A, from about 10 A to about 20 A, from about 20 A to about 30 A, from about 30 A to about 50 A, or from about 50 A to about 100 A.
  • the persistence length of the linker can be a measure of the flexibility of the peptide linker and can be quantified as the peptide length over which correlations in the direction of the tangent are lost.
  • the peptide linker is derived from an immunoglobulin peptide. In some embodiments, the peptide linker is derived from a double-knot toxin peptide.
  • a peptide linker can be selected based on a desired linker length, hydrodynamic radius, chromatographic mobility, posttranslational modification propensity, or combinations thereof.
  • a linker separating two or more functional domains of a peptide complex e.g., separating a TfR-binding peptide and an EGFR target-binding peptide
  • a linker separating two or more functional domains of a peptide complex can comprise a small, flexible linker, for example to reduce the hydrodynamic radius of the complex for use in tight spaces like dense-core tumor stroma. Examples of selective depletion complexes formed from a single polypeptide chain comprising a target-binding peptide and a receptor-binding peptide connected via a peptide linker are illustrated in FIG. 15 and FIG. 16.
  • a peptide linker can support independent folding of the two or more functional domains and may not inhibit interactions between the two or more functional domains and their binding targets (e.g., between a TfR-binding peptide and TfR or between a target-binding peptide and a target molecule).
  • a peptide can be appended to the N-terminus of any peptide of the present disclosure following an N-terminal GS dipeptide and preceding, for example, a GGGS (SEQ ID NO: 129) spacer.
  • a peptide e.g., an EGFR target-binding peptide
  • a peptide linker such as G x S y (SEQ ID NO: 130) peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
  • the peptide linker comprises (GS)x (SEQ ID NO: 131), wherein x can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
  • the peptide linker comprises GGSSG (SEQ ID NO: 132), GGGGG (SEQ ID NO: 133), GSGSGSGS (SEQ ID NO: 134), GSGG (SEQ ID NO: 135), GGGGS (SEQ ID NO: 136), GGGS (SEQ ID NO: 129), GGS (SEQ ID NO: 137), GGGSGGGSGGGS (SEQ ID NO: 138), or a variant or fragment thereof.
  • KKYKPYVPVTTN SEQ ID NO: 139
  • EPKSSDKTHT SEQ ID NO: 140
  • the peptide linker comprises GGGSGGSGGGS (SEQ ID NO: 141). In some embodiments, the peptide linker comprises a linker of any one of SEQ ID NO: 195 - SEQ ID NO: 218. Examples of peptide linkers compatible with the target depletion complexes of the present disclosure are provided in TABLE 4. It is understood that any of the foregoing linkers or a variant or fragment thereof can be used with any number of repeats or any combinations thereof. It is also understood that other peptide linkers in the art or a variant or fragment thereof can be used with any number of repeats or any combinations thereof.
  • a tag peptide (e.g., a peptide of any one of SEQ ID NO: 142 - SEQ ID NO: 147) can be appended to the peptide (e.g., a target-binding peptide, a TfR-binding peptide, or a selective depletion complex) at any amino acid residue.
  • the tag peptide e.g., a peptide of any one of SEQ ID NO: 142 - SEQ ID NO: 147) can be appended to the peptide at any amino acid residue without interfering with TfR-binding activity, target-binding activity, selective depletion activity, or a combination thereof.
  • the tag peptide is appended via conjugation, linking, or fusion techniques.
  • a peptide e.g., an EGFR target-binding peptide
  • a second peptide e.g., a TfR-binding peptide or a PD-L1 -binding peptide
  • the peptide e.g., an EGFR target-binding peptide
  • the second peptide e.g., a TfR-binding peptide or a PD-Ll-binding peptide
  • the peptide is appended via conjugation, linking, or fusion techniques.
  • the peptide e.g., an EGFR target-binding peptide
  • the second peptide e.g., a TfR-binding peptide or a PD-L1 -binding peptide
  • a peptide complex may comprise multiple polypeptide chains.
  • a selective depletion complex may comprise two or more polypeptide chains.
  • a target-binding peptide and a receptor-binding peptide may be complexed via a dimerization domain to form a selective depletion complex.
  • the dimerization domain comprises an Fc domain.
  • the dimerization domain may be a heterodimerization domain or a homodimerization domain.
  • Examples of selective depletion complexes comprising a target-binding peptide and a receptor-binding peptide connected via a dimerization domain (e.g., an Fc homodimerization domain or a knob-in-hole heterodimerization domain) are illustrated in FIG. 15 and FIG. 16.
  • a dimerization domain e.g., an Fc homodimerization domain or a knob-in-hole heterodimerization domain
  • a target-binding peptide and a receptor-binding peptide may be complexed by forming a heterodimer via a hetero dimerization domain.
  • the target-binding peptide may be linked or fused to a first heterodimerization domain and the receptor-binding peptide may be linked or fused to a second heterodimerization domain.
  • the first heterodimerization domain may bind to the second heterodimerization domain to form a heterodimeric complex comprising the target-binding peptide and the receptor-binding peptide.
  • the receptor-binding peptide may be linked or fused to an Fc “knob” peptide (e.g., SEQ ID NO: 260, SEQ ID NO: 536, or SEQ ID NO: 707) and the target-binding peptide may be linked or fused to an Fc “hole” peptide (e.g., SEQ ID NO: 261, SEQ ID NO: 537, or SEQ ID NO: 708).
  • Fc “knob” peptide e.g., SEQ ID NO: 260, SEQ ID NO: 536, or SEQ ID NO: 707
  • Fc “hole” peptide e.g., SEQ ID NO: 261, SEQ ID NO: 537, or SEQ ID NO: 708
  • the receptorbinding peptide may be linked or fused to an Fc “hole” peptide (e.g., SEQ ID NO: 261, SEQ ID NO: 537, or SEQ ID NO: 708) and the target-binding may be linked or fused to an Fc “knob” peptide (e.g., SEQ ID NO: 260, SEQ ID NO: 536, or SEQ ID NO: 707).
  • a receptor-binding peptide e.g., any one of SEQ ID NO: 1 - SEQ ID NO: 222
  • the receptor-binding peptide may be fused to chain 1 of an Fc pair (e.g., SEQ ID NO: 260) and the target-binding peptide may be fused to chain 2 of the Fc pair (e.g., SEQ ID NO: 261).
  • the receptor-binding peptide may be fused to chain 2 of an Fc pair (e.g., SEQ ID NO: 263) and the target-binding peptide may be fused to chain 1 of the Fc pair (e.g., SEQ ID NO: 262).
  • a selective depletion complex comprising a heterodimerization domain may form a monovalent selective depletion complex, as shown in FIG. 15 and FIG. 16, or a selective depletion complex comprising a heterodimerization domain may form a multivalent selective depletion complex, as shown in FIG. 15 and FIG. 16. TABLE 5 - Exemplary Heterodimerization Domains
  • a target-binding peptide and a receptor-binding peptide may form a selective depletion complex comprising a homodimer complexed via a homodimerization domain.
  • the target-binding peptide may be linked or fused to the N-terminus of the homodimerization domain and the receptor-binding peptide may be linked or fused to the C- terminus of the homodimerization domain.
  • the target-binding peptide may be linked or fused to the C-terminus of the homodimerization domain and the receptorbinding peptide may be linked or fused to the N-terminus of the homodimerization domain.
  • the target-binding peptide and the receptor-binding peptide may both be fused on the N-terminal, or both be fused on the C-terminal end of the homodimerization domain.
  • a selective depletion complex comprising a homodimerization domain may form a multivalent selective depletion complex, as shown in FIG. 15 and FIG. 16. Examples of homodimerization domains that may be used to link or fuse a target-binding peptide to a receptor-binding peptide are provided in TABLE 6.
  • a peptide can be modified (e.g., chemically modified) one or more of a variety of ways.
  • the peptide can be mutated to add function, delete function, or modify the in vivo behavior.
  • One or more loops between the disulfide linkages of a peptide e.g., a TfR- binding peptide, a PD-L1 -binding peptide, a target-binding peptide, or a selective depletion complex
  • can be modified or replaced to include active elements from other peptides such as described in Moore and Cochran, Methods in Enzymology, 503, p. 223-251, 2012).
  • the peptides of the present disclosure can be further functionalized and multimerized by adding an additional functional domain.
  • an albumin-binding domain from a Finegoldia magna peptostreptococcal albumin-binding protein (SEQ ID NO: 192, MKLNKKLLMAALAGAIWGGGVNTFAADEPGAIKVDKAPEAPSQELKLTKEEAEKAL KKEKPIAKERLRRLGITSEFILNQIDKATSREGLESLVQTIKQSYLKDHPIKEEKTEETPKY NNLFDKHELGGLGKDKGPGRFDENGWENNEHGYETRENAEKAAVKALGDKEINKSYT ISQGVDGRYYYVLSREEAETPKKPEEKKPEDKRPKMTIDQWLLKNAKEDAIAELKKAGI TSDFYFNAINKAKTVEEVNALKNEILKAHAGKEVNPSTPEVTPSVPQNHYHENDYANIG AGEGTKEDGKKENSKEGIKRKTAREEKPGKEEKPAKEDKKENKKKENTDSPNKKKKE KAALPEAGRRKA
  • an albumin-binding domain of SEQ ID NO: 193 (LKNAKEDAIAELKKAGITSDFYFNAINKAKTVEEVNALKNEILKA) can be added to a peptide of the present disclosure.
  • a peptide of the present disclosure can be functionalized with an albumin-binding domain that has been modified for improved albumin affinity, improved stability, reduced immunogenicity, improved manufacturability, or a combination thereof.
  • a peptide can be functionalized with a modified albuminbinding domain of SEQ ID NO: 194 (LKEAKEKAIEELKKAGITSDYYFDLINKAKTVEGVNALKDEILKA) or SEQ ID NO: 227 (LKEAKEKAIEELKKAGITSDYYFDLINKAKAVEGVNALKDEILKA) having high thermostability and improved serum half-life compared to the albumin binding domain of SEQ ID NO: 193.
  • an albumin-binding peptide may be selected based on a desired off rate for albumin.
  • an albumin-binding peptide of SEQ ID NO: 227 may be selected for its faster off rate relative to SEQ ID NO: 194.
  • the albumin-binding domain comprises a simple three-helical structure that would be unlikely to disturb the independent folding of the other peptide domains (e.g., CDP domains).
  • a functional domain e.g., an albumin-binding domain
  • a functional domain can be included in any orientation relative to the TfR-b inding peptide or the targetbinding peptide.
  • a functional domain can be linked to the TfR-b inding peptide, the target-binding peptide, or in between the TfR-binding peptide and the target-binding peptide.
  • an albumin binding peptide (e.g., SEQ ID NO: 194 or SEQ ID NO: 227) may be used to link a target-binding peptide to a receptor-binding peptide.
  • An additional functional domain can be linked to one or more peptides (e.g., a TfR-binding peptide, a PD-L1- binding peptide, or a target-binding peptide) via a linker (e.g., any one of SEQ ID NO: 129 - SEQ ID NO: 141 or SEQ ID NO: 195 - SEQ ID NO: 218).
  • a peptide of the present disclosure may be modified with a signal peptide to mark the peptide for secretion.
  • a peptide may be modified with a signal peptide corresponding to SEQ ID NO: 230 (METDTLLLWVLLLWVPGSTG).
  • the signal peptide may be appended to an N-terminus or a C-terminus of the peptide.
  • a peptide may be modified for additional stability during translation or secretion.
  • a peptide may be modified with a siderocalin with a furin cleavage site corresponding to SEQ ID NO: 229 (GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYWGLAGNAILREDKDPQKMYATIY ELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRWSTNY NQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCI DGGGSRRRRKRSGS).
  • the siderocalin with the furin cleavage site may be appended to an N-terminus or a C-terminus of the peptide.
  • a peptide may be modified with a signal peptide to mark the peptide for secretion and for additional stability during translation or secretion.
  • a peptide may be modified with a signal peptide and a siderocalin with a furin cleavage site corresponding to SEQ ID NO: 231
  • the signal peptide and the siderocalin with the furin cleavage site may be appended to an N-terminus or a C-terminus of the peptide.
  • a peptide of the present disclosure may be modified with a signal peptide to mark the peptide for secretion and further have the signal peptide removed without loss of function or binding-properties.
  • a peptide may be modified with a signal peptide corresponding to SEQ ID NO: 230 (METDTLLLWVLLLWVPGSTG) and have the signal peptide removed without loss of function or binding-properties.
  • Amino acids of a peptide or a peptide complex can also be mutated, such as to increase half-life, modify, add or delete binding behavior in vivo, add new targeting function, modify surface charge and hydrophobicity, or allow conjugation sites.
  • N-methylation is one example of methylation that can occur in a peptide of the disclosure.
  • the peptide is modified by methylation on free amines. For example, full methylation can be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
  • the peptides can be modified to add function, such as to graft loops or sequences from other proteins or peptides onto peptides of this disclosure.
  • domains, loops, or sequences from this disclosure can be grafted onto other peptides or proteins such as antibodies that have additional function.
  • a selective depletion complex can comprise a tissue targeting domain and can accumulate in the target tissue upon administration to a subject.
  • selective depletion complexes can be conjugated to, linked to, or fused to a molecule (e.g., small molecule, peptide, or protein) with targeting or homing function for a cell of interest or a target protein located on the surface or inside said cell.
  • a molecule e.g., small molecule, peptide, or protein
  • selective depletion complexes can be conjugated to, linked to, or fused to a molecule that extends the plasma and/or biological half-life, or modifies the pharmacodynamic (e.g., enhanced binding to a target protein) and/or pharmacokinetic properties (e.g., rate and mode of clearance) of the peptides, or any combination thereof.
  • a chemical modification can, for instance, extend the half-life of a peptide or change the biodistribution or pharmacokinetic profile.
  • a chemical modification can comprise a polymer, a polyether, polyethylene glycol, a biopolymer, a polyamino acid, a fatty acid, a dendrimer, an Fc region, a simple saturated carbon chain such as palmitate or myristolate, or albumin.
  • a polyamino acid can include, for example, a poly amino acid sequence with repeated single amino acids (e.g., poly glycine), and a poly amino acid sequence with mixed poly amino acid sequences (e.g., Gly-Ala-Gly-Ala (SEQ ID NO: 712)) that can or may not follow a pattern, or any combination of the foregoing.
  • the peptides of the present disclosure can be modified such that the modification increases the stability and/or the half-life of the peptides.
  • the attachment of a hydrophobic moiety, such as to the N-terminus, the C-terminus, or an internal amino acid, can be used to extend half-life of a peptide of the present disclosure.
  • the peptides can also be modified to increase or decrease the gut permeability or cellular permeability of the peptide.
  • the peptides of the present disclosure show high accumulation in glandular cells of the intestine, demonstrating applicability in the treatment and-or prevention of diseases or conditions of the intestines, such as Crohn’s disease or more generally inflammatory bowel diseases.
  • the peptide of the present disclosure can include post-translational modifications (e.g., methylation and/or amidation and/or glycosylation), which can affect, e.g., serum half-life.
  • post-translational modifications e.g., methylation and/or amidation and/or glycosylation
  • simple carbon chains e.g., by myristoylation and/or palmitylation
  • the simple carbon chains can render the fusion proteins or peptides easily separable from the unconjugated material.
  • methods that can be used to separate the fusion proteins or peptides from the unconjugated material include, but are not limited to, solvent extraction and reverse phase chromatography. Lipophilic moieties can extend half-life through reversible binding to serum albumin.
  • Conjugated moieties can, e.g., be lipophilic moieties that extend half-life of the peptides through reversible binding to serum albumin.
  • the lipophilic moiety can be cholesterol or a cholesterol derivative including cholestenes, cholestanes, cholestadienes and oxysterols.
  • the peptides can be conjugated to, linked to, myristic acid (tetradecanoic acid) or a derivative thereof.
  • the peptides of the present disclosure can be coupled (e.g., conjugated, linked, or fused) to a half-life modifying agent.
  • half-life modifying agents can include, but is not limited to: a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, an albumin, or a molecule that binds to albumin.
  • the cellular receptor-binding peptide and the target-binding peptide form a single polypeptide chain.
  • the peptide complex comprises a dimer dimerized via a dimerization domain.
  • the distance between the cellular receptor-binding peptide and the target-binding peptide is at least 1 nm, at least 2 nm, at least 5 nm, at least 10 nm, at least 20 nm, at least 50 nm, or at least 100 nm.
  • the half-life modifying agent can be a serum albumin binding peptide, for example SA21 (SEQ ID NO: 178, RLIEDICLPRWGCLWEDD).
  • a SA21 peptide can be conjugated or fused to the CDPs of the present disclosure (e.g., any of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64).
  • a SA21 fhsion peptide can include the SA21 TfR-binding peptide complexes disclosed herein (e.g., SEQ ID NO: 181 or SEQ ID NO: 184).
  • the SA21 peptide can comprise a linker sequence for conjugation to, or fusion between, one or more peptides (e.g., SEQ ID NO: 179, GGGGSGGGGSRLIEDICLPRWGCLWEDDGGGGSGGGGS).
  • exemplary SA21 peptides, fusion peptides, and linkers are provided in TABLE 7.
  • a control SA21 fusion peptide can comprise a control peptide fused to SA21 (e.g., SEQ ID NO: 180 (GSRLIEDICLPRWGCLWEDDGGGGSGGGGSKCLPPGKPCYGATQKIPCCGVCSHNNCT ), SEQ ID NO: 183 (RLIEDICLPRWGCLWEDDGGGGSGGGGSKCLPPGKPCYGATQKIPCCGVCSHNNCT), SEQ ID NO: 182 (GSRLIEDICLPRWGCLWEDDGGGGSGGGGSVRIPVSCKHSGQCLKPCKDAGMRFGKC MNGKCDCTPK), or SEQ ID NO: 185 (RLIEDICLPRWGCLWEDDGGGGSGGGGSVRIPVSCKHSGQCLKPCKDAGMRFGKCMN GKCDCTPK)).
  • SEQ ID NO: 180 GSRLIEDICLPRWGCLWEDDGGGGSGGGGSKCLPPGKPCYGATQKIPCCGVCSHNNCT
  • SEQ ID NO: 183 RLIEDICLPR
  • conjugation of the peptide to a near infrared dye, such as Cy5.5, or to an albumin binder such as Albu-tag can extend serum half-life of any peptide as described herein.
  • immunogenicity is reduced by using minimal non-human protein sequences to extend serum half-life of the peptide.
  • the first two N-terminal amino acids (GS) of SEQ ID NO: 1 - SEQ ID NO: 64 serve as a spacer or linker in order to facilitate conjugation or fusion to another molecule, as well as to facilitate cleavage of the peptide from such conjugated to, linked to, or fused molecules.
  • the fusion proteins or peptides of the present disclosure can be conjugated to, linked to, or fused to other moieties that, e.g., can modify or effect changes to the properties of the peptides.
  • peptides or peptide complexes of the present disclosure can also be conjugated to, linked to, or fused to other affinity handles.
  • Other affinity handles can include genetic fusion affinity handles.
  • Genetic fusion affinity handles can include 6xHis (HHHHHH (SEQ ID NO: 142), 6xHisN (HHHHHHGGGGS (SEQ ID NO: 542)) or GGGGSHHHHHH (SEQ ID NO: 228); immobilized metal affinity column purification possible), FLAG (DYKDDDDK (SEQ ID NO: 143); anti-FLAG immunoprecipitation), “shorty” FLAG (DYKDE (SEQ ID NO: 144); anti-FLAG immunoprecipitation), hemagglutinin (YPYDVPDYA (SEQ ID NO: 145); anti-HA immunoprecipitation), streptavidin binding peptide (e.g., DVEAWLGAR (SEQ ID NO: 146); streptavidin-mediated precipitation), biotinylation
  • peptides of the present disclosure may comprise a biotinylation tag (e.g., SEQ ID NO: 543) and undergo biotinylation by a BirA enzyme.
  • peptides or peptide complexes of the present disclosure can also be conjugated to, linked to, or fused to an expression tag or sequence to improve protein expression and/or purification.
  • expression tags can include genetic fusion expression tags.
  • Genetic fusion expression tags can include siderocalin (SEQ ID NO: 147,
  • a peptide of the present disclosure may be modified with an affinity handle for to improve protein expression and/or purification and further have the affinity handle removed without loss of function or binding-properties.
  • a peptide may be modified with a 6xHis (HHHHHH (SEQ ID NO: 142) and have the 6xHis (HHHHHH (SEQ ID NO: 142) removed without loss of function or binding-properties.
  • a peptide may be modified with a 6xHisN (HHHHHHGGGGS (SEQ ID NO: 542)) and have the 6xHisN (HHHHHHGGGGS (SEQ ID NO: 542)) removed without loss of function or binding-properties. It is understood that such modification of peptide of the present disclosure can use any length of His affinity handle. Additionally, more than one peptide sequence (e.g., a peptide derived from a toxin or knotted venom protein) can be present on, conjugated to, linked to, or fused with a particular peptide. A peptide can be incorporated into a biomolecule by various techniques.
  • a peptide can be incorporated by a chemical transformation, such as the formation of a covalent bond, such as an amide bond.
  • a peptide can be incorporated, for example, by solid phase or solution phase peptide synthesis.
  • a peptide can be incorporated by preparing a nucleic acid sequence encoding the biomolecule, wherein the nucleic acid sequence includes a subsequence that encodes the peptide. The subsequence can be in addition to the sequence that encodes the biomolecule or can substitute for a subsequence of the sequence that encodes the biomolecule.
  • one or more peptides of the present disclosure can form a selective depletion complex (SDC).
  • a peptide complex of the present disclosure can be a selective depletion complex (SDC).
  • a selective depletion complex may comprise a target-binding peptide that binds a target molecule and a receptor-binding peptide that binds a cellular receptor (e.g., a cell surface receptor).
  • the cell surface receptor is a receptor that is endocytosed (e.g., a transferrin receptor or a programmed death-ligand 1).
  • the cell surface receptor is a receptor that is recycled back to the cell surface following endocytosis.
  • a receptor-binding peptide of the present disclosure may be a transferrin receptor (TfR)-b inding peptide or a programmed death ligand 1 (PD-Ll)-b inding peptide.
  • a selective depletion complex can comprise a TfR- binding peptide and a target-binding peptide.
  • the receptor-binding peptide e.g., the TfR-binding peptide or the PD-Ll-binding peptide
  • the target-binding peptide can be connected via a linker (e.g., a peptide linker).
  • the receptor -binding peptide and the target-binding peptide can be directly connected without a linker. In some embodiments, the receptor-binding peptide and the target-binding peptide can be connected via a heterodimerization domain. In some embodiments, the receptor-binding peptide can bind the receptor (e.g., TfR or PD-L1) with high affinity at both extracellular pH (such as about pH 7.4) and at endosomal pH (such as about pH 5.5).
  • TfR or PD-L1 bind the receptor (e.g., TfR or PD-L1) with high affinity at both extracellular pH (such as about pH 7.4) and at endosomal pH (such as about pH 5.5).
  • the receptorbinding peptide of a selective depletion complex may be a TfR-binding peptide (e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64).
  • TfR-binding peptide e.g., any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64).
  • the receptor-binding peptide of a selective depletion complex may be a PD-L1 -binding peptide (e.g., any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 141).
  • PD-L1 -binding peptide e.g., any one of SEQ ID NO: 187, SEQ ID NO: 233 - SEQ ID NO: 239, SEQ ID NO: 400 - SEQ ID NO: 456, or SEQ ID NO: 141).
  • the target-binding peptide can bind a target molecule with an affinity that is pH- dependent.
  • the target-binding molecule can bind to the target molecule with higher affinity at extracellular pH (about pH 7.4) and with lower affinity at a lower endosomal pH (such as about pH 5.5, about pH 5.8, or about pH 6.5).
  • the target-binding molecule can release the target molecule upon internalization into an endosomal compartment and acidification of the endosome.
  • Such release of the target molecule upon acidification of the endosome can occur at about pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • release of the target molecule can occur at a pH of from about pH 7.0 to about pH 4.5, from about pH 6.5 to about pH 5.0, or from about pH 6.0 to about pH 5.5.
  • the receptor-binding peptide binds a receptor (e.g., a receptor that undergoes recycling) with pH-independent binding (e.g., high affinity at extracellular pH and high affinity at endosomal pH) and the target-binding peptide binds the target with pH-dependent binding (e.g., high affinity at extracellular pH and low affinity at endosomal pH).
  • a selective depletion complex (SDC) comprising a pH-independent receptor-binding peptide and a pH-dependent target-binding peptide may be catalytic (e.g., reused).
  • the SDC may stay bound to the receptor through multiple rounds of endocytosis and has the potential to carry another target molecule in each round and leave the target molecule in the endosome/lysosome for degradation. Thus, one catalytic SDC molecule may cause the degradation of multiple target molecules.
  • the receptor-binding peptide can bind to the receptor with an affinity that is pH dependent. For example, the receptor-binding molecule can bind to the receptor with higher affinity at extracellular pH (such as about pH 7.4) and with lower affinity at a lower endosomal pH (such as about pH 5.5, about pH 5.8, or about pH 6.5), thereby releasing the selective depletion complex from the receptor upon internalization and acidification of the endosomal compartment.
  • the receptor-binding peptide can bind the receptor with an affinity that is pH dependent and the target-binding peptide can bind the target with an affinity that is pH dependent or that is pH-independent.
  • the selective depletion complex releases the target (or the receptor) in the endosome with fast enough dissociation kinetics that the target (or the target-selective depletion complex complex) is released in the endosome regardless of the effect of pH on binding.
  • a selective depletion molecule can be used to selectively deplete a target molecule (e.g., a soluble protein or a cell surface protein).
  • a selective depletion complex comprising a receptor-binding peptide and a target-binding peptide can bind to the receptor via the receptor-binding peptide and to a target molecule (e.g., a soluble protein or a cell surface protein).
  • the target molecule can be delivered to an endocytic compartment via receptor-mediated endocytosis of the receptor and the selective depletion molecule.
  • the selective depletion complex In the endocytic compartment, the selective depletion complex can remain bound to the receptor, and the target molecule can be released from the selective depletion complex as the endocytic compartment acidifies.
  • the selective depletion molecule can be recycled to the cell surface along with the receptor, and the target molecule can continue to the lysosome where it is degraded.
  • the target molecule can remain in the endosome or lysosome without being degraded, resulting in enrichment of the target molecule in the endosome or lysosome.
  • the selective depletion complexes of the present disclosure can have a low molecular weight compared to targetbinding antibodies and can be used to bind and deplete a target without requiring a supply and distribution cold chain.
  • a receptor-binding peptide may bind to a cellular receptor (e.g., TfR or PD-L1) with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM.
  • KD equilibrium dissociation constant
  • a receptor-binding peptide may bind to a cellular receptor (e.g., TfR or PD-L1) with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM.
  • KD equilibrium dissociation constant
  • a receptor-binding peptide may bind to a cellular receptor (e.g., TfR or PD-L1) with a dissociation rate constant (k o ff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4
  • a receptor-binding peptide has an off rate that is slower than the recycling rate of the cellular receptor, such that the receptor-binding peptide is likely to remain bound to receptor during the recycling process.
  • the receptor-binding peptide may have an off rate that is no faster than 1 minute, no faster than 2 minutes, no faster than 3 minutes, no faster than 4 minutes, no faster than 5 minutes, no faster than 7 minutes, no faster than 10 minutes, no faster than 15 minutes, or no faster than 20 minutes.
  • the receptor-binding peptide may have an off rate that is from about 1 minute to about 20 minutes, from about 2 minutes to about 15 minutes, from about 2 minutes to about 10 minutes, or from about 5 minutes to about 10 minutes.
  • the selective depletion complexes of the present disclosure can be used to treat a disease or a condition by selectively depleting a target molecule that is associated with the disease or the condition.
  • a selective depletion complex can be used to selectively deplete a soluble or cell surface protein that accumulates, contains a disease-associated mutation (e.g., a mutation causing constitutive activity, resistance to treatment, or dominant negative activity), or is over-expressed in a disease state.
  • the selective depletion complexes of the present disclosure can be used for the treatment and prevention of various neurological diseases including but not limited to epilepsy, schizophrenia, depression, anxiety, bipolar disorder, developmental brain disorders (e.g., autism spectrum), or mood disorder.
  • Binding of the herein described selective depletion complexes e.g., peptide conjugates, fusion peptides, or recomb inantly produced peptide complexes
  • TfR a cell layer or barrier
  • BBB e.g., via vesicular transcytosis
  • a cell membrane e.g., via endocytosis
  • Binding of the herein described selective depletion complexes e.g., peptide conjugates, fusion peptides, or recomb inantly produced peptide complexes
  • TfR a cell layer or barrier
  • BBB e.g., via vesicular transcytosis
  • a cell membrane e.g., via endocytosis
  • Cancers that can treated or prevented with the herein described selective depletion complexes can include breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin lymphoma, myeloma, blood-cell-derived cancer, spleen cancer, lung cancer, pancreatic cancer, prostate cancer, sarcoma, stomach cancer, esophageal cancer, gastrointestinal (GI) cancers, thyroid cancer, endometrial cancer, bladder cancer, cancers of the salivary gland, kidney cancer, muscle cancers, ovarian cancer, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, diffuse intrinsic pontine glioma, lung cancer, bone marrow cell cancers, skin cancer, melanoma, genitourinary cancer, osteosarcoma, muscle- derived sarcoma, mela
  • a selective depletion complex comprising a target-binding peptide that binds a protein associated with cancer (e.g., EGFR) can be used to treat a cancer.
  • a selective depletion complex for treatment of a cancer can comprise a target-binding peptide that binds an extracellular, soluble, or cell surface protein associated with cell growth, cell division, avoidance of cell death, immune evasion, suppression of inflammatory responses, promotion of vascular growth, or protection from hypoxia.
  • a selective depletion complex e.g., comprising a target-binding peptide and a cellular receptor-binding peptide
  • a selective depletion complex component e.g., comprising a target-binding peptide or a cellular receptor-binding peptide and a dimerization domain capable of facilitating dimerization to form a complete selective depletion complex
  • an EGFR inhibitor peptide complex (e.g., comprising a target-binding peptide and a dimerization domain capable of dimerizing to form a peptide complex capable of EGFR inhibition) may comprise a sequence of SEQ ID NO: 498 or SEQ ID NO: 502.
  • a selective depletion complex e.g., comprising a target-binding peptide and a cellular receptor-binding peptide
  • a selective depletion complex component e.g., comprising a target-binding peptide or a cellular receptor-binding peptide and a dimerization domain capable of facilitating dimerization to form a complete selective depletion complex
  • an EGFR inhibitor peptide complex (e.g., comprising a target-binding peptide and a dimerization domain capable of dimerizing to form a peptide complex capable of EGFR inhibition) may comprise a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 96, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 498 or SEQ ID NO: 502.
  • the target-binding peptide portion of the EGFR inhibitor peptide complex comprising a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 498 or SEQ ID NO: 502 may be replaced with an EGFR target-binding peptide of any one of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • a non-activating EGF variant peptide or peptide complex of the present disclosure e.g., any one of SEQ ID NO: 388 - SEQ ID NO: 390, SEQ ID NO: 457 - SEQ ID NO: 494, SEQ ID NO: 498, or SEQ ID NO: 502 or a non-activating EGF variant peptide complex may be administered to a subject (e.g., a human or non-human animal subject) to inhibit EGFR activity in the subject.
  • EGFR activity may be associated with uncontrolled cell growth, cell survival, immunosuppression, therapeutic treatment resistance, transcriptional program alteration, or other processes contributing to cancer progression, and inhibiting EGFR activity may reduce cancer cell growth, survival, immunosuppression, therapeutic treatment resistance, transcriptional program alteration, other processes contributing to cancer progression, or a combination thereof.
  • Inhibition of EGFR may be beneficial in diseases such as cancer driven by MEK/ERK and/or PI3K/AKT signaling or other signaling pathways to which EGFR signaling contributes.
  • inhibiting EGFR e.g., by administering a non-activating EGF variant peptide
  • the non-activating EGF variant peptides of the present disclosure may inhibit EGFR by blocking interactions between EGFR and normal EGF.
  • SEQ ID NO: 494 shares its EGFR Domain III binding site with normal EGF, preventing EGF from accessing the binding interface.
  • the non-activating EGF variant peptides of the present disclosure may inhibit EGFR by binding to EGFR Domain III and preventing normal EGF from contacting both Domain III and Domain I, which is mechanistically known to induce a conformation change in Domain II that permits homo- and hetero-dimerization.
  • Administration of a non-activating EGF variant peptide or non-activating EGF variant peptide complex may be used in a method of treating cancer by binding to and inhibiting EGFR upon administration to a subject. Inhibition of EGFR may disrupt cancer cell growth, survival, immunosuppression, therapeutic treatment resistance, transcriptional program alteration, or a combination thereof.
  • the non-activating EGF variant peptides described herein may be used to treat any cancer driven in part by signaling arising from EGFR homo- or heterodimerization.
  • melanoma non-small cell lung cancer, small cell lung cancer, renal cancer, esophageal cancer, oral cancer, hepatocellular cancer, ovarian cancer, cervical cancer, colorectal cancer, lymphoma, bladder cancer, liver cancer, gastric cancer, breast cancer, pancreatic cancer, prostate cancer, Merkel cell carcinoma, mes
  • Percent (%) sequence identity or homology is determined by conventional methods. (See e.g., Altschul et al. (1986), Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff (1992), Proc. Natl. Acad. Sci. USA 89:10915). Briefly, two amino acid sequences can be aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the “BLOSUM62” scoring matrix of Henikoff and Henikoff (Id.). The sequence identity or homology is then calculated as: ([Total number of identical matches]/[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences])(100).
  • Various methods and software programs can be used to determine the homology between two or more peptides, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm. Pairwise sequence alignment can be used to identify regions of similarity that can indicate functional, structural and/or evolutionary relationships between two biological sequences (e.g., amino acid or nucleic acid sequences).
  • multiple sequence alignment is the alignment of three or more biological sequences. From the output of MSA applications, homology can be inferred and the evolutionary relationship between the sequences assessed.
  • sequence homology and “sequence identity” and “percent (%) sequence identity” and “percent (%) sequence homology” are used interchangeably to mean the sequence relatedness or variation, as appropriate, to a reference polynucleotide or amino acid sequence.
  • the “FASTA” similarity search algorithm of Pearson and Lipman can be a suitable protein alignment method for examining the level of sequence identity or homology shared by an amino acid sequence of a peptide disclosed herein and the amino acid sequence of a peptide variant.
  • the FASTA algorithm is described, for example, by Pearson and Lipman, Proc. Nat’l Acad. Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990).
  • the ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are “trimmed” to include only those residues that contribute to the highest score.
  • the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps.
  • the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, Siam J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions.
  • FASTA can also be used to determine the sequence identity or homology of nucleic acid sequences or molecules using a ratio as disclosed above.
  • the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as described herein.
  • ⁇ amino acids that are a “conservative amino acid substitution” are illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine.
  • the BLOSUM62 table is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, Proc. Nat ’I Acad. Sci.
  • the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that can be introduced into the amino acid sequences of the present invention.
  • conservative amino acid substitution preferably refers to a substitution represented by a BLOSUM62 value of greater than -1.
  • an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3.
  • preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).
  • Determination of amino acid residues that are within regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that can be more or less tolerant of change and maintain the overall tertiary structure of the molecule.
  • Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity or homology and computer analysis using available software (e.g., the Insight II.RTM. viewer and homology modeling tools; MSI, San Diego, Calif.), secondary structure propensities, binary patterns, complementary packing and buried polar interactions (Barton, G.J., Current Opin. Struct. Biol. 5:372-6 (1995) and Cordes, M.H. et al., Current Opin. Struct. Biol. 6:3-10 (1996)).
  • determination of structure can typically be accompanied by evaluating activity of modified molecules.
  • a peptide of the present disclosure can be engineered to improve or alter a property of the peptide.
  • a peptide can be modified to alter the affinity of the peptide for a binding partner (e.g., an EGFR target molecule or a TfR).
  • a peptide can be modified to alter binding affinity in a pH-dependent manner.
  • a peptide can be modified my introducing one or more amino acid variations into the peptide sequence and testing the effect of the variation on peptide properties (e.g., binding affinity).
  • a peptide or a library of peptides is designed in silico without derivation from a naturally occurring scaffold of a knotted peptide.
  • a peptide or a library of peptides is designed in silico by derivation, grafting relevant proteinbinding residues, or conserved residues in the protein-binding interface a naturally occurring peptide or protein known to bind to a protein or receptor of interest.
  • the peptide e.g., a TfR-binding peptide of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64
  • a TfR-binding peptide of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 is a simple helix-turn-helix.
  • the helix-turn-helix can be used for pharmacophore transfer onto other scaffolds, for example engraftment of the required TfR-engaging surface onto the helix-tum-helix scaffold using fusion tagging.
  • a peptide comprising SEQ ID NO: 1 is used as a scaffold or base sequence for further modifications, including addition, deletion, or amino acid substitution.
  • short sequences of amino acid residues such as GS are added at the N- terminus of a peptide.
  • peptides lack GS at the N-terminus.
  • peptides undergo one or more post-translational modifications.
  • a peptide capable of binding TfR and transcytosis across a cell membrane comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the exemplary peptide sequences listed in TABLE 1 (SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64), or a functional fragment thereof.
  • Two or more peptides can share a degree of sequence identity or homology and share similar properties in vivo.
  • a peptide can share a degree of sequence identity or homology with any one of the peptides of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64.
  • one or more peptides of the present disclosure have up to about 20% pairwise sequence identity or homology, up to about 25% pairwise sequence identity or homology, up to about 30% pairwise sequence identity or homology, up to about 35% pairwise sequence identity or homology, up to about 40% pairwise sequence identity or homology, up to about 45% pairwise sequence identity or homology, up to about 50% pairwise sequence identity or homology, up to about 55% pairwise sequence identity or homology, up to about 60% pairwise sequence identity or homology, up to about 65% pairwise sequence identity or homology, up to about 70% pairwise sequence identity or homology, up to about 75% pairwise sequence identity or homology, up to about 80% pairwise sequence identity or homology, up to about 85% pairwise sequence identity or homology, up to about 90% pairwise sequence identity or homology, up to about 95% pairwise sequence identity or homology, up to about 96% pairwise sequence identity or homology, up to about 97% pairwise sequence identity or homology, up to about 98% pairwise sequence identity or homology
  • one or more peptides of the disclosure have at least about 20% pairwise sequence identity or homology, at least about 25% pairwise sequence identity or homology, at least about 30% pairwise sequence identity or homology, at least about 35% pairwise sequence identity or homology, at least about 40% pairwise sequence identity or homology, at least about 45% pairwise sequence identity or homology, at least about 50% pairwise sequence identity or homology, at least about 55% pairwise sequence identity or homology, at least about 60% pairwise sequence identity or homology, at least about 65% pairwise sequence identity or homology, at least about 70% pairwise sequence identity or homology, at least about 75% pairwise sequence identity or homology, at least about 80% pairwise sequence identity or homology, at least about 85% pairwise sequence identity or homology, at least about 90% pairwise sequence identity or homology, at least about 95% pairwise sequence identity or homology, at least about 96% pairwise sequence identity or homology, at least about 97% pairwise sequence identity or homology, at least about 98% pairwise sequence identity or homology,
  • peptides that exhibit an improved TfR receptor binding show improved transcytosis function. In some cases, peptides that exhibit an improved TfR receptor binding show no or small changes in transcytosis function. In some cases, peptides that exhibit an improved TfR receptor binding show reduced transcytosis function.
  • the KA and KD values of a TfR-binding peptide can be modulated and optimized (e.g., via amino acid substitutions) to provide an optimal ratio of TfR-binding affinity and efficient transcytosis function.
  • the peptide or peptide complex is any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64, or a functional fragment thereof.
  • the peptide or peptide complex of the disclosure further comprises a peptide with 99%, 95%, 90%, 85%, or 80% sequence identity or homology to any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 or functional fragment thereof.
  • the peptide or peptide complex can be a peptide that is homologous to any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64, or a functional fragment thereof.
  • homologous can be used herein to denote peptides or peptide complexes having at least 70%, at least 80%, at least 90%, at least 95%, or greater than 95% sequence identity or homology to a sequence of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 or a functional fragment thereof.
  • a fragment can be least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 600, at least 700, at least 800, at least 900 or at least 1000 amino acids in length.
  • fragments can be at most 1000, at most 900, at most 800, at most 700, at most 600, at most 500, at most 450, at most 400, at most 350, at most 300, at most 250, at most 200, at most 150, at most 100, at most 50, at most 45, at most 40, at most 35, at most 30, at most 25, at most 20, at most 15, at most 10, or at most 5 amino acids in length.
  • a fragment can be from about 5 to about 50, from about 10 to about 50, from about 10 to about 40, from about 10 to about 30, or from about 10 to about 20 amino acids in length.
  • nucleic acid molecules that encode a peptide or peptide complex of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 can be identified by either a determination of the sequence identity or homology of the encoded peptide amino acid sequence with the amino acid sequence of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64, or by a nucleic acid hybridization assay.
  • Such peptide variants or peptide complex variants of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 can be characterized as nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1x-0.2x
  • a peptide of the present disclosure can be identified or modified through affinity maturation.
  • a target-binding peptide that binds a target of interest can be identified by affinity maturation of a binding peptide (e.g., a CDP, a nanobody, an affibody, a DARPin, a centyrin, a nanofittin, an adnectin, or an antibody fragment).
  • a binding peptide can undergo affinity maturation by generating a library of every possible point mutation, or in the case of a CDP, every possible non-cysteine point mutation.
  • the variant library can be expressed via surface display (e.g., in yeast or mammalian cells) and screened for binding to a binding partner (e.g., an EGFR target molecule or TfR).
  • a binding partner e.g., an EGFR target molecule or TfR.
  • Library members with increased binding affinity relative to the initial peptide or relative to other members of the variant library can undergo subsequent rounds of maturation. During each round, a variant library of every possible non-cysteine point mutation is generated and screened.
  • a peptide can undergo 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 rounds of affinity maturation to identify a peptide with improved binding affinity to the binding partner of interest (e.g., an EGFR target molecule or TfR).
  • Variants can be identified by Sanger sequencing, next generation sequencing, or high throughput sequencing (e.g., Illumina sequencing).
  • a peptide e.g., a TfR-binding peptide, a PD-Ll-binding peptide, or an EGFR target-binding peptide
  • a peptide can be selected for pH-independent binding.
  • a peptide can be selected for high affinity binding to a binding partner (e.g., an EGFR target molecule or a TfR) at both extracellular pH (about pH 7.4) and at endosomal pH (such as about pH 5.5).
  • a peptide with pH-independent binding can bind to a binding partner with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at extracellular pH (about pH 7.4).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at endosomal pH (such as about pH 5.5).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at endosomal pH (such as about pH 5.8).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH- dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.8.
  • KD equilibrium dissociation constant
  • the affinity of a target-binding peptide with pH-dependent binding to a target molecule at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25- fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of a target-binding peptide with pH-dependent binding to a target molecule at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • a target-binding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (k o ff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 7.4.
  • k o ff or kd dissociation rate constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ no more than 5xl0’ 4 s’ 1 , or no more than 2xl0’ 4 s’ 1 at pH 5.5.
  • koff or kd dissociation rate constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O' 2 s' 1 , no more than 5x1 O' 2 s' 1 , no more than 2x1 O' 2 s' 1 , no more than 1x1 O' 2 s' 1 , no more than 5x1 O' 3 s' 1 , no more than 2x1 O' 3 s' 1 , no more than 1x1 O' 3 s' 1 , no more than 5x1 O' 4 s' or no more than 2x1 O' 4 s' 1 at pH 5.8.
  • koff or kd dissociation rate constant
  • the dissociation rate constant (k o ff or kd) of a target-binding peptide with pH-dependent binding to a target molecule at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of a target-binding peptide with pH-dependent binding to a target molecule at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the TfR-binding peptides are stable at endosomal pH, and do not release in the endosome for example under acidic conditions, such as pH 6.9, pH 6.8, pH 6.7, pH
  • a peptide that has high affinity for binding to a selected target and used in selective depletion complexes as the peptide or peptide complex that binds such selected target molecule and is released in the endosome for degradation within the cell can be a pH-dependent targetbinding CDP such that it is released in the endosome.
  • the target-binding peptides are less stable at endosomal pH, and release wholly or in part in the endosome for example under acidic conditions, such as pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH
  • the peptides of the present disclosure can be modified for pH-dependent binding properties.
  • Imparting pH-dependent binding to a target-binding peptide e.g., a target-binding EGF variant
  • a library of peptide variant containing histidine (His) point mutations can be designed.
  • Histidine amino acids are introduced into the target-binding peptide because His is the only natural amino acid whose side chain has a pKa value between neutral (pH 7.4) and acidic (pH ⁇ 6) endosomal conditions, and this change of charge as pH changes can alter binding, either directly (e.g., changing charge-charge interaction upon formation of a positive charge at low pH) or indirectly (e.g., the change in charge imparts a subtle change in the structure of the targetbinding peptide, disrupting an interface between the target molecule and the target-binding peptide).
  • a variant screen of the target-binding peptide can be implemented by generating double-His doped libraries.
  • a double-His doped library of a target-binding CDP can comprise a library where every non-Cys, non-His residue is substituted with a His amino acid one- or two-at-a-time.
  • a variant library can be expressed in cells (e.g., yeast cells or mammalian cells) via surface display, with each target-binding peptide variant containing one or two His substitutions.
  • Target-binding peptide variants can be tested for maintenance of binding under neutral pH (about pH 7.4), and for reduced binding under low pH (about pH 6.0, about pH 5.8, or about pH 5.5). Variants that demonstrated reduced binding affinity under low pH as compared to neutral pH can be identified as target-binding peptides with pH-dependent binding.
  • a pH-dependent EGFR target-binding peptide may comprise one or more His substitutions in a sequence of any one of SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • the target-binding peptides of the present disclosure can have a high target-binding affinity at physiologic extracellular pH but a significantly reduced binding affinity at lower pH levels such as endosomal pH of 5.5.
  • the target-binding peptides of the present disclosure can be optimized for improved intra- vesicular (e.g., intra-endosomal) and/or intracellular delivery function while retaining high target-binding capabilities.
  • histidine scans and comparative binding experiments can be performed to develop and screen for such peptides.
  • an amino acid residue in a peptide of the present disclosure is substituted with a different amino acid residue to alter a pH-dependent binding affinity to a target molecule.
  • the amino acid substitution can increase a binding affinity at low pH, increase a binding affinity at high pH, decrease a binding affinity at low pH, decrease a binding affinity at high pH, or a combination thereof.
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of less than 50 pM, less than 5 pM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at extracellular pH (such as about pH 7.4).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 20 nM, at least 50 nM, of at least 100 nM, at least 200 nM, at least 500 nM, at least 1 pM, at least 2 pM, at least 5 pM, at least 10 pM, at least 20 pM, at least 50 pM, at least 100 pM, at least 500 pM, at least 1 mM, at least 2 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 50 mM, at least 100 mM, at least 200 mM, at least 500 mM, or at least 1 M at endosomal pH (such as about pH 5.5).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 20 nM, at least 50 nM, of at least 100 nM, at least 200 nM, at least 500 nM, at least 1 pM, at least 2 pM, at least 5 pM, at least 10 pM, at least 20 pM, at least 50 pM, at least 100 pM, at least 500 pM, at least 1 mM, at least 2 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 50 mM, at least 100 mM, at least 200 mM, at least 500 mM, or at least 1 M at endosomal pH (such as about pH 5.8).
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 7.4.
  • KD equilibrium dissociation constant
  • a target-binding peptide with pH- dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.5.
  • KD equilibrium dissociation constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with an equilibrium dissociation constant (KD) of no more than 100 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, or no more than 0.1 nM at pH 5.8.
  • KD equilibrium dissociation constant
  • the affinity of a target-binding peptide with pH-dependent binding can bind a target molecule at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the affinity of a target-binding peptide with pH-dependent binding can bind a target molecule at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • a target-binding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (k o ff or kd) of no more than 1 s’ 1 , no more than 5x1 O’ 1 s’ 1 , no more than 2x1 O’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , or no more than 2x1 O’ 4 s’ 1 at pH 7.4.
  • k o ff or kd dissociation rate constant
  • a target-binding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x1 O’ 1 s’ 1 , no more than 2x1 O’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ no more than 5xl0’ 4 s’ 1 , or no more than 2xl0’ 4 s’ 1 at pH 5.5.
  • koff or kd dissociation rate constant
  • a targetbinding peptide with pH-dependent binding can bind a target molecule with a dissociation rate constant (koff or kd) of no more than 1 s’ 1 , no more than 5x1 O’ 1 s’ 1 , no more than 2x1 O’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ or no more than 2x1 O’ 4 s’ 1 at pH 5.8.
  • koff or kd dissociation rate constant
  • the dissociation rate constant (koff or kd) of a target-binding peptide with pH-dependent binding can bind a target molecule at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the dissociation rate constant (koff or kd) of a target-binding peptide with pH-dependent binding can bind a target molecule at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • the TfR-binding peptides are stable at endosomal pH, and do not release in the endosome for example under acidic conditions, such as pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • acidic conditions such as pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • a peptide that has high affinity for binding to a selected target and used in selective depletion complexes as the peptide or peptide complex that binds such selected target and is released in the endosome for degradation within the cell can be a pH-dependent target-binding CDP such that it is released in the endosome.
  • the target-binding peptides are less stable at endosomal pH, and release wholly or in part in the endosome for example under acidic conditions, such as pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower.
  • acidic conditions such as pH 7.4, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH
  • the selective depletion complexes of the present disclosure may be used to exert an effect on a cell, tissue, or subject.
  • the effect may be a therapeutic, pharmacological, biological, or biochemical effect.
  • the effect may result from selective depletion of a target molecule to which the selective depletion complex binds.
  • the effect may result from ternary complex formation between a target molecule, a receptor, and a selective depletion complex that binds the target molecule and the receptor.
  • a method of the present disclosure can comprise selectively recruiting a molecule to an endocytic compartment via transferrin receptor-mediated endocytosis and enriching the target molecule in the lysosome.
  • a method of the present disclosure can comprise selectively depleting a molecule from the external environment or the cell surface.
  • a method of the present disclosure can comprise selectively depleting a molecule from the external environment or the cell surface via transferrin receptor-mediated endocytosis.
  • a selective depletion complex (e.g., a peptide complex comprising a receptorbinding peptide conjugated to a target-binding peptide such as an EGFR target-binding peptide) can bind to the receptor via the receptor-binding peptide and to a target molecule (e.g., a soluble protein, an extracellular protein, or a cell surface protein).
  • the target molecule can be delivered to an endocytic compartment via receptor-mediated endocytosis of the receptor and the selective depletion molecule.
  • the selective depletion complex In the endocytic compartment, the selective depletion complex can remain bound to the receptor, and the target molecule can be released from the selective depletion complex as the endocytic compartment acidifies.
  • the selective depletion molecule can be recycled to the cell surface along with the receptor, and the target molecule can continue to the lysosome where it is degraded.
  • the target molecule can remain in the endosome or the lysosome without being degraded, resulting in enrichment of the target molecule in the endosome or the lysosome, such as lysosomal enzymes in lysosomal storage diseases.
  • the methods of the present disclosure for selectively depleting a target molecule can be used to treat a disease or condition associated with the target molecule.
  • a target molecule e.g., an EGFR target molecule
  • selective depletion of a target molecule associated with cancer can be used to treat the cancer.
  • Depletion of a cell surface molecule can allow the cancer cell to be targeted by the immune system, to lose checkpoint inhibition, can disable survival signaling, or remove drug resistance pumps.
  • selective enrichment in the lysosome of a lysosomal enzyme associated with a lysosomal storage disease can be used to treat the lysosomal storage disease.
  • a lysosomal enzyme can be administered in co-therapy with the target-depleting complex, such that the target depleting complex drives the lysosomal enzyme into the lysosomal compartment.
  • a method of treating a disease or condition can comprise contacting a cell (e.g., a cell expressing the receptor) with a selective depletion complex of the present disclosure.
  • the selective depletion complex can be administered to a subject (e.g., a human subject) having a disease or condition (e.g., a neurodegenerative disease, a cancer, harmful inflammation, or a lysosomal storage disease).
  • TfR is a fairly ubiquitous protein, as all mammalian cells require iron and therefore take up transferrin through this constitutive pathway. By this mechanism, virtually any target tissue would be amenable to the selective depletion methods or selective enrichment methods of the present disclosure comprising a TfR-binding peptide. Tumor tissue can be particularly well- suited for the methods of the present disclosure as most tumors are enriched for TfR, which can impart natural tumor selectivity in the selective depletion molecules. TfR has been identified as a potential universal cancer marker.
  • Tumors promoting angiogenesis can also overexpress TfR, as both vascular endothelial growth factor (VEGF) and TfR can be expressed as a result of hypoxia-inducible factor (HIF-la)-driven transcriptional programs, and thus be a favorable tissue for selective depletion methods involving transferrin receptor-mediated use of SDCs described herein.
  • VEGF vascular endothelial growth factor
  • HIF-la hypoxia-inducible factor
  • Liver tissue can also be highly enriched for TfR and thus be a favorable tissue for selective depletion methods.
  • the selective depletion complexes of the present disclosure e.g., selective depletion complexes comprising a CDP
  • a selective depletion complex of the present disclosure can have a half-life in the liver of at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 hours.
  • Serum proteins which can already largely be subject to hepatic metabolism as a class, could be targeted for selective depletion with relatively low doses of selective depletion complexes.
  • Serum half-life of the selective depletion complexes of the present disclosure could be improved to create a molecule that requires infrequent dosing, for example by addition of a serum half-life extension peptide.
  • Selective depletion complexes with a shorter half-life can serve as an acute target elimination drug, for example to treat harmful inflammatory signaling.
  • a selective depletion complex can be administered to a subject systemically or peripherally and can accumulate in tissue with high levels of TfR expression (e.g., tumor tissue, kidney tissue, spleen, bone marrow, or liver tissue) or high levels of target expression or with high levels of both receptor (e.g., TfR) and target.
  • a selective depletion complex can be administered to a subject systemically or peripherally and can accumulate in tumor tissue, kidney tissue, or liver tissue.
  • a selective depletion complex can comprise a tissue targeting domain and can accumulate in the target tissue upon administration to a subject.
  • selective depletion complexes can be conjugated to, linked to, or fused to a molecule (e.g., small molecule, peptide, or protein) with targeting or homing function for a cell of interest or a target protein located on the surface or inside said cell.
  • a selective depletion complex can be administered to a subject orally and can reach the gastrointestinal tract.
  • Orally administered selective depletion complexes can be used for clearance of disease-associated proteins in the gastrointestinal tract.
  • a selective depletion complex of the present disclosure can be genetically encoded into a benign cell with a secretory phenotype.
  • the selective depletion complex can be expressed by the secretory cell and administered as a secreted molecule in a localized cellular therapy.
  • a gene encoding a selective depletion complex can be delivered as a gene therapy to a tissue of interest (e.g., liver, hematopoietic, kidney, skin, tumor, central nervous system (CNS), or neurons).
  • an EGF variant peptide construct may comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, an scFv, an (scFv)2, a DARPin, or an afflbody.
  • the target-binding peptide may comprise a cystine-dense peptide, an affltin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • the target molecule is over-expressed in the disease or condition and depleting the target molecule reduces the level of the target molecule, thereby treating the disease or condition. In some embodiments, the target molecule accumulates in the disease or condition and depleting the target molecule clears or reduces the accumulation, thereby treating the disease or condition. In some embodiments, the target molecule is hyper-activated or over-stimulated, and depleting the target molecule reduces a level of activity of the target molecule, thereby treating the disease or condition.
  • cancers e.g., non-small-cell lung cancer, primary non-small-cell lung cancer, metastatic non- small-cell lung cancer, head and neck cancer, head and neck squamous cell carcinoma, glioblastoma, brain cancer,
  • the cancer has one or more of the following: overexpresses EGFR, KRAS mutation, KRAS G12S mutation, KRAS G12C mutation, PTEN loss, EGFR exonl9 deletion, EGFR L858R mutation, EGFR T790M mutation, a cetuximab-resistant EGFR, a panitumumab-resistant EGFR, PIK3CA mutation, TP53 R273H mutation, PIK3CA amplification, PIK3CA G118D, TP53 R273H, EGFR C797X mutation, EGFR G724S mutation, EGFR L718Q mutation, EGFR S768I mutation, an EGFR mutation, or a combination thereof.
  • the cancer expresses or has upregulated c-MET, Her2, Her3 that heterodimerizes with EGFR.
  • Administration of a selective depletion complex of the present disclosure may be combined with an additional therapy to treat a disease or condition.
  • the additional therapy is adjuvant, first-line, or combination therapy.
  • the additional therapy comprises radiation, chemotherapy, platinum therapy, anti-metabolic therapy, targeted therapy to other oncogenic signaling pathways, targeted therapy to immune response pathways, therapy aimed at directly driving an immune response to cancer cells, or targeted therapies disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells.
  • the targeted therapy to other oncogenic signaling pathways comprises administration of inhibitors of MEK/ERK pathway signaling, PI3K/AKT pathway signaling, JAK/STAT pathway signaling, or WNT/p-catenin pathway signaling.
  • the targeted therapy to immune response pathways comprises PD-1/PD-L1 checkpoint inhibition.
  • the therapy aimed at therapy aimed at directly driving an immune response to cancer cells comprises bispecific T cell engagers or chimeric antigen receptor expressing T cells.
  • the targeted therapies disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells comprises administering seno lytic agents to a subject.
  • administration of a selective depletion complex to treat a cancer may be combined with administration of radiation therapy, chemotherapy, platinum therapy, or anti-metabolic therapy.
  • the additional therapy may comprise administering fluorouracil, FOLFIRI, irinotecan, FOLFOX, gemcitabine, cisplatin, irinotecan, oxiplatin, or fluoropyrimidine to the subject.
  • the ternary complex may form through binding of the receptor-binding peptide to the receptor and binding of the target-binding peptide to the target.
  • Ternary complex formation between the target, the receptor, and the selective depletion complex may exert a therapeutic, pharmacological, biological, or biochemical effect on a cell, tissue, or subject expressing the target and the receptor.
  • formation of a ternary complex between a receptor, a target, and a selective depletion complex may increase recycling or turnover of the target molecule, the receptor, or both. Increased recycling or turnover of the target or the receptor may alter (e.g., increase) activity of the target or the receptor, thereby exerting a therapeutic, pharmacological, biological, or biochemical effect.
  • Formation of the ternary complex may exert a therapeutic, pharmacological, biological, or biochemical by recruiting the target molecule to the receptor. Recruitment of the target molecule to the receptor may promote a binding interaction between the receptor and the target. In some embodiments, subsequent recycling of the receptor and the target may facilitate the therapeutic, pharmacological, biological, or biochemical effect. In some embodiments, formation of the ternary complex may increase, facilitate, or stabilize the interaction between the target and the receptor.
  • peptide complexes comprising one or more EGFR-binding peptides (e.g., target-binding EGF variants) as described herein conjugated to, linked to, or fused to, or complexed with one or more active agents (e.g., therapeutic agents, detectable agents, diagnostic, contrast, stabilizing agent, or other agent), or combinations thereof.
  • active agents e.g., therapeutic agents, detectable agents, diagnostic, contrast, stabilizing agent, or other agent
  • Active agents that may be complexed with or administered with a target-binding peptide may comprise a peptide (e.g., an oligopeptide or a polypeptide), a peptidomimetic, an oligonucleotide, a DNA (e.g., cDNA, ssDNA, or dsDNA), an RNA (e.g., an RNAi, microRNA, snRNA, dsRNA, or antisense oligonucleotide), an antibody, a single chain variable fragment (scFv), an antibody fragment, nanobody, an aptamer, or a small molecule.
  • a peptide e.g., an oligopeptide or a polypeptide
  • a peptidomimetic e.g., an oligonucleotide
  • a DNA e.g., cDNA, ssDNA, or dsDNA
  • an RNA e.g., an RNA
  • an EGF variant peptide may comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, an scFv, an (scFv)2, a DARPin, or an afflbody.
  • the target-binding peptide may comprise a cystine-dense peptide, an affltin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • the active agent may be an anti-cancer agent.
  • anti-cancer agents include radionuclides, radioisotopes, chemotherapeutic agents, platinum therapeutics, toxins, enzymes, sensitizing drugs, nucleic acids, including interfering RNAs, antibodies, anti-angiogenic agents, cisplatin, anti-metabolites, anti-metabolic therapeutics, mitotic inhibitors, growth factor inhibitors, paclitaxel, temozolomide, topotecan, fluorouracil, vincristine, vinblastine, procarbazine, decarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubicin, plicamycin, mitomycin,
  • An active agent may have an anti- metabolic effect, target oncogenic signaling pathways, target immune response pathways, directly drive an immune response to cancer cells, or target disrupting the growth, metabolism, or oncogenic signaling capabilities of senescent cells.
  • a peptide construct of the present disclosure can comprise an EGFR-binding peptide (e.g., an EGF variant of any of SEQ ID NO: 314, SEQ ID NO: 318 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494), that is linked to one or more active agents via one or more linker moieties (e.g., cleavable or stable linker) as described herein (e.g., a linker of any one of SEQ ID NO: 129 - SEQ ID NO: 141, SEQ ID NO: 195 - SEQ ID NO: 218, SEQ ID NO: 538, SEQ ID NO: 540, or SEQ ID NO: 541) or a half-life extending peptide (
  • An EGFR-binding peptide may be complexed with a detectable agent that comprises a dye, a fluorophore, a fluorescent biotin compound, a luminescent compound, a chemiluminescent compound, a radioisotope, nanoparticle, a paramagnetic metal ion, or a combination thereof.
  • a detectable agent that comprises a dye, a fluorophore, a fluorescent biotin compound, a luminescent compound, a chemiluminescent compound, a radioisotope, nanoparticle, a paramagnetic metal ion, or a combination thereof.
  • the compounds and methods of the present disclosure can be used alone or in combination with a companion diagnostic, therapeutic or imaging agent (whether such diagnostic, therapeutic or imaging agent is a fluorophore alone, or conjugated, fused, linked, or otherwise attached to a chemical agent or other moiety, small molecule, therapeutic, drug, protein, peptide, antibody protein or fragment of the foregoing, and in any combination of the foregoing; or used as a separate companion diagnostic, therapeutic or imaging agent in conjunction with the fluorophore or other detectable moiety is alone, conjugated, fused, linked, or otherwise attached to a chemical agent or other moiety, small molecule, therapeutic, drug, peptide, antibody protein or fragment of the foregoing, and in any combination of the foregoing).
  • a companion diagnostic, therapeutic or imaging agent is a fluorophore alone, or conjugated, fused, linked, or otherwise attached to a chemical agent or other moiety, small molecule, therapeutic, drug, peptide, antibody protein or fragment of the foregoing, and in any combination of
  • Such companion diagnostics can utilize agents including chemical agents, radiolabel agents, radiosensitizing agents, fluorophores, imaging agents, diagnostic agents, protein, peptide, or small molecule such agent intended for or having diagnostic or imaging effect.
  • Agents used for companion diagnostic agents and companion imaging agents, and therapeutic agents can include the diagnostic, therapeutic and imaging agents described herein or other known agents. Diagnostic tests can be used to enhance the use of therapeutic products, such as those disclosed herein or other known agents. The development of therapeutic products with a corresponding diagnostic test, such as a test that uses diagnostic imaging (whether in vivo, ex vivo or in vitro) can aid in diagnosis, treatment, identify patient populations for treatment, and enhance therapeutic effect of the corresponding therapy.
  • the compounds and methods of the present disclosure can also be used to detect therapeutic products, such as those disclosed herein or other known agents, to aid in the application of a therapy and to measure it to assess the agent’s safety and physiologic effect, e.g. to measure bioavailability, uptake, distribution and clearance, metabolism, pharmacokinetics, localization, blood concentration, tissue concentration, ratio, measurement of concentrations in blood and/or tissues, assessing therapeutic window, extending visibility window, range and optimization, and the like of the therapeutic agent.
  • therapeutic products such as those disclosed herein or other known agents
  • tests also aid therapeutic product development to obtain the data FDA uses to make regulatory determinations.
  • such a test can identify appropriate subpopulations for treatment or identify populations who should not receive a particular treatment because of an increased risk of a serious side effect, making it possible to individualize, or personalize, medical therapy by identifying patients who are most likely to respond, or who are at varying degrees of risk for a particular side effect.
  • the present disclosure includes the joint development of therapeutic products and diagnostic devices, including the compounds and methods herein (used to detect the therapeutic and/or imaging agents themselves, or used to detect the companion diagnostic or imaging agent, whether such diagnostic or imaging agent is linked to the therapeutic and/or imaging agents or used as a separate companion diagnostic or imaging agent linked to the peptide for use in conjunction with the therapeutic and/or imaging agents) that are used in conjunction with safe and effective use of the therapeutic and/or imaging agents as therapeutic or imaging products.
  • the compounds and methods herein used to detect the therapeutic and/or imaging agents themselves, or used to detect the companion diagnostic or imaging agent, whether such diagnostic or imaging agent is linked to the therapeutic and/or imaging agents or used as a separate companion diagnostic or imaging agent linked to the peptide for use in conjunction with the therapeutic and/or imaging agents
  • Non-limiting examples of companion devices include a surgical instrument, such as an operating microscope, confocal microscope, fluorescence scope, exoscope, endoscope, or a surgical robot and devices used in biological diagnosis or imaging or that incorporate radiology, including the imaging technologies of X-ray radiography, magnetic resonance imaging (MRI), medical ultrasonography or ultrasound, endoscopy, elastography, tactile imaging, thermography, medical photography and nuclear medicine functional imaging techniques as positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
  • a surgical instrument such as an operating microscope, confocal microscope, fluorescence scope, exoscope, endoscope, or a surgical robot and devices used in biological diagnosis or imaging or that incorporate radiology, including the imaging technologies of X-ray radiography, magnetic resonance imaging (MRI), medical ultrasonography or ultrasound, endoscopy, elastography, tactile imaging, thermography, medical photography and nuclear medicine functional imaging techniques as positron emission tomography (PET) and single-photon emission computed tom
  • Companion diagnostics and devices can comprise tests that are conducted ex vivo, including detection of signal from tissues or cells that are removed following administration of the companion diagnostic to the subject, or application of the companion diagnostic or companion imaging agent directly to tissues or cells following their removal from the subject and then detecting signal.
  • a peptide of the present disclosure can comprise a wide range of physicochemical properties such as molecular size and structure, pH, isoelectric point, and overall molecular net charge. These parameters can have an effect on the peptides ability to bind TfR, bind a target molecule (e.g., an EGFR target molecule), promote transcytosis, transport of cargo molecules across cell barrier such as the BBB, or combinations thereof.
  • a target molecule e.g., an EGFR target molecule
  • a peptide of the present disclosure can comprise at least one amino acid residue in D configuration.
  • a peptide is about 5-100 amino acid residues long.
  • a peptide is about 10-90 amino acid residues long.
  • a peptide is about 15-80 amino acid residues long.
  • a peptide is about 15-75 amino acid residues long.
  • a peptide is about 15-70 amino acid residues long.
  • a peptide is about 20-65 amino acid residues long.
  • a peptide is about 20-60 amino acid residues long.
  • a peptide is about 25-55 amino acid residues long.
  • a peptide is about 25-50 amino acid residues long. In some embodiments, a peptide is about 25-40 amino acid residues long. In some embodiments, a peptide is about 11-35 amino acid residues long. In some embodiments, a peptide is about 10-25 amino acid residues long.
  • a peptide is at least 5 amino acid residues long. In some embodiments, a peptide is at least 10 amino acid residues long. In some embodiments, a peptide is at least 15 amino acid residues long. In some embodiments, a peptide is at least 20 amino acid residues long. In some embodiments, a peptide is at least 25 amino acid residues long. In some embodiments, a peptide is at least 30 amino acid residues long. In some embodiments, a peptide is at least 35 amino acid residues long. In some embodiments, a peptide is at least 40 amino acid residues long. In some embodiments, a peptide is at least 45 amino acid residues long.
  • a peptide is at least 50 amino acid residues long. In some embodiments, a peptide is at least 55 amino acid residues long. In some embodiments, a peptide is at least 60 amino acid residues long. In some embodiments, a peptide is at least 65 amino acid residues long. In some embodiments, a peptide is at least 70 amino acid residues long. In some embodiments, a peptide is at least 75 amino acid residues long.
  • an amino acid sequence of a peptide as described herein comprises at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58 residues, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70,
  • a three-dimensional or tertiary structure of a peptide is primarily comprised of beta-sheets and/or alpha-helix structures.
  • designed or engineered peptides e.g., target-binding peptides, TfR-binding peptides, or selective depletion complexes
  • designed or engineered peptides are small, compact peptides or polypeptides stabilized by intra-chain disulfide bonds (e.g., mediated by cysteines) and a hydrophobic core.
  • engineered peptides have structures comprising helical bundles with at least one disulfide bridge between each of the alpha helices, thereby stabilizing the peptides.
  • the engineered TfR-b inding peptides comprise structures with three alpha helices and three intra-chain disulfide bonds, one between each of the three alpha helices in the bundle of alpha helices.
  • peptides as described herein can have an overall molecular net charge, for example, of -5, -4, -3, -2, -1, 0, +1, +2, +3, +4, or +5. When the net charge is zero, the peptide can be uncharged or zwitterionic.
  • a peptide contains one or more disulfide bonds and has a positive net charge at physiologic extracellular pH where the net charge can be +0.5 or less than +0.5, +1 or less than +1, +1.5 or less than +1.5, +2 or less than +2, +2.5 or less than +2.5, +3 or less than +3, +3.5 or less than +3.5, +4 or less than +4, +4.5 or less than +4.5, +5 or less than +5, +5.5 or less than +5.5, +6 or less than +6, +6.5 or less than +6.5, +7 or less than +7, +7.5 or less than +7.5, +8 or less than +8, +8.5 or less than +8.5, +9 or less than +9.5, +10 or less than +10.
  • a peptide has a negative net charge at physiologic extracellular pH where the net charge can be -0.5 or less than -0.5, -1 or less than -1, -1.5 or less than -1.5, -2 or less than -2, -2.5 or less than -2.5, -3 or less than -3, -3.5 or less than -3.5, -4 or less than -4, -4.5 or less than -4.5, -5 or less than -5, -5.5 or less than -5.5, -6 or less than -6, -6.5 or less than -6.5, -7 or less than -7, -7.5 or less than -7.5, -8 or less than -8, -8.5 or less than -8.5, -9 or less than -9.5, -10 or less than -10.
  • peptides of the present disclosure can have an isoelectric point (pl) value from 3 and 10. In other embodiments, peptides of the present disclosure can have a pl value from 4.3 and 8.9. In some embodiments, peptides of the present disclosure can have a pl value from 3-4. In some embodiments, peptides of the present disclosure can have a pl value from 3-5. In some embodiments, peptides of the present disclosure can have a pl value from 3-6. In some embodiments, peptides of the present disclosure can have a pl value from 3-7. In some embodiments, peptides of the present disclosure can have a pl value from 3-8.
  • pl isoelectric point
  • peptides of the present disclosure can have a pl value from 3-9. In some embodiments, peptides of the present disclosure can have a pl value from 4-5. In some embodiments, peptides of the present disclosure can have a pl value from 4-6. In some embodiments, peptides of the present disclosure can have a pl value from 4-7. In some embodiments, peptides of the present disclosure can have a pl value from 4-8. In some embodiments, peptides of the present disclosure can have a pl value from 4-9. In some embodiments, peptides of the present disclosure can have a pl value from 4-10. In some embodiments, peptides of the present disclosure can have a pl value from 5-6.
  • peptides of the present disclosure can have a pl value from 5-7. In some embodiments, peptides of the present disclosure can have a pl value from 5-8. In some embodiments, peptides of the present disclosure can have a pl value from 5-9. In some embodiments, peptides of the present disclosure can have a pl value from 5-10. In some embodiments, peptides of the present disclosure can have a pl value from 6-7. In some embodiments, peptides of the present disclosure can have a pl value from 6-8. In some embodiments, peptides of the present disclosure can have a pl value from 6-9. In some embodiments, peptides of the present disclosure can have a pl value from 6-10.
  • peptides of the present disclosure can have a pl value from 7-8. In some embodiments, peptides of the present disclosure can have a pl value from 7-9. In some embodiments, peptides of the present disclosure can have a pl value from 7-10. In some embodiments, peptides of the present disclosure can have a pl value from 8-9. In some embodiments, peptides of the present disclosure can have a pl value from 8-10. In some embodiments, peptides of the present disclosure can have a pl value from 9-10.
  • the engineering of one or more mutations within a peptide of the present disclosure yields a peptide with an altered isoelectric point, charge, surface charge, or rheology at physiologic extracellular pH.
  • Such engineering of a mutation to a peptide that can be derived from a scorpion or spider complex can change the net charge of the peptide, for example, by decreasing the net charge by 1, 2, 3, 4, or 5, or by increasing the net charge by 1, 2, 3, 4, or 5.
  • the engineered mutation can facilitate the ability of the peptide to bind a target protein, promote transcytosis, and penetrate a cell, an endosome, or the nucleus.
  • Suitable amino acid modifications for improving the rheology and potency of a peptide can include conservative or non-conservative mutations.
  • a peptide can comprise at most 1 amino acid mutation, at most 2 amino acid mutations, at most 3 amino acid mutations, at most 4 amino acid mutations, at most 5 amino acid mutations, at most 6 amino acid mutations, at most 7 amino acid mutations, at most 8 amino acid mutations, at most 9 amino acid mutations, at most 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin component that the peptide is derived from.
  • a peptide, or a functional fragment thereof comprises at least 1 amino acid mutation, at least 2 amino acid mutations, at least 3 amino acid mutations, at least 4 amino acid mutations, at least 5 amino acid mutations, at least 6 amino acid mutations, at least 7 amino acid mutations, at least 8 amino acid mutations, at least 9 amino acid mutations, at least 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin component that the peptide is derived from.
  • mutations can be engineered within a peptide to provide a peptide that has a desired charge or stability at physiologic extracellular pH.
  • a peptide of the current disclosure may have a binding affinity to a molecule (e.g., a target molecule or cellular receptor.
  • the binding affinity may be measured as an equilibrium dissociation constant (KD), a dissociation rate constant (koff or kd), or an off rate (k o ff).
  • a dissociation constant may be no more than 500 nM, no more than 200 nM, 100 nM, no more than 50 nM, no more than 20 nM, no more than 10 nM, no more than 5 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, no more than 0.4 nM, no more than 0.3 nM, no more than 0.2 nM, no more than 1 nM, or no more than 0.1 nM.
  • a dissociation rate constant may be no more than 1 s’ 1 , no more than 5x10’ 1 s’ 1 , no more than 2x10’ 1 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 2 s’ 1 , no more than 2x1 O’ 2 s’ 1 , no more than 1x1 O’ 2 s’ 1 , no more than 5x1 O’ 3 s’ 1 , no more than 2x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 1x1 O’ 3 s’ 1 , no more than 5x1 O’ 4 s’ 1 , 2x1 O’ 4 s’ 1 , no more than 1x1 O’ 4 s’ 1 , no more than 5x10’ 5 s’ 1 , or no more than 2x10’ 5 s’ 1 .
  • a lower equilibrium dissociation constant (KD) corresponds to
  • the nuclear magnetic resonance (NMR)solution structures, the X-ray crystal structures, as well as the primary structure sequence alignment of related structural peptide or protein homologs or in silico design can be used to generate mutational strategies that can improve the folding, stability, and/or manufacturability, while maintaining a particular biological function (e.g., TfR affinity/b inding).
  • a general strategy for producing homologs or in silico designed peptides or polypeptides can include identification of a charged surface patch or conserved residues of a protein, mutation of critical amino acid positions and loops, followed by in vitro and in vivo testing of the peptides.
  • the overall peptide optimization process can be of iterative nature to the extent that, for example, information obtained during in vitro or in vivo testing is used for the design of the next generation of peptides.
  • the herein disclosed methods can be used to design peptides with improved properties or to correct deleterious mutations that complicate folding and manufacturability.
  • Key amino acid positions and loops can be retained while other residues in the peptide sequences can be mutated to improve, change, remove, or otherwise modify function, such as binding, transcytosis, or the ability to penetrate a cell, endosome, or nucleus in a cell, homing, or another activity of the peptide.
  • This strategy can be used to predict the 3D pharmacophore of a group of structurally homologous scaffolds, as wells as to predict possible graft regions of related proteins to create chimeras with improved properties (e.g., binding properties). For example, this strategy is used to identify critical amino acid positions and loops that are used to design peptides with improved TfR receptor binding and transcytosis properties, high expression, high stability in vivo, or any combination of these properties.
  • the present disclosure also encompasses multimers of the various peptides described herein.
  • multimers include dimers, trimers, tetramers, pentamers, hexamers, heptamers, and so on.
  • a multimer can be a homomer formed from a plurality of identical subunits or a heteromer formed from a plurality of different subunits.
  • a peptide of the present disclosure is arranged in a multimeric structure with at least one other peptide, or two, three, four, five, six, seven, eight, nine, ten, or more other peptides.
  • the peptides of a multimeric structure each have the same sequence. In other embodiments, one or more or all of the peptides of a multimeric structure have different sequences.
  • the present disclosure provides peptide scaffolds that can be used as a starting point for generating additional, next-generation peptides with more specific or improved properties.
  • these scaffolds are derived from a variety of CDPs or knotted peptides.
  • Suitable peptides for scaffolds can include, but are not limited to, chlorotoxin, brazzein, circulin, stecrisp, hanatoxin, midkine, hefutoxin, potato carboxypeptidase inhibitor, bubble protein, attractin, a-GI, a-GID, p-PIIIA, co-MVIIA, co-CVID, y-MrlA, p-TIA, conantokin G, conantokin G, conantokin G, conantakin G, GsMTx4, margatoxin, shK, toxin K, chymotrypsin inhibitor (CTI), and EGF epiregulin core.
  • the peptide sequence is flanked by additional amino acids.
  • One or more additional amino acids can confer a desired in vivo charge, isoelectric point, chemical conjugation site, stability, or physiologic property to a peptide.
  • the pharmacokinetics of any of the peptides of the present disclosure can be determined after administration of the peptide via different routes of administration.
  • the pharmacokinetic parameters of a peptide of this disclosure can be quantified after intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, sublingual, inhalation, dermal, intrathecal, intranasal, peritoneal, buccal, synovial, intratumoral, or topical administration.
  • Peptides of the present disclosure can be analyzed by using tracking agents such as radiolabels or fluorophores.
  • radiolabeled peptides of this disclosure can be administered via various routes of administration.
  • Peptide concentration or dose recovery in various biological samples such as plasma, urine, feces, any organ, skin, muscle, and other tissues can be determined using a range of methods including HPLC, fluorescence detection techniques (TECAN quantification, flow cytometry, iVIS), or liquid scintillation counting.
  • the methods and compositions described herein relate to pharmacokinetics of peptide administration via any route to a subject.
  • Pharmacokinetics can be described using methods and models, for example, compartmental models or non-compartmental methods.
  • Compartmental models include but are not limited to monocompartmental model, the two compartmental model, the multicompartmental model or the like. Models are often divided into different compartments and can be described by the corresponding scheme. For example, one scheme is the absorption, distribution, metabolism and excretion (ADME) scheme. For another example, another scheme is the liberation, absorption, distribution, metabolism and excretion (LADME) scheme. In some aspects, metabolism and excretion can be grouped into one compartment referred to as the elimination compartment.
  • ADME absorption, distribution, metabolism and excretion
  • LADME liberation, absorption, distribution, metabolism and excretion
  • metabolism and excretion can be grouped into one compartment referred to as the elimination compartment.
  • liberation includes liberation of the active portion of the composition from the delivery system
  • absorption includes absorption of the active portion of the composition by the subject
  • distribution includes distribution of the composition through the blood plasma and to different tissues
  • metabolism which includes metabolism or inactivation of the composition
  • excretion which includes excretion or elimination of the composition or the products of metabolism of the composition.
  • Compositions administered intravenously to a subject can be subject to multiphasic pharmacokinetic profiles, which can include but are not limited to aspects of tissue distribution and metabolism/excretion.
  • the decrease in plasma or serum concentration of the composition is often biphasic, including, for example an alpha phase and a beta phase, occasionally a gamma, delta or other phase is observed.
  • Pharmacokinetics includes determining at least one parameter associated with administration of a peptide to a subject.
  • parameters include at least the dose (D), dosing interval (T), area under curve (AUC), maximum concentration (C max ), minimum concentration reached before a subsequent dose is administered (C m in), minimum time (T m in), maximum time to reach Cmax (T max ), volume of distribution (Vd), steady-state volume of distribution (V ss ), back-extrapolated concentration at time 0 (Co), steady state concentration (Css), elimination rate constant (k e ), infusion rate (kin), clearance (CL), bioavailability (f), fluctuation (%PTF) and elimination half-life (ti/2).
  • the peptides or peptide complexes of any of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 exhibit optimal pharmacokinetic parameters after oral administration.
  • the peptides or peptide complexes of any of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 exhibit optimal pharmacokinetic parameters after any route of administration, such as oral administration, inhalation, intranasal administration, topical administration, intravenous administration, subcutaneous administration, intra-articular administration, intramuscular administration, intraperitoneal administration, intra- synovial, or any combination thereof.
  • any peptide or peptide complex of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 exhibits an average Truax of 0.5 - 12 hours, or 1-48 hours at which the Cmax is reached, an average bioavailability in serum of 0.1% - 10% in the subject after administering the peptide to the subject by an oral route, an average bioavailability in serum of less than 0.1% after oral administration to a subject for delivery to the GI tract, an average bioavailability in serum of 10-100% after parenteral administration, an average t>/ 2 of 0.1 hours - 168 hours, or 0.25 hours - 48 hours in a subject after administering the peptide to the subject, an average clearance (
  • a peptide of the present disclosure can be stable in various biological or physiological conditions, such as physiologic extracellular pH, endosomal or lysosomal pH, or reducing environments inside a cell, in the cytosol, in a cell nucleus, or endosome or a tumor.
  • any peptide or peptide complex comprising any of SEQ ID NO: 96, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 - SEQ ID NO: 95, SEQ ID NO: 97 - SEQ ID NO: 128, SEQ ID NO: 220 - SEQ ID NO: 222, or SEQ ID NO: 1 - SEQ ID NO: 64 can exhibit resistance to reducing agents, proteases, oxidative conditions, or acidic conditions.
  • biologic molecules such as peptides and proteins
  • the GI tract can contain a region of low pH (e.g., pH ⁇ 1), a reducing environment, or a protease-rich environment that can degrade peptides and proteins.
  • a region of low pH e.g., pH ⁇ 1
  • a reducing environment e.g., a reducing environment
  • a protease-rich environment e.g., a protease-rich environment that can degrade peptides and proteins.
  • Proteolytic activity in other areas of the body such as the mouth, eye, lung, intranasal cavity, joint, skin, vaginal tract, mucous membranes, and serum, can also be an obstacle to the delivery of functionally active peptides and polypeptides.
  • the half-life of peptides in serum can be very short, in part due to proteases, such that the peptide can be degraded too quickly to have a lasting therapeutic effect when administering reasonable dosing regimens.
  • proteolytic activity in cellular compartments such as lysosomes and reduction activity in lysosomes and the cytosol can degrade peptides and proteins such that they can be unable to provide a therapeutic function on intracellular targets. Therefore, peptides that are resistant to reducing agents, proteases, and low pH can be able to provide enhanced therapeutic effects or enhance the therapeutic efficacy of co-formulated or conjugated, linked, or fused active agents in vivo.
  • Various expression vector/host systems can be utilized for the recombinant expression of peptides described herein.
  • Non-limiting examples of such systems include microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a nucleic acid sequence encoding peptides, peptide complexes, or peptide fusion proteins/chimeric proteins described herein, yeast transformed with recombinant yeast expression vectors containing the aforementioned nucleic acid sequence, insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the aforementioned nucleic acid sequence, plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV), tobacco mosaic virus (TMV)), or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the aforementioned nucleic acid sequence, or
  • a host cell can be adapted to express one or more peptides described herein.
  • the host cells can be prokaryotic, eukaryotic, or insect cells.
  • host cells are capable of modulating the expression of the inserted sequences or modifying and processing the gene or protein product in the specific fashion desired. For example, expression from certain promoters can be elevated in the presence of certain inducers (e.g., zinc and cadmium ions for metallothionine promoters).
  • inducers e.g., zinc and cadmium ions for metallothionine promoters.
  • modifications e.g., phosphorylation
  • processing e.g., cleavage
  • Host cells can have characteristic and specific mechanisms for the post-translational processing and modification of a peptide.
  • the host cells used to express the peptides secrete minimal amounts of proteolytic enzymes.
  • the selective depletion complexes of this disclosure can be advantageously made by a single recombinant expression system, with no need for chemical synthesis or modifications.
  • a selective depletion complex can be expressed in CHO cells, HEK cells, yeast, pichia, E. coli, or other organisms.
  • the selective depletion complex may be expressed within the cells and require cell lysis to isolate, or the selective depletion complex may be expressed with trafficking sequences driving secretion from the cell, in which case the selective depletion complex may be purified from the cell culture media.
  • the selective depletion complex may be captured by chromatography, such as by a protein A column or a Ni-affinity column, through use of any manner of expressed affinity tags, size or ion exchange chromatography, and then purified by one or more steps, which may include chromatography, and then optionally buffer exchanged.
  • the selective depletion complexes of this disclosure may be advantageously manufactured by standard manufacturing methods for recombinant proteins or recombinant Fc- containing molecules, such as those described in Shukla et a., 2017 Bioengineering & Translational Medicine 2017: 2:58-69.
  • organisms can be treated prior to purification to preserve and/or release a target polypeptide.
  • the cells are fixed using a fixing agent.
  • the cells are lysed.
  • the cellular material can be treated in a manner that does not disrupt a significant proportion of cells, but which removes proteins from the surface of the cellular material, and/or from the interstices between cells.
  • cellular material can be soaked in a liquid buffer, or, in the case of plant material, can be subjected to a vacuum, in order to remove proteins located in the intercellular spaces and/or in the plant cell wall.
  • proteins can be extracted from the microorganism culture medium.
  • the peptides can be packed in inclusion bodies. The inclusion bodies can further be separated from the cellular components in the medium. In some embodiments, the cells are not disrupted.
  • a cellular or viral peptide that is presented by a cell or virus can be used for the attachment and/or purification of intact cells or viral particles.
  • peptides can also be synthesized in a cell-free system prior to extraction using a variety of known techniques employed in protein and peptide synthesis.
  • a host cell produces a peptide that has an attachment point for a cargo molecule (e.g., a therapeutic agent).
  • An attachment point could comprise a lysine residue, an N- terminus, a cysteine residue, a cysteine disulfide bond, a glutamic acid or aspartic acid residue, a C-terminus, or a non-natural amino acid.
  • the peptide could also be produced synthetically, such as by solid-phase peptide synthesis, or solution-phase peptide synthesis. Peptide synthesis can be performed by fluorenylmethyloxycarbonyl (Fmoc) chemistry or by butyloxycarbonyl (Boc) chemistry.
  • the peptide could be folded (formation of disulfide bonds) during synthesis or after synthesis or both.
  • Peptide fragments could be produced synthetically or recombinantly. Peptide fragments can be then be joined together enzymatically or synthetically.
  • the peptides of the present disclosure can be prepared by conventional solid phase chemical synthesis techniques, for example according to the Fmoc solid phase peptide synthesis method (“Fmoc solid phase peptide synthesis, a practical approach,” edited by W. C. Chan and P. D. White, Oxford University Press, 2000).
  • the peptides of this disclosure can be more stable during manufacturing.
  • peptides of this disclosure can be more stable during recombinant expression and purification, resulting in lower rates of degradation by proteases that are present in the manufacturing process, a higher purity of peptide, a higher yield of peptide, or any combination thereof.
  • the peptides can also be more stable to degradation at high temperatures and low temperatures during manufacturing, storage, and distribution.
  • peptides of this disclosure can be stable at 25 °C.
  • peptides of this disclosure can be stable at 70 °C or higher than 70 °C.
  • peptides of this disclosure can be stable at 100 °C or higher than 100 °C.
  • a pharmaceutical composition of the disclosure can be a combination of any peptide as described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, antioxidants, solubilizers, buffers, osmolytes, salts, surfactants, amino acids, encapsulating agents, bulking agents, cryoprotectants, and/or excipients.
  • the pharmaceutical composition facilitates administration of a peptide described herein to an organism.
  • the pharmaceutical composition comprises factors that extend half-life of the peptide and/or help the peptide to penetrate the target cells.
  • a pharmaceutical composition comprises a cell modified to express and secrete a selective depletion complex of the present disclosure.
  • compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, sublingual, inhalation, dermal, intrathecal, intratumoral, intranasal, and topical administration.
  • a pharmaceutical composition can be administered in a local or systemic manner, for example, via injection of the peptide described herein directly into an organ, optionally in a depot.
  • Parenteral injections can be formulated for bolus injection, infusion, or continuous infusion.
  • the pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • Pharmaceutical formulations for parenteral administration include aqueous solutions of a peptide described herein in water-soluble form. Suspensions of peptide-antibody complexes described herein can be prepared as oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension can also contain suitable stabilizers or agents which increase the solubility and/or reduce the aggregation of such peptide-antibody complexes described herein to allow for the preparation of highly concentrated solutions.
  • the peptide described herein can be lyophilized or in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, water for injection, or a formulated buffer before use.
  • a purified peptide is administered intravenously.
  • a peptide described herein can be administered to a subject in order to home, target, migrate to, or be directed to a CNS cell, a brain cell, a cancerous cell, or a tumor.
  • a peptide can be conjugated to, linked to, or fused to another peptide that provides a targeting function to a specific target cell type in the central nervous system or across the blood brain barrier.
  • Exemplary target cells include a CNS cell, erythrocyte, an erythrocyte precursor cell, an immune cell, a stem cell, a muscle cell, a brain cell, a thyroid cell, a parathyroid cell, an adrenal gland cell, a bone marrow cell, an appendix cell, a lymph node cell, a tonsil cell, a spleen cell, a muscle cell, a liver cell, a gallbladder cell, a pancreas cell, a cell of the gastrointestinal tract, a glandular cell, a kidney cell, a urinary bladder cell, an endothelial cell, an epithelial cell, a choroid plexus epithelial cell, a neuron, a glial cell, an astrocyte, or a cell associated with a nervous system.
  • a CNS cell erythrocyte, an erythrocyte precursor cell, an immune cell, a stem cell, a muscle cell, a brain cell, a thyroid cell,
  • a peptide of the disclosure can be applied directly to an organ, or an organ tissue or cells, such as brain or brain tissue or cells, during a surgical procedure.
  • the recombinant peptide described herein can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments.
  • Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers, and preservatives.
  • therapeutically effective amounts of a peptide described herein can be administered in pharmaceutical compositions to a subject suffering from a condition that affects the immune system.
  • the subject is a mammal such as a human or a primate.
  • a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.
  • a peptide is cloned into a viral or non-viral expression vector.
  • Such expression vector can be packaged in a viral particle, a virion, or a non-viral carrier or delivery mechanism, which is administered to patients in the form of gene therapy.
  • patient cells are extracted and modified to express a peptide capable of binding TfR ex vivo before the modified cells are returned back to the patient in the form of a cell-based therapy, such that the modified cells will express the peptide once transplanted back in the patient.
  • compositions can be formulated using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulation can be modified depending upon the route of administration chosen.
  • Pharmaceutical compositions comprising a peptide described herein can be manufactured, for example, by expressing the peptide in a recombinant system, purifying the peptide, lyophilizing the peptide, mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
  • the pharmaceutical compositions can include at least one pharmaceutically acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically acceptable salt form.
  • Methods for the preparation of peptide described herein comprising the compounds described herein include formulating peptide described herein with one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid, or liquid composition.
  • Solid compositions include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically acceptable additives.
  • Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington ’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety.
  • compositions can also include permeation or absorption enhancers (Aungst et al. AAPS J. 14(1): 10-8. (2012) and Moroz et al. Adv Drug Deliv Rev 101:108-21.
  • Permeation enhancers can facilitate uptake of molecules from the GI tract into systemic circulation.
  • Permeation enhancers can include salts of medium chain fatty acids, sodium caprate, sodium caprylate, N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC), N-(5- chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), hydrophilic aromatic alcohols such as phenoxyethanol, benzyl alcohol, and phenyl alcohol, chitosan, alkyl glycosides, dodecyl-2-N,N- dimethylamino propionate (DDAIPP), chelators of divalent cations including EDTA, EGTA, and citric acid, sodium alkyl sulfate, sodium salicylate, lecithin-based, or bile salt-derived agents such as deoxy cholates.
  • SNAC N-(8-[2-hydroxybenzoyl]amino)caprylic acid
  • compositions can also include protease inhibitors including soybean trypsin inhibitor, aprotinin, sodium glycocholate, camostat mesilate, vacitracin, or cyclopentadecalactone.
  • protease inhibitors including soybean trypsin inhibitor, aprotinin, sodium glycocholate, camostat mesilate, vacitracin, or cyclopentadecalactone.
  • a method of treating a subject using the selective depletion complexes of the present disclosure includes administering an effective amount of a peptide as described herein to a subject in need thereof.
  • a method of treating a subject using the selective depletion complexes of the present disclosure includes modifying a cell of a subject to express and secrete a selective depletion complex of the present disclosure.
  • the cell is a cell in the subject.
  • the cell is a cell that has been removed from the subject and is re-introduced following modification.
  • the cell is modified using a viral vector (e.g., an oncolytic herpes simplex virus).
  • a gene encoding expression and secretion of a selective depletion complex is engineered into a CAR-T cell or other cellular therapy.
  • TfR can be expressed in various tissues such as the brain, the stomach, the liver, of the gall bladder.
  • the peptides of the present disclosure e.g., a selective depletion complex comprising a TfR-b inding peptide
  • the peptides of the present disclosure can be used in the diagnosis and treatment of disease and conditions associated with various tissues and organs.
  • drug delivery to these tissues and organs can be improved by using the herein described peptides and peptide complexes carrying a diagnostic and/or therapeutic payload.
  • the term “effective amount,” as used herein, refers to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. Compositions containing such agents or compounds can be administered for prophylactic, enhancing, and/or therapeutic treatments. An appropriate “effective” amount in any individual case can be determined using techniques, such as a dose escalation study.
  • the methods, compositions, and kits of this disclosure can comprise a method to prevent, treat, arrest, reverse, or ameliorate the symptoms of a condition.
  • the treatment can comprise treating a subject (e.g., an individual, a domestic animal, a wild animal, or a lab animal afflicted with a disease or condition) with a peptide of the disclosure.
  • the disease can be a cancer or tumor.
  • the peptide can contact the tumor or cancerous cells.
  • the subject can be a human.
  • Subjects can be humans; non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • a subject can be of any age.
  • Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, and fetuses in utero.
  • Treatment can be provided to the subject before clinical onset of disease. Treatment can be provided to the subject after clinical onset of disease.
  • Treatment can be provided to the subject after 1 day, 1 week, 6 months, 12 months, or 2 years or more after clinical onset of the disease. Treatment can be provided to the subject for more than 1 day, 1 week, 1 month, 6 months, 12 months, 2 years or more after clinical onset of disease. Treatment can be provided to the subject for less than 1 day, 1 week, 1 month, 6 months, 12 months, or 2 years after clinical onset of the disease. Treatment can also include treating a human in a clinical trial.
  • a treatment can comprise administering to a subject a pharmaceutical composition, such as one or more of the pharmaceutical compositions described throughout the disclosure.
  • a treatment can comprise a once daily dosing.
  • a treatment can comprise delivering a peptide of the disclosure to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, dermally, topically, by intra-articular injection, orally, sublingually, intrathecally, transdermally, intranasally, via a peritoneal route, directly into a tumor e.g., injection directly into a tumor, directly into the brain, e.g., via and intracerebral ventricle route, or directly onto a joint, e.g. via topical, intra-articular injection route.
  • a treatment can comprise administering a peptide-active agent complex to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, by intra-articular injection, dermally, topically, orally, intrathecally, transdermally, intransally, parenterally, orally, via a peritoneal route, nasally, sublingually, or directly onto cancerous tissues.
  • a target-binding peptide (e.g., a target-binding EGF variant of any one of SEQ ID NO: 318 - SEQ ID NO: 390, SEQ ID NO: 457 - SEQ ID NO: 494) may be administered for a therapeutic effect.
  • the target-binding peptide may bind to and inhibit an EGFR receptor, producing a therapeutic effect in a subject.
  • the target-binding peptide may be complexed with an active agent (e.g., a therapeutic agent or a detectable agent).
  • an EGFR-b inding peptide may be complexed with an anticancer agent (e.g., a chemotherapeutic agent).
  • Administration of an EGFR-binding peptide complexed with an anti-cancer agent may be used in a method of treating a disease or condition (e.g., cancer).
  • peptides described herein can be provided as a kit.
  • peptide complexes described herein can be provided as a kit.
  • a kit comprises amino acids encoding a peptide described herein, a vector, a host organism, and an instruction manual.
  • a kit includes written instructions on the use or administration of the peptides.
  • the EGFR- binding peptide of embodiment 1 comprising a first cysteine amino acid residue, a second cysteine amino acid residue, a third cysteine amino acid residue, a fourth cysteine amino acid residue, a fifth cysteine amino acid residue, and a sixth cysteine amino acid residue; wherein the EGFR-b inding peptide comprises: seven amino acid residues between the first cysteine amino acid residue and the second cysteine amino acid residue, five amino acid residues between the second cysteine amino acid residue and the third cysteine amino acid residue, ten amino acid residues between the third cysteine amino acid residue and the fourth cysteine amino acid residue, one amino acid residue between the fourth cysteine amino acid residue and the fifth cysteine amino acid residue, and eight amino acid residues between the fifth cysteine amino acid residue and the sixth cysteine amino acid residue.
  • the EGFR-binding peptide of any one of embodiments 1-3 wherein the at least one mutation comprises an amino acid substitution of D11R, I23S, V35E, S51P, L52E, R53E, M21R, A30W, I38D, W49R, V34S, Q43I, Q43V, Q43W, Q43Y, K48N, K48T, K48A, K48L, E51S, E51H, L52H, R53H, or a combination thereof.
  • the EGFR-binding peptide of any one of embodiments 1-4 wherein the at least one mutation comprises an amino acid substitution of M21R, A30W, I38D, W49R, or a combination thereof. 6.
  • An EGFR-binding peptide comprising a sequence of SEQ ID NO: 314.
  • An EGFR-binding peptide comprising a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • the EGFR-binding peptide of embodiment 9 comprising a sequence having at least 90% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494.
  • a peptide complex comprising: (a) a cellular receptor-binding peptide; and (b) a target-binding peptide complexed with the cellular receptor-binding peptide, wherein the targetbinding peptide has affinity for a target molecule, and wherein the target-binding peptide comprises the EGFR-binding peptide of any one of embodiments 1-14. 16.
  • a peptide complex comprising: (a) a cellular receptor-binding peptide; and (b) a target-binding peptide complexed with the cellular receptor-binding peptide, wherein the target-binding peptide has affinity for a target molecule, and wherein the target-binding peptide comprises a sequence of SEQ ID NO: 314 or a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 388 - SEQ ID NO: 390 or SEQ ID NO: 457 - SEQ ID NO: 494. 17.
  • CI-M6PR cationindependent mannose 6 phosphate receptor
  • ASGPR asialoglycoprotein receptor
  • CXCR7 CXCR7
  • folate receptor folate receptor
  • Fc receptor including but not limited to neonatal Fc receptor (FcRn) or FcyRIIb.
  • KD equilibrium dissociation constant
  • KD equilibrium dissociation constant
  • koff or kd dissociation rate constant
  • the peptide complex of any one of embodiments 15-31, wherein the affinity of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25- fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold. 33.
  • the peptide complex of any one of embodiments 15-32, wherein the affinity of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25- fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold. 34.
  • the peptide complex of any one of embodiments 15-32, wherein the dissociation rate constant (koff or kd) of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25 -fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold. 35.
  • the peptide complex of any one of embodiments 15-32, wherein the dissociation rate constant (koff or kd) of the cellular receptor-binding peptide for the cellular receptor at pH 7.4 and at pH 5.8 differs by no more than 2-fold, no more than 5 -fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
  • 36. The peptide complex of any one of embodiments 15- 35, wherein the affinity of the cellular receptor-binding peptide for the cellular receptor is pH dependent. 37.
  • the peptide complex of embodiment 36 wherein the affinity of the cellular receptor-binding peptide for the cellular receptor decreases as pH decreases. 38.
  • the peptide complex of embodiment 36 or embodiment 37 wherein the affinity of the cellular receptorbinding peptide for the cellular receptor is higher at pH 7.4 than at pH 5.5.
  • the peptide complex of embodiment 36 or embodiment 37, wherein the affinity of the cellular receptorbinding peptide for the cellular receptor is higher at pH 7.4 than at pH 5.8.
  • 40 The peptide complex of any one of embodiments 15-39, wherein the affinity of the target-binding peptide for the target molecule is pH dependent. 41.
  • the peptide complex of embodiment 42 or embodiment 43, wherein the lower pH is pH 6.5, pH 6.0, pH 5.8, pH 5.5, pH 5.0, or pH 4.5. 45.
  • KD equilibrium dissociation constant
  • koff or kd dissociation rate constant
  • koff or kd dissociation rate constant
  • koff or kd dissociation rate constant
  • the peptide complex of any one of embodiments 15-51, wherein the dissociation rate constant (koff or kd) for target-binding peptide binding the target molecule is at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.5 than at pH 7.4. 53.
  • the peptide complex of any one of embodiments 15-52, wherein the dissociation rate constant (koff or kd) for target-binding peptide binding the target molecule is at least 2 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1,000 fold, at least 2,000 fold, at least 5,000 fold, at least 10,000 fold, at least 20,000 fold, or at least 50,000 fold higher at pH 5.8 than at pH 7.4. 54.
  • KD equilibrium dissociation constant
  • KD equilibrium dissociation constant
  • the peptide complex of any one of embodiments 15-57 wherein the affinity of the targetbinding peptide for the target molecule at pH 7.4 is less than 0.5-fold, less than 1-fold, less than, 1.5-fold, less than 2-fold, less than 3-fold, or less than 10-fold, greater than the affinity of the target-binding peptide for the target molecule at pH 5.8.
  • 59. The peptide complex of any one of embodiments 15-58, wherein the target-binding peptide comprises one or more histidine amino acid residues.
  • polymer linker is a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer comprising proline, alanine, serine, or a combination thereof, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, a palmitic acid, an albumin, or an albumin binding molecule.
  • PEG polyethylene glycol
  • a hydroxyethyl starch polyvinyl alcohol
  • water soluble polymer a zwitterionic water soluble polymer
  • a water soluble poly(amino acid) a water soluble poly(amino acid)
  • a water soluble poly(amino acid) a water soluble poly(amino acid)
  • a water soluble polymer comprising proline,
  • the distance between the cellular receptor-binding peptide and the target-binding peptide is at least 1 nm, at least 2 nm, at least 5 nm, at least 10 nm, at least 20 nm, at least 50 nm, or at least 100 nm.
  • the dimerization domain comprises an Fc domain.
  • the dimer is a homodimer dimerized via a homodimerization domain. 70.
  • the peptide complex of embodiment 69 wherein the homodimerization domain comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 535, SEQ ID NO: 706, or SEQ ID NO: 246.
  • 76. The peptide complex of any one of embodiments 15-75, wherein the cellular receptor-binding peptide is linked to the target-binding peptide via a peptide linker.
  • 77. The peptide complex of embodiment 15-76, wherein the peptide linker has a length of from 1 to 50 amino acid residues, from 2 to 40 amino acid residues, from 3 to 20 amino acid residues, or from 3 to 10 amino acid residues. 78.
  • the antibody comprises an IgG, or wherein the antibody fragment comprises a Fab, a F(ab)2, an scFv, or an (scFv)2.
  • the miniprotein comprises a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanofittin, a fynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
  • the cellular receptor-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • the peptide complex comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
  • 89. The peptide complex of any one of embodiments 15-88, wherein the cellular receptor-binding peptide comprises at least six cysteine residues. 90.
  • the peptide complex of embodiment 89 wherein the at least six cysteine residues are positioned at amino acid positions 4, 8, 18, 32, 42, and 46 of the cellular receptor-binding peptide.
  • peptide complex of any one of embodiments 15-93, wherein the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 96, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 96. 95.
  • the peptide complex of embodiment 96 or embodiment 97, wherein the cellular receptor-binding peptide comprises a sequence that has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 187, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 400, or SEQ ID NO: 401 or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a fragment of SEQ ID NO: 187.
  • 101 The peptide complex of any one of embodiments 15-100, wherein the cellular receptor-binding peptide comprises one or more histidine residues at a cellular receptor-binding interface.
  • 102 The peptide complex of any one of embodiments 15-101, wherein the target-binding peptide comprises one or more histidine residues at a target-binding interface.
  • 103 The peptide complex of any one of embodiments 15- 102, wherein the target-binding peptide is an EGFR-binding peptide.
  • 104 The peptide complex of any one of embodiments 15-103, wherein the target molecule comprises an EGFR. 105.
  • EGFR is wild-type EGFR, EGFRvIII, tyrosine kinase inhibitor-resistant EGFR, EGFR containing an exon 19 deletion, EGFR containing an exon21 L858R mutation, EGFR mutant T790M, or a combination thereof.
  • the tyrosine kinase inhibitor-resistant EGFR comprises a EGFR L692V mutant, EGFR E709K mutant, EGFR L718Q mutant, EGFR L718V mutant, EGFR G719A mutant, EGFR G724S mutant, EGFR L747S mutant, EGFR D761Y mutant, EGFR S768I mutant, EGFR SV768IL mutant, EGFR G769X mutant, EGFR T790M mutant, EGFR L792X mutant, EGFR G796R mutant, EGFR G796S mutant, EGFR G796D mutant, EGFR C797X mutant, EGFR L798I mutant, EGFR V834I mutant, EGFR V834L mutant, EGFR V843I mutant, EGFR T854I mutant, or EGFR H870R mutant.
  • peptide complex of any one of embodiments 15-106 wherein an off rate of the cellular receptor-binding peptide from the cellular receptor is slower than a recycling rate of the cellular receptor.
  • peptide complex of any one of embodiments 15-107 wherein a half-life of dissociation of the cellular receptor-binding peptide from the cellular receptor is no faster than 1 minute, no faster than 2 minutes, no faster than 3 minutes, no faster than 4 minutes, no faster than 5 minutes, no faster than 7 minutes, no faster than 10 minutes, no faster than 15 minutes, no faster than 20 minutes, no faster than 30 minutes, no faster than 45 minutes, no faster than 60 minutes, no faster than 90 minutes, or no faster than 120 minutes.
  • 109 a half-life of dissociation of the cellular receptor-binding peptide from the cellular receptor is no faster than 1 minute, no faster than 2 minutes, no faster than 3 minutes, no faster than 4 minutes, no faster than 5 minutes, no faster than 7 minutes, no faster than 10 minutes, no faster than 15 minutes, no
  • a half-life of dissociation of the target binding-binding peptide from the target molecule is less than 10 seconds, less than 20 seconds, less than 30 seconds, less than 1 minute, less than 2 minutes, less than 5 minutes, less than 10 minutes, less than 20 minutes, less than 30 minutes, less than 45 minutes, or less than 60 minutes in endosomal conditions.
  • 116. The peptide complex of any one of embodiments 15-115, wherein the target molecule is released or dissociated from the target-binding peptide after the peptide complex is endocytosed via receptor-mediated endocytosis.
  • 117. The peptide complex of any one of embodiments 15-116, wherein the target molecule is an extracellular protein, a circulating protein, or a soluble protein.
  • the peptide complex of embodiment 120 wherein the half-life modifying agent is a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, an albumin, or a molecule that binds to albumin.
  • the half-life modifying agent is a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a
  • the peptide complex of embodiment 121, wherein the molecule that binds to albumin is a serum albumin-binding peptide.
  • the peptide complex of any one of embodiments 1-126 wherein the peptide complex comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of SEQ ID NO: 495 - SEQ ID NO: 497, SEQ ID NO: 503, or SEQ ID NO: 506.
  • a peptide-active agent complex comprising a peptide complexed to an active agent, wherein the peptide comprises the EGFR-binding peptide of any one of embodiments 1-14 or the peptide complex of any one of embodiments 15-128. 130.
  • the peptideactive agent complex of embodiment 129 wherein the active agent comprises a peptide, a peptidomimetic, an oligonucleotide, a DNA, an RNA, an antibody, a single chain variable fragment (scFv), an antibody fragment, an aptamer, or a small molecule.
  • the DNA comprises cDNA, ssDNA, or dsDNA.
  • the RNA comprises RNAi, microRNA, snRNA, dsRNA, or an antisense oligonucleotide.
  • the detectable agent comprises a dye, a fluorophore, a fluorescent biotin compound, a luminescent compound, a chemi luminescent compound, a radioisotope, nanoparticle, a paramagnetic metal ion, or a combination thereof. 135.
  • the anti-cancer agent comprises a radionuclide, radioisotope, a chemotherapeutic agent, a platinum therapeutic, a toxin, an enzyme, a sensitizing drug, an anti-angiogenic agent, cisplatin, an anti-metabolite, an anti-metabolic therapeutic, a mitotic inhibitor, a growth factor inhibitor, paclitaxel, temozolomide, topotecan, fluorouracil, vincristine, vinblastine, procarbazine, decarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions et des procédés pour la déplétion sélective de molécules cibles d'EGFR à l'aide d'un complexe médié par liaison au récepteur recyclable pour déclencher l'absorption ou l'endocytose et la dégradation cellulaire de la molécule cible. Des compositions illustratives contenant un peptide, tel qu'un peptide CDP qui se lie à un récepteur de la transferrine, peuvent être liées à un peptide qui se lie à une molécule cible d'EGFR. De telles compositions peuvent être utilisées pour appauvrir sélectivement l'EGFR à partir de la surface cellulaire ou recruter sélectivement l'EGFR vers des endosomes par l'intermédiaire de l'endocytose médiée par le récepteur de la transferrine de la composition et de la molécule cible liée. Une fois à l'intérieur de l'endosome, le pH acide peut conduire à la libération de l'EGFR, de la composition, due à une liaison dépendante du pH de la composition pour la molécule cible, et la partie de récepteur de transferrine est recyclée en retour vers la surface cellulaire pour un "rechargement". L'EGFR peut ensuite être envoyé dans des lysosomes où il est dégradé.
PCT/US2024/031938 2023-06-01 2024-05-31 Variants d'egf et leurs méthodes d'utilisation Pending WO2024249812A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470404P 2023-06-01 2023-06-01
US63/470,404 2023-06-01

Publications (2)

Publication Number Publication Date
WO2024249812A2 true WO2024249812A2 (fr) 2024-12-05
WO2024249812A3 WO2024249812A3 (fr) 2025-05-01

Family

ID=93658472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031938 Pending WO2024249812A2 (fr) 2023-06-01 2024-05-31 Variants d'egf et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2024249812A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247531B2 (en) * 2006-03-20 2012-08-21 Cochran Jennifer R Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
GB0815264D0 (en) * 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
US9636419B2 (en) * 2013-10-11 2017-05-02 The Universit of Kansas Targeting multiple receptors on a cell surface for specific cell targeting

Also Published As

Publication number Publication date
WO2024249812A3 (fr) 2025-05-01

Similar Documents

Publication Publication Date Title
US20230151068A1 (en) Peptide compositions and methods of use thereof for disrupting tead interactions
EP3893913B1 (fr) Peptides ciblant un récepteur de la transferrine
RU2645256C2 (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
US10156559B2 (en) Lipocalin fusion partners
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
US20250195673A1 (en) Compositions and methods for selective depletion of target molecules
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
US20240287147A1 (en) Pd-l1 binding peptides and peptide complexes and methods of use thereof
JP7186940B2 (ja) 血液－脳関門を移行する抗体変種及びその使用
WO2023235522A1 (fr) Compositions et procédés d'épuisement sélectif de molécules cibles d'egfr
WO2024200988A1 (fr) Polypeptides de liaison au tnfr2 et procédés d'utilisation
EP3927375A1 (fr) Compositions pour le traitement de maladies
WO2024249812A2 (fr) Variants d'egf et leurs méthodes d'utilisation
WO2019165105A1 (fr) Ligands du récepteur d'urokinase et leur utilisation dans le traitement, le dépistage et l'imagerie du cancer
AU2012358248A1 (en) Serum amyloid P-antibody fusion proteins
US20210252159A1 (en) Conjugates of cartilage-homing peptides
KR20230121575A (ko) Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
CN117615774A (zh) Pd-l1结合肽和肽复合物及其使用方法
WO2025093877A1 (fr) Nanostructure
JP2023515124A (ja) タンパク質を標的化する分子

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24816539

Country of ref document: EP

Kind code of ref document: A2